Volume 5

# Schedule 1—Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

Note: See sections 5 and 6.

-	gredients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
3624	P-ALPHA-DIMETHYL STYRENE	Ε	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3625	P-ANISIC ACID	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.
			The concentration in the medicine must be no more than 0.3%.
3626	PADIMATE O	А	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must not be more than 8%.
			When used in primary sunscreen products, the following warning statements

Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			are required on the label:
			- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and
			- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
3627	PADINA PAVONICA THALLUS PHYTOSTEROLS	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.01%.
3628	PAEONIA LACTIFLORA	А, Е, Н	
3629	PAEONIA OBOVATA	A, H	
3630	PAEONIA SUFFRUTICOSA	А, Е, Н	
3631	PAEONIA VEITCHII	A, H	
3632	PALIURUS SPINA-CHRISTI	A, H	
3633	PALLADIUM	Н	Only for use as an active homoeopathic ingredient.
3634	PALM FRUIT OIL	A, E, H	
3635	PALM GLYCERIDES	E	
3636	PALM KERNEL OIL	А, Е, Н	
3637	PALM TOCOTRIENOLS COMPLEX	А, Н	
3638	PALMARIA PALMATA	А, Н	
3639	PALMAROSA OIL	А, Е, Н	

volume J	Vol	lume	5
----------	-----	------	---

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
3640	PALMIDROL	A	Only to be used in a medicine where Pharmako Biotechnologies Pty Ltd (Client ID 62358), who applied to have the ingredient included in this Determination, is the sponsor of the medicine or has given written authorisation to the sponsor of a medicine to include the ingredient in the medicine. This paragraph ceases to be a requirement for this ingredient after 02 December 2021.
			Only permitted for use in medicines limited to oral route of administration.
			The maximum recommended daily dose of the medicine must not contain more than 600mg of palmidrol.
			The following warning statements are required on the medicine label:
			- 'The medicine may interact with other prescription analgesic medicines, please consult your healthcare practitioner before use' (or words to that effect).
			- (ADULT) 'Adults only' (or words to that effect)
			- 'Not to be used for more than 21 consecutive days' (or word to that effect).
3641	PALMITIC ACID	E	
3642	PALMITOLEIC ACID-RICH FATTY ACID ETHYL ESTERS	А	

Volume	5
--------	---

Column 1	column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
3643	PALMITOYL DIPEPTIDE-7	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.002%.
3644	PALMITOYL HYDROXYPROPYLTRIMONIUM AMYLOPECTIN/GLYCERIN CROSSPOLYMER	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.01%
3645	PALMITOYL OLIGOPEPTIDE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.002%.
3646	PALMITOYL PENTAPEPTIDE-3	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.0005%.
3647	PALMITOYL TETRAPEPTIDE-3	Е	Only for use in topical medicines for dermal

	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements           application and not to be
			included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.001%.
3648	PANAX GINSENG	A, E, H	
3649	PANAX JAPONICUS	А, Н	
3650	PANAX NOTOGINSENG	А, Н	
3651	PANAX PSEUDOGINSENG	А, Н	
3652	PANAX QUINQUEFOLIUS	А, Н	
3653	PANICUM MILIACEUM	А, Н	
3654	PANTETHINE	Е	Only for use in topical medicines for dermal application.
3655	PANTHENOL	A, E	
3656	PANTHENYL ETHYL ETHER	Е	Only for use in topical medicines for dermal application.
3657	PANTOLACTONE	Е	
3658	PANTOTHENIC ACID	Α, Ε	When used topically, the concentration in the medicine must be no more than 0.1%.
3659	PANTOTHENIC ACID POLYPEPTIDE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than

Volume 5

Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2020

773

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			0.1%.
3660	PAPAIN	A, E	
3661	PAPER	Е	Only for use in topical medicines for dermal application.
3662	PAPRIKA OLEORESIN	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3663	PARA-CRESOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3664	PARA-CRESYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total

	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			fragrance concentration in a medicine must be no more 1%.
3665	PARA-CRESYL ISOBUTYRATE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3666	PARA-CRESYL PHENYLACETATE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3667	PARA-CYMENE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3668	PARA- ETHOXYBENZALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a flavour.
			If used in a flavour the total

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			flavour concentration in a medicine must be no more than 5%.
3669	PARA-ETHYLPHENOL	E	Permitted for use only in combination with other permitted ingredients as part of a flavour proprietary excipient formulation.
			The maximum recommended daily dose must contain no more than 0.12 mg of para- ethylphenol.
			The total flavour proprietary excipient formulation in a medicine must be no more than 5%.
3670	PARA-HYDROXY BENZALACETONE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3671	PARA-HYDROXYBENZOIC ACID	Е	
3672	PARA-MENTHA-8-THIOL-3-ONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a

Volume	5
--------	---

Column 1	column 2	Column 3	Column 4
			Specific requirements
Item	Ingredient name	Purpose	medicine must be no more 1%
3673	PARA-METHYL ACETOPHENONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%
3674	PARA-METHYL ANISOLE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3675	PARA-METHYL DIMETHYLBENZYL CARBINOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%
3676	PARA-PROPYL ANISOLE	E	Permitted for use only in combination with other permitted ingredients as a

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3677	PARA-TERT- BUTYLCYCLOHEXYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3678	PARA-TERT-BUTYLPHENYL- ALPHA- METHYLHYDROCINNAMIC ALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more thar 1%.
3679	PARA-TOLUALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3680	PARA-TOLYL ACETALDEHYDE	Е	Permitted for use only in combination with other

Vol	lume	5
101	unit	$\mathcal{I}$

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			<ul> <li>permitted ingredients as a flavour or a fragrance.</li> <li>If used in a flavour the total flavour concentration in a medicine must be no more than 5%.</li> <li>If used in a fragrance the total fragrance concentration in a medicine must be no more 1%</li> </ul>
3681	PARAMERIA LAEVIGATA	A, H	
3682	PARIETARIA JUDAICA	A, H	
3683	PARIS POLYPHYLLA	A, H	
3684	PARIS QUADRIFOLIA	A, H	
3685	PARSLEY	E, H	
3686	PARSLEY HERB DRY	А, Е, Н	
3687	PARSLEY HERB OIL	А, Е, Н	
3688	PARSLEY HERB POWDER	А, Е, Н	
3689	PARSLEY SEED OIL	А, Е, Н	
3690	PARTHENOCISSUS TRICUSPIDATA	А, Н	
3691	PARTIALLY DEHYDRATED LIQUID SORBITOL	Ε	Sorbitol is a mandatory component of partially dehydrated liquid sorbitol. Permitted for use only as part of the capsule in medicines where the dosage form is a soft capsule.
3692	PARTIALLY HYDROGENATED SOYA OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total

Volume 5

Column 1	column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
		1 urpose	flavour concentration in the medicine must be no more than 5%.
3693	PARTIALLY REFINED PORPHYRA YEZOENSIS CYTOPLASM EXTRACT	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.00002%.
3694	PASPALUM NOTATUM	А, Н	
3695	PASSIFLORA CAERULEA	A, H	
3696	PASSIFLORA EDULIS	Е	
3697	PASSIFLORA HERB DRY	A, H	
3698	PASSIFLORA INCARNATA	А, Е, Н	
3699	PATCHOULI OIL	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3700	PATENT BLUE V	Е	Permitted for use only as a colour in medicines limited to topical and oral routes of administration.

Vol	ume	5

Column 1	column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
3701	PATENT BLUE V ALUMINIUM LAKE	E	Permitted for use only as a colour in medicines limited to topical and oral routes of administration.
3702	PATRINIA SCABIOSIFOLIA	A, H	
3703	PATRINIA VILLOSA	A, H	
3704	PAULLINIA CUPANA	А, Е, Н	Caffeine is a mandatory component of Paullinia cupana When the medicine is
			packaged for supply as an undivided preparation and is for internal use or oral application, the medicine must not contain a concentration of total caffeine greater than 4%.
			When the medicine is packaged for supply as a divided preparation and is for internal use or oral application, the medicine must not contain a concentration of total caffeine greater than 33%.
			The requirements specified in paragraphs (a) to (e) below apply in relation to a medicine that contains the ingredient that:
			- is listed in the Register on or after 2 September 2019; or
			- is supplied after 2 March 2021.
			A medicine that contains the ingredient and that:
			- was listed in the Register before 2 September 2019; and
			- is supplied before 2 March 2021;

Volume 5

Column 1	Column 2	Column 3	Column 4
ltem	Ingredient name	Purpose	Specific requirements
			may comply with the requirements in paragraphs (a) to (e) below.
			a) When for internal use or ora application, the maximum recommended daily dose of th medicine must provide no more than 400mg of total caffeine.
			b) When the medicine is packaged for supply as an undivided preparation and is for internal use or oral application, the medicine mus not contain a concentration of total caffeine greater than 1%.
			c) When the medicine is for internal use or oral application a maximum recommended dose of the medicine must not provide more than 100 mg of total caffeine within a 3 hour period.
			<ul> <li>d) When the maximum</li> <li>recommended daily dose of the medicine provides greater than 10 mg of total caffeine and the medicine is for internal use or oral application, the following warning statements are required on the label:</li> </ul>
			- (ADULT) 'Adults only' (or words to that effect).
			- (CAFF) 'Contains [state quantity per dosage unit or pe mL or per gram of product] total caffeine [per dosage unit or per mL or per gram]. A cup of instant coffee contains approximately 80mg of caffeine.'

volume J	Vo	lume	5
----------	----	------	---

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			- (CAFFPREG) 'Caffeine intake more than 200 mg per day is not recommended durin pregnancy or breastfeeding.'
			e) When the maximum recommended daily dose of the medicine provides greater than 80 mg of total caffeine and the medicines is for internal use or oral application, the following warning statements are required on the label:
			- (CAFFLMT) 'Limit the use c caffeine-containing products (including tea and coffee) when taking this product.'
			- (CAFFCYP) 'Caffeine interacts with enzyme CYP1A in the liver. Consult your health professional before taking with other medicines' (or words to that effect).
3705	PAULLINIA PINNATA	A, H	
3706	PAWPAW	E	
3707	PEA	E	
3708	PEA STARCH	E	
3709	РЕАСН	E	
3710	PEANUT	Ε	The medicine requires the following warning statement on the medicine label: - (PEANUT) 'Contains Peanut (or words to that effect).

	3711	PEAR	E
--	------	------	---

## Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
3712	PECAN	Е	
3713	PECTIN	A, E	
3714	PEG-10 DIMETICONE	Ε	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or damaged skin.
			The concentration in the medicine must be no more than 4.0%.
3715	PEG-10 SOYA STEROL	E	Only for use in topical medicines for dermal application.
3716	PEG-100 STEARATE	Е	Only for use in topical medicines for dermal application.
3717	PEG-12 DILAURATE	Е	
3718	PEG-12 DIMETICONE/PPG-20 CROSSPOLYMER	Ε	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.
			The concentration in the medicine must be no more than 2%.
3719	PEG-120 METHYL GLUCOSE DIOLEATE	Е	Only for use in topical medicines for dermal application.
3720	PEG-120 STEARATE	Е	Only for use in topical

785

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			medicines for dermal application.
3721	PEG-15 COCAMINE	Е	Only for use in topical medicines for dermal application.
3722	PEG-150 DISTEARATE	Е	Only for use in topical medicines for dermal application.
3723	PEG-20 ALMOND GLYCERIDES	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.5%.
3724	PEG-20 METHYL GLUCOSE DISTEARATE	Е	Only for use in topical medicines for dermal application.
3725	PEG-20 METHYL GLUCOSE SESQUISTEARATE	Е	Only for use in topical medicines for dermal application.
3726	PEG-20 SORBITAN ISOSTEARATE	Е	Only for use in topical medicines for dermal application.
3727	PEG-20 STEARATE	Е	Only for use in topical medicines for dermal application.

Volume 5

Column 1 Column 2 Column 3 Column 4			
Item	Ingredient name	Purpose	Specific requirements
3728	PEG-25 PABA	A	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must not be more than 10%.
			When used in primary sunscreen products, the following warning statements are required on the label:
			- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and
			- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
3729	PEG-30 DIPOLYHYDROXYSTEARATE	Е	Only for use in topical medicines for dermal application.
3730	PEG-30 STEARATE	Е	Only for use in topical medicines for dermal application.
3731	PEG-35 CASTOR OIL	Е	
3732	PEG-4 DILAURATE	Е	Only for use in topical medicines for dermal application.
3733	PEG-4 LAURATE	Е	Only for use in topical medicines for dermal application. Dioxane and Ethylene oxide

## Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			are mandatory components of PEG-4 laurate. The concentration of Dioxane in the medicine must be no more than 10 mg/kg or 10 mg/L or 0.001%.
			The concentration of Ethylene oxide in the medicine must be no more than 1 mg/kg or 1 mg/L or 0.0001%.
3734	PEG-4 STEARATE	Е	Only for use in topical medicines for dermal application.
3735	PEG-40 CASTOR OIL	Е	
3736	PEG-40 HYDROGENATED CASTOR OIL	Е	
3737	PEG-40 SORBITAN DIISOSTEARATE	Е	Only for use in topical medicines for dermal application.
			Dioxane and Ethylene oxide are mandatory components of PEG-40 sorbitan diisostearate.
			The concentration of Dioxane in the medicine must be no more than 10 mg/kg or 10 mg/L or 0.001%.
			The concentration of Ethylene oxide in the medicine must be no more than 1 mg/kg or 1 mg/L or 0.0001%.
3738	PEG-40 STEARATE	Е	Only for use in topical medicines for dermal application.

## Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
3739	PEG-45/DODECYL GLYCOL COPOLYMER	E	Only for use in topical medicines for dermal application.
3740	PEG-5 GLYCERYL STEARATE	Е	Only for use in topical medicines for dermal application.
3741	PEG-50 STEARATE	Е	Only for use in topical medicines for dermal application.
3742	PEG-55 PROPYLENE GLYCOL OLEATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more thar
3743	PEG-6 LAURAMIDE	Е	0.6%. Only for use in topical medicines for dermal application.
3744	PEG-60 ALMOND GLYCERIDES	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration when used in medicines applied directly to the skin must be no more than 10%.
			The concentration when used in bath oil medicines must be no more than 30%.

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
3745	PEG-60 GLYCERYL ISOSTEARATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 2%.
3746	PEG-60 HYDROGENATED CASTOR OIL	E	Only for use in topical medicines for dermal application.
3747	PEG-7 COCAMIDE	E	Only for use in topical medicines for dermal application.
3748	PEG-7 GLYCERYL COCOATE	E	Only for use in topical medicines for dermal application.
3749	PEG-7 HYDROGENATED CASTOR OIL	Е	Only for use in topical medicines for dermal application.
3750	PEG-75 LANOLIN	Е	Only for use in topical medicines for dermal application.
3751	PEG-75 STEARATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than

Volume 5

Permissible ing	Permissible ingredients and requirements				
Column 1	Column 2	Column 3	Column 4		
Item	Ingredient name	Purpose	Specific requirements		
			1.5%.		
3752	PEG-8 CETYL DIMETHICONE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.		
			The concentration in the medicine must be no more tha 0.0005%.		
3753	PEG-8 DILAURATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.		
			The concentration in the medicine must be no more that 4%.		
3754	PEG-8 DISTEARATE	E	Only for use in topical medicines for dermal application.		
3755	PEG-8 LAURATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.		
			The concentration in the medicine must be no more that 4%.		
			The levels of possible impurities such as ethylene oxide (and related material) must be kept below the level o detection.		

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
3756	PEG-8 PROPYLENE GLYCOL COCOATE	E	Specific requirements
3757	PEG-8 STEARATE	Е	Only for use in topical medicines for dermal application.
3758	PEG-9 POLYDIMETHYLSILOXYETHYL DIMETICONE	E	Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin. The concentration in the medicine must be no more than
3759	PEG/PPG-14/7 DIMETHYL ETHER	Е	3.5%. Only for use in topical
			medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin.
			The concentration in the medicine must be no more than 7%.
3760	PEG/PPG-18/18 DIMETHICONE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 5%.
3761	PELARGONIUM GRAVEOLENS	А, Е, Н	
3762	PELLITORINE	E	Permitted for use only in combination with other permitted ingredients as a

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3763	PELTIGERA CANINA	А, Н	
3764	PENICILLIUM EXPANSUM	A, H	
3765	PENNYROYAL OIL	E	D-Pulegone/Pulegone is a mandatory component of Pennyroyal Oil.
			The concentration of D Pulegone/ Pulegone in the medicine must be no more than 4%.
			Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in the medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in the medicine must be no more than 1%.
			When the medicine is for a use other than topical, the maximum recommended daily dose must be no more than 50 mg of Pennyroyal Oil.
3766	PENTAERYTHRITYL TETRA-DI- T-BUTYL HYDROXYHYDROCINNAMATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

Vol	lume	5
101	unit	~

Permissible ingredients and requirements			
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			The concentration in the medicine must be no more than 0.018%
3767	PENTAERYTHRITYL TETRAISOSTEARATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 61%.
3768	PENTAERYTHRITYL TETRALAURATE	E	Only for use in topical medicines for dermal application.
			The concentration in the medicine must be no more than 80%.
3769	PENTAMETHYLHEPTENONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3770	PENTANE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total

Volume 5

	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			fragrance concentration in a medicine must be no more 1%
3771	PENTASODIUM ETHYLENEDIAMINE TETRAMETHYLENE PHOSPHONATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.1%.
3772	PENTYLENE GLYCOL	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more that
3773	PEPPER BLACK	Е, Н	5%.
3774	PEPPER OIL TERPENELESS	E	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3775	PEPPER WHITE	E, H	
3776	PEPPERMINT AMERICAN EXT.	E	Menthol is a mandatory component of peppermint american ext.
			When the medicine is for topical use for dermal

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			application:
			a) the medicine must not be intended for use in the eye or on damaged skin;
			b) the medicine must not deliver more than 25% total menthol when administered according to the directions for use;
			c) the following warning statement is required on the medicine label:
			- (EYE) Avoid contact with eyes (or words to that effect).
			d) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label:
			- (SKTEST) If you have sensitive skin, test this produc on a small area of skin before applying it to a large area;
			- (IRRIT) If irritation develop discontinue use.
			e) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine labe
			- (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation.
			When the medicine is for internal use, the maximum recommended daily dose mus

## Volume 5

	gredients and requirements		~
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			not contain more than 1 gram of menthol.
3777	PEPPERMINT LEAF DRY	A, E, H	Menthol is a mandatory component of peppermint lea dry.
			When the medicine is for topical use for dermal application:
			(i) the medicine must not be intended for use in the eye or on damaged skin;
			(ii) the medicine must not deliver more than 25% total menthol when administered according to the directions fo use;
			(iii) the following warning statement is required on the medicine label:
			- (EYE) Avoid contact with eyes (or words to that effect).
			(iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label:
			- (SKTEST) If you have sensitive skin, test this produc on a small area of skin before applying it to a large area;
			- (IRRIT) If irritation develop discontinue use.
			(v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the

Volume 5
----------

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			following warning statement is required on the medicine label: – (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation.
			When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.
3778	PEPPERMINT LEAF POWDER	А, Е, Н	Menthol is a mandatory component of peppermint leaf powder.
			When the medicine is for topical use for dermal application:
			(i) the medicine must not be intended for use in the eye or on damaged skin;
			(ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use;
			(iii) the following warning statement is required on the medicine label:
			- (EYE) Avoid contact with eyes (or words to that effect).
			(iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label:

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			sensitive skin, test this product on a small area of skin before applying it to a large area; - (IRRIT) If irritation develops discontinue use.
			<ul> <li>(v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label – (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation.</li> <li>When the medicine is for internal use, the maximum</li> </ul>
3779	PEPPERMINT OIL	А, Е, Н	recommended daily dose must not contain more than 1 gram of menthol. Menthol is a mandatory
5117		Λ, L, Π	component of peppermint oil.
			When the medicine is for topical use for dermal application:
			(i) the medicine must not be intended for use in the eye or on damaged skin;
			(ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use;
			(iii) the following warning statement is required on the medicine label:
			- (EYE) Avoid contact with eyes (or words to that effect).

Vol	lume	5
V UI	unic	J

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			(iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label:
			<ul> <li>- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;</li> <li>- (IRRIT) If irritation develops discontinue use.</li> </ul>
			(v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement i required on the medicine label
			<ul> <li>– (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation.</li> </ul>
			When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.
3780	PEPPERMINT OIL TERPENELESS	Е	Permitted for use only in combination with other permitted ingredients as a flavour proprietary excipient formulation or fragrance proprietary excipient formulation.
			The total flavour proprietary excipient formulation in a medicine must be no more tha 5%.

Volume 5

Column 1	Column 2	Column 3	Column 4
ltem	Ingredient name	Purpose	Specific requirements
			The total fragrance proprietary excipient formulation in a medicine must be no more 1%
			Menthol is a mandatory component of peppermint oil terpeneless.
			When the medicine is for topical use for dermal application:
			i) the medicine must not be intended for use in the eye or on damaged skin;
			ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use;
			<ul><li>iii) the following warning statement is required on the medicine label:</li></ul>
			- (EYE) Avoid contact with eyes (or words to that effect).
			iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label:
			<ul> <li>- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;</li> <li>- (IRRIT) If irritation develop discontinue use.</li> </ul>
			v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement i

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
		-	required on the medicine label
			<ul> <li>– (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation.</li> </ul>
			When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.
3781	PEPPERMINT OIL TERPENES AND TERPENOIDS	E	Permitted for use only in combination with other permitted ingredients as a flavour proprietary excipient formulation.
			The total flavour proprietary excipient formulation in a medicine must be no more than 5%.
			Menthol is a mandatory component of peppermint oil terpenes and terpenoids.
			When the medicine is for topical use for dermal application:
			i) the medicine must not be intended for use in the eye or on damaged skin;
			ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use;
			iii) the following warning statement is required on the medicine label:
			- (EYE) Avoid contact with eyes (or words to that effect).

Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label:
			<ul> <li>- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;</li> <li>- (IRRIT) If irritation develops discontinue use.</li> </ul>
			<ul> <li>v) if the medicine delivers</li> <li>more than 5% total menthol</li> <li>when administered according</li> <li>to the directions for use, the</li> <li>following warning statement is</li> <li>required on the medicine label</li> </ul>
			<ul> <li>– (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation.</li> </ul>
			When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.
3782	PERFLUOROPOLYMETHYLISOP ROPYL ETHER	Е	Only for use in topical medicines for dermal application.
3783	PERHYDRO-3,6-DIMETHYL- BENZO [B] FURAN-2-ONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a

Vol	lume	5
V U	unit	~

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
		i u pose	medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3784	PERILLA FRUTESCENS	А, Е, Н	Rosmarinic acid and vicenin-2 are only permitted for use if the plant part of Perilla frutescens is leaf.
3785	PERILLALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3786	PERLITE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the
			medicine must be no more than 2%.
3787	PERMETHRIN	Е	The concentration of in the medicine must be no more than 2%.
3788	PERSEA AMERICANA	А, Е, Н	

Volume	5
--------	---

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
3789	PERSIC OIL	A, E, H	Amygdalin and Hydrocyanic acid are mandatory components of Persic oil.
			The concentration of amygdalin in the medicine must be no more than 0%.
			The concentration of Hydrocyanic acid in the medicine must be no more thar 1 microgram/kg or 1 microgram/L or 0.0000001%.
3790	PERSICARIA CHINENSIS	A, H	
3791	PERSICARIA TINCTORIA	A, H	
3792	PERSIMMON	Е	
3793	PERU BALSAM	А, Е, Н	
3794	PERU BALSAM OIL	А, Е, Н	
3795	PETITGRAIN MANDARIN OIL	Е	Permitted for use only in combination with other permitted ingredients as a flavour
			The final concentration of the oil in the flavour does not exceed 30%
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%
3796	PETITGRAIN OIL	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more that

Vo	lume	5
۷U	iunic	$\mathcal{I}$

Permissible ingredients and requirements         Column 1       Column 2       Column 3       Column 4				
Item	Ingredient name	Purpose	Specific requirements	
Item .		i ui pose	5%.	
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.	
3797	PETITGRAIN OIL CITRONNIER	Е	<ul> <li>Permitted for use only in combination with other permitted ingredients as part of a fragrance proprietary excipient formulation.</li> <li>When included in a medicine for use on the lips the concentration of petitgrain oil citronnier must be no more than 0.1%.</li> <li>When included in dermal creams for infant use the concentration of petitgrain oil citronnier must be no more than 0.5%</li> <li>The total fragrance proprietary maining for use only in a second second</li></ul>	
			excipient formulation in a medicine must be no more than 1%.	
3798	PETITGRAIN OIL PARAGUAY	А, Е, Н	When used internally, oxedrine is a mandatory component of petitgrain oil paraguay.	
			The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 milligrams.	
3799	PETITGRAIN OIL TERPENELESS	Е	Permitted for use only in combination with other permitted ingredients as a	

Volume 5

Column 1	column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
Item	ingreutent name	1 ul pose	flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more thar 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3800	PETROSELINUM CRISPUM	А, Е, Н	
3801	PEUCEDANUM PRAERUPTORUM	А, Е, Н	
3802	PEUMUS BOLDUS	А, Н	Volatile oil components (of Peumus boldus) is a mandatory component.
			The maximum recommended daily dose must be no more than 100 mg of volatile oil components (of Peumus boldus).
3803	PHALARIS ARUNDINACEA	A, H	
3804	PHALARIS CANARIENSIS	A, H	
3805	PHASEOLUS COCCINEUS	A, H	
3806	PHASEOLUS VULGARIS	A, H	
3807	PHELLINUS ROBINIAE	А, Е, Н	
3808	PHELLODENDRON AMURENSE	А, Е, Н	
3809	PHELLODENDRON CHINENSE	A, H	
3810	PHENACETIN	E	Only for use in topical medicines for dermal application.
			The concentration in the medicine must be no more than 0.1%.

Permissible ingredients and requirements

Column

Item

3811

3812

3813

1	Column 2	Column 3	Column 4
	Ingredient name	Purpose	Specific requirements
	PHENETHYL 2- METHYLBUTYRATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
	PHENETHYL ACETATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
	PHENETHYL ALCOHOL	E	Permitted for use only:
			a) in topical medicines for dermal application; and
			b) for internal use in combination with other permitted ingredients as part of a flavour proprietary excipient

Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2020

formulation.

The total flavour proprietary excipient formulation concentration in a medicine must be no more than 5%.

Volume 5

Permissible ing	Permissible ingredients and requirements			
Column 1	Column 2	Column 3	Column 4	
Item	Ingredient name	Purpose	Specific requirements	
3814	PHENETHYL BENZOATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.	
			The concentration in the medicine must be no more than 6%.	
3815	PHENETHYL DIMETHICONE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.	
			The concentration in the medicine must be no more than 0.2%	
3816	PHENETHYL ISOAMYL ETHER	E	Permitted for use only in combination with other permitted ingredients as a fragrance.	
			If used as in a fragrance the total fragrance concentration in a medicine must be no more than 1%.	
3817	PHENETHYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.	
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.	
			If used in a fragrance the total fragrance concentration in a	

Permissible ingredients and requirements			
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			medicine must be no more 1%.
3818	PHENETHYL ISOVALERATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3819	PHENETHYL PHENYLACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3820	PHENETHYL SALICYLATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Volume	5
--------	---

Permissible ingredients and requirements				
Column 1	Column 2	Column 3	Column 4	
Item	Ingredient name	Purpose	Specific requirements	
3821	PHENOL	Е	Only for use in topical medicines for dermal application.	
			The concentration of phenol in the medicine must be no more than 1%.	
3822	PHENOXYACETALDEHYDE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.	
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.	
3823	PHENOXYETHANOL	E	Only for use in topical medicines for dermal application.	
			The concentration of phenoxyethanol in the preparation must not exceed 15%.	
3824	PHENOXYETHYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.	
			If used in a flavour the total flavour concentration in a medicine must be no more that 5%.	
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%	

810

-	column 2	Column 3	Column 4
Column 1	Column 2		Column 4
<b>Item</b> 3825	Ingredient name PHENOXYETHYLPARABEN	<b>Purpose</b> E	Specific requirements Only for use in topical medicines for dermal application.
3826	PHENYL DIMETHICONE	Е	Only for use in topical medicines for dermal application.
3827	PHENYL TRIMETHICONE	Е	Only for use in topical medicines for dermal application.
3828	PHENYLACETALDEHYDE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3829	PHENYLACETALDEHYDE DIMETHYL ACETAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3830	PHENYLACETALDEHYDE	Е	Permitted for use only in

Volume	5
--------	---

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
	GLYCERYLACETAL		combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3831	PHENYLACETIC ACID	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%
3832	PHENYLALANINE	A, E	When for oral ingestion the medicine requires the following warning statement on the medicine label:
			- (PKU) 'Phenylketonurics are warned that this medicine contains phenylalanine' (or words to that effect).
			When the medicine contains more than 500mg in the maximum recommended daily dose it requires the following warning statement on the medicine label:
			- (PREGNT2) 'Do not use if pregnant or likely to become pregnant'.

volume J	Vol	lume	5
----------	-----	------	---

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
3833	PHENYLBENZIMIDAZOLE SULFONIC ACID	А	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must not be more than 4%.
			When used in primary sunscreen products, the following warning statements are required on the label:
			- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and
			- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
3834	PHENYLETHYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a
			flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3835	PHENYLETHYL CAPROATE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
3836	PHENYLETHYL CAPRYLATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3837	PHENYLETHYL CINNAMATE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3838	PHENYLETHYL FORMATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3839	PHENYLETHYL METHYLETHYL CARBINOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

Permissible ingredients and requirements

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3840	PHENYLETHYL PROPIONATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3841	PHENYLETHYL TIGLATE	Ε	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total
			fragrance concentration in a medicine must be no more than 1%.
3842	PHENYLISOPROPYL DIMETICONE	Ε	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 5%.
3843	PHENYLPROPANOL	E	Only for use in topical medicines for dermal

Volume 5

Volume 5

Column 1	column 2	Column 3	Column 4
Item	Ingredient name		Specific requirements
Item		Purpose	application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.16%.
3844	PHLEUM PRATENSE	А, Н	
3845	PHLOXINE B	E	Permitted for use only as a colour in medicines limited to topical and oral routes of administration.
3846	PHLOXINE B ALUMINIUM LAKE	Е	Permitted for use only as a colour in medicines limited to topical and oral routes of administration.
3847	PHOENIX DACTYLIFERA	А, Е, Н	
3848	PHOSPHATIDYL CHOLINE	E	
3849	PHOSPHOLIPIDS	E	Only for use in topical medicines for dermal application and not intended for use in the eye. The concentration in the medicine must be no more than
3850	PHOSPHORIC ACID	E, H	20%. The concentration in liquid
			medicines must be no more than 15%.
3851	PHOSPHORUS	Н	Only for use as an active homoeopathic ingredient.

817

	redients and requirements	<u> </u>	
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
3852	PHOTINIA SERRULATA	A, H	
3853	PHRAGMITES AUSTRALIS	A, H	
3854	PHYLLANTHUS AMARUS	A, H	
3855	PHYLLANTHUS EMBLICA	А, Е, Н	When used as an excipient, only for use in topical medicines for dermal application. When ascorbic acid is claimed as a component the plant part is restricted to fruit.
3856	PHYLLOSTACHYS NIGRA	A, E, H	
3857	PHYSALIS ALKEKENGI	A, H	
3858	PHYSALIS PUBESCENS	A, H	
3859	PHYTANTRIOL	Е	Only for use in topical medicines for dermal application. The concentration in the
			medicine must be no more than 0.5%.
3860	PHYTOL	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3861	PHYTOLACCA AMERICANA	А, Н	The maximum recommended daily dose of the medicine must contain no more than 1mg of the equivalent dry herb.

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
3862	PHYTOMENADIONE	Α, Ε	
3863	PHYTOSPHINGOSINE	Ε	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.1%.
3864	PHYTOSTERYL/OCTYLDODECY L LAUROYL GLUTAMATE	Ε	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.1%.
3865	PICEA ABIES	A, H	
3866	PICEA MARIANA	A, H	
3867	PICRASMA EXCELSA	А, Е, Н	
3868	PICRORRHIZA KURROA	А, Е, Н	
3869	PIGMENT BLUE 15	Ε	Permitted for use only as a colour for topical and dental use. The concentration in medicine must be no more than 0.003%.
3870	PIGMENT BLUE 15:1	Е	Permitted for use only as a colour for topical use. Only for use in topical medicines for dermal application and not to be included in medicines intended

	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			for use in the eye. The concentration in the medicine must be no more than 0.21%.
3871	PIGMENT GREEN 7	E	Permitted for use only as a colour for topical and dental use. When for dental use, the concentration in the medicine must be no more than 0.003%. When for topical use, the concentration in the medicine must be no more than 0.17%.
3872	PIGMENT RED 4	Е	Permitted for use only as a colour for topical use.
3873	PIGMENT RED 53	E	Permitted for use only as a colour for topical use.
3874	PIGMENT RED 57	Е	Permitted for use only as a colour for topical use.
3875	PIGMENT RED 57 ALUMINIUM LAKE	E	Permitted for use only as a colour for topical use.
3876	PIGMENT RED 57 BARIUM LAKE	E	Permitted for excipient use as a colour in topical medicines for dermal application. Not to be included in medicines intended for use in the eye.
3877	PIGMENT RED 63	Е	Permitted for use only as a colour for topical use.

Volume 5

-	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
3878	PIGMENT WHITE 26	E	Permitted for use only as a colour for topical use.
3879	PIGMENT YELLOW 12	Е	Permitted for use only as a colour for topical use.
3880	PILOCARPUS JABORANDI	А, Н	Pilocarpine is a mandatory component of Pilocarpus jaborandi. The concentration of pilocarpine in the medicine must be no more than 0.025%.
3881	PILOCARPUS MICROPHYLLUS	А, Н	Pilocarpine is a mandatory component of Pilocarpus microphyllus.
			The concentration of pilocarpine in the medicine must be no more than 0.025%.
3882	PILOCARPUS PINNATIFOLIUS	А, Н	Pilocarpine is a mandatory component of Pilocarpus pinnatifolius.
			The concentration of pilocarpine in the medicine must be no more than 0.025%.
3883	PIMENTA FRUIT OIL	А, Е, Н	
3884	PIMENTA LEAF OIL	А, Е, Н	
3885	PIMENTA OFFICINALIS	А, Е, Н	
3886	PIMENTA RACEMOSA	А, Е, Н	When the plant preparation for Pimenta racemosa is an oil and the concentration of this oil in

Volume 5
----------

Column 1	column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			the medicine is more than 25% the nominal capacity of the container must be no more than 25 mL.
			When the plant preparation for Pimenta racemosa is an oil, the concentration of this oil in the medicine is more than 25%, and the nominal capacity of the container is more than 15 mL, a restricted flow insert must be fitted on the container.
			When the plant preparation for Pimenta racemosa is an oil, the concentration of this oil in the medicine is more than 25%, and the nominal capacity of the container is more than 15 mL but no more than 25 mL, a child resistant closure and restricted flow insert must be fitted on the container.
			The medicine requires the following warning statements on the medicine label:
			- (CHILD) 'Keep out of reach of children' (or word to that effect)
			- (NTAKEN) 'Not to be taken'.
3887	PIMPINELLA ANISUM	А, Е, Н	When the plant preparation for Pimpinella anisum is an oil or distillate and the concentration of this oil or distillate in the medicine is more than 50%:
			<ul><li>a) the nominal capacity of the container must be no more than</li><li>50 millilitres; and</li></ul>
			b) a restricted flow insert is must be fitted on the container

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			and
			c) the medicine requires the following warning statement on the medicine label:
			- (CHILD) 'Keep out of reach of children' (or words to that effect).
3888	PIMPINELLA SAXIFRAGA	А, Е, Н	
3889	PINE NEEDLE OIL SCOTCH	A, E, H	
3890	PINE NEEDLE OIL TERPENELESS	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3891	PINE OIL AROMATIC	A, E, H	
3892	PINE OIL PUMILIO	А, Е, Н	
3893	PINEAPPLE	Е	
3894	PINEAPPLE OILS	Е	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a
			fragrance concentration in a medicine must be no more than 1%.
3895	PINELLIA TERNATA	A, H	

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
3896	PINUS CONTORTA	A, E, H	speenie requirements
3897	PINUS ELLIOTTII	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3898	PINUS MASSONIANA	A, E, H	When the plant preparation is oil or distillate the total concentration of Pinus massoniana oil or distillate in the preparation must be no more than 25%.
3899	PINUS MONTICOLA	A, E, H	
3900	PINUS MUGO	A, E, H	
3901	PINUS PALUSTRIS	E	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3902	PINUS PINASTER	A, E, H	When the plant preparation is oil or distillate the total concentration of Pinus pinaster oil or distillate in the preparation must be no more

## Volume 5

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			than 25%.
3903	PINUS PONDEROSA	A, E, H	
3904	PINUS RADIATA	А, Е, Н	
3905	PINUS STROBUS	А, Е, Н	
3906	PINUS SYLVESTRIS	А, Е, Н	
3907	PINUS TABULIFORMIS	А, Е, Н	
3908	PINUS YUNNANENSIS	Е	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more that
3909	PIPENZOLATE BROMIDE	E	Permitted for use only in combination with other permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in a medicine must be no more that 5%.
3910	PIPER CHABA	А, Е, Н	
3911	PIPER CUBEBA	А, Е, Н	
3912	PIPER KADSURA	А, Е, Н	
3913	PIPER LONGUM	А, Е, Н	
3914	PIPER METHYSTICUM	А, Н	Kavalactones (of Piper methysticum) is a mandatory component of Piper methysticum.
			Only for oral use when the

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			dosage form is 'tablet' or 'capsule'; or when the containe type is 'tea bag'.
			When used in oral medicines, the maximum daily dose of kavalactones (of Piper methysticum) must be no more than 250 mg.
			If the dosage form is tablet or capsule then the quantity of kavalactones (of Piper methysticum) must be no more than 125 mg per tablet or capsule.
			Oral medicines containing more than 25 mg of kavalactones (of Piper methysticum) per dose require the following warning statement on the medicine label:
			- (PIPER) 'Not for prolonged use. If symptoms persist - seel advice from a healthcare practitioner. Not recommende for pregnant or lactating women (or words to that effect). May harm the liver'.
			The plant part must be root or rhizome.
			When for oral use, the medicine may only contain dried whole or peeled root or rhizome or aqueous dispersion or aqueous extracts of whole o peeled root or rhizome.
			When for topical use on the rectum, vagina or throat, the medicine may only contain dried whole or peeled root or rhizome or aqueous dispersion

Volume 5

Permissible ingredients and requirements				
Column 1	Column 2	Column 3	Column 4	
Item	Ingredient name	Purpose	Specific requirements	
			or aqueous extracts of whole or peeled root or rhizome. When the container type is tea bag the maximum quantity per tea bag must be no more than 3 grams of dried whole or peeled root or rhizomes.	
3915	PIPER NIGRUM	A, E, H		
3916	PIPER SARMENTOSUM	А, Е, Н		
3917	PIPERIDINE	Ε	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.	
3918	PIPERINE	Ε	Permitted for use only in combination with other permitted ingredients as a flavour proprietary formulation. The total flavour proprietary formulation in a medicine must not be more than 5% and the concentration of piperine in the medicine must not be more than 0.15%.	
3919	PIPERITONE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a	

Column 1	redients and requirements Column 2	Column 3	Column 4
Item			Specific requirements
Item	Ingredient name	Purpose	medicine must be no more than 5%.
3920	PIPERONAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3921	PIPERONYL ACETONE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used as a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used as in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3922	PIPERONYL BUTOXIDE	E	Only for use in topical medicines for dermal application.
			The medicine requires the following warning statement on the medicine label:
			- (PIPBUT) 'Contains piperonyl butoxide' (or words to that effect).

Volume	5
--------	---

Column 1	column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
3923	PIROCTONE OLAMINE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 1% in wash-on/wash-off medicines and 0.5% in leave-on medicines.
3924	PISCIDIA PISCIPULA	A, E, H	
3925	PISTACIA LENTISCUS	А, Е, Н	
3926	PISUM SATIVUM	А, Е, Н	
3927	PLACENTA	Н	Only for use as an active homoeopathic ingredient.
3928	PLANTAGO AFRA	А, Е, Н	The requirement specified in paragraph (a) below applies to a medicine that contains the ingredient that:
			- is listed in the Register on or after 2 March 2020; or
			- is supplied after 2 March 2021.
			(a) When a dose for children is stated and the plant part is flower, seed or pollen, the following warning statement is required on the label:
			- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).
			The requirement specified in paragraph (b) below applies in relation to a medicine that

Permissible ingredients and requirements			
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			contains the ingredient that:
			<ul> <li>is listed in the Register before</li> <li>2 March 2020; and</li> </ul>
			- is supplied before 2 March 2021; and
			- does not have the warning statement (PSYLL1) on the label.
			(b) When a dose for children is stated and the plant part is flower, seed or pollen, the medicine requires the following warning statement on the medicine label:
			- (PSYLL) 'On medical advice' (or words to that effect).
3929	PLANTAGO ARENARIA	А, Н	The requirement specified in paragraph (a) below applies to a medicine that contains the ingredient that:
			- is listed in the Register on or after 2 March 2020; or
			- is supplied after 2 March 2021.
			(a) When a dose for children is stated and the plant part is flower, seed or pollen, the following warning statement is required on the label:
			- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).
			The requirement specified in paragraph (b) below applies in relation to a medicine that contains the ingredient that:
			- is listed in the Register before

Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2020

Volume 5

Volume 5

	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			2 March 2020; and
			- is supplied before 2 March 2021; and
			- does not have the warning statement (PSYLL1) on the label.
			(b) When a dose for children i stated and the plant part is flower, seed or pollen, the following warning statement i required on the label:
			- (PSYLL) 'On medical advice (or words to that effect).
3930	PLANTAGO ASIATICA	А, Н	The requirement specified in paragraph (a) below applies to a medicine that contains the ingredient that:
			- is listed in the Register on or after 2 March 2020; or
			- is supplied after 2 March 2021.
			(a) When a dose for children i stated and the plant part is flower, seed or pollen, the following warning statement i required on the label:
			- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).
			The requirement specified in paragraph (b) below applies ir relation to a medicine that contains the ingredient that:
			- is listed in the Register befor 2 March 2020; and
			- is supplied before 2 March 2021; and

Vol	lume	5
V UI	unit	$\mathcal{I}$

Permissible ingredients and requirements			
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			- does not have the warning statement (PSYLL1) on the label.
			<ul> <li>(b) When a dose for children is stated and the plant part is flower, seed or pollen, the following warning statement is required on the medicine label</li> <li>(PSYLL) 'On medical advice</li> </ul>
			(or words to that effect).
3931	PLANTAGO LANCEOLATA	А, Е, Н	The medicine requires the following warning statement on the medicine label:
			- (CHILD5) 'Use in children under 3 years is not recommended'
			The requirement specified in paragraph (a) below applies to a medicine that contains the ingredient that:
			- is listed in the Register on or after 2 March 2020; or
			- is supplied after 2 March 2021.
			(a) When a dose for children is stated and the plant part is flower, seed or pollen, the following warning statement is required on the label:
			- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).
			The requirement specified in paragraph (b) below applies in relation to a medicine that contains the ingredient that:
			- is listed in the Register befor

Volume 5

	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			2 March 2020; and
			- is supplied before 2 March 2021; and
			- does not have the warning statement (PSYLL1) on the label.
			(b) When a dose for children is stated and the plant part is flower, seed or pollen, the following warning statement is required on the label:
			- (PSYLL) 'On medical advice (or words to that effect).
3932	PLANTAGO MAJOR	A, E, H	The requirement specified in paragraph (a) below applies to a medicine that contains the ingredient that:
			- is listed in the Register on or after 2 March 2020; or
			- is supplied after 2 March 2021.
			(a) When a dose for children i stated and the plant part is flower, seed or pollen, the following warning statement i required on the label:
			- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).
			The requirement specified in paragraph (b) below applies ir relation to a medicine that contains the ingredient that:
			- is listed in the Register befor 2 March 2020; and
			- is supplied before 2 March 2021; and

Vol	lume	5

Column 1	redients and requirements Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
		r ur pose	- does not have the warning statement (PSYLL1) on the label.
			(b) When a dose for children is stated and the plant part is flower, seed or pollen, the following warning statement is required on the label:
			- (PSYLL) 'On medical advice' (or words to that effect).
3933	PLANTAGO OVATA	А, Н	The requirement specified in paragraph (a) below applies to a medicine that contains the ingredient that:
			- is listed in the Register on or after 2 March 2020; or
			- is supplied after 2 March 2021.
			(a) When a dose for children is stated and the plant part is flower, seed or pollen, the following warning statement is required on the label:
			- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).
			The requirement specified in paragraph (b) below applies in relation to a medicine that contains the ingredient that:
			- is listed in the Register before 2 March 2020; and
			- is supplied before 2 March 2021; and
			- does not have the warning statement (PSYLL1) on the label.

Volume 5

Permissible ingredients and requirements			
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			(b) When a dose for children is stated and the plant part is flower, seed or pollen, the medicine requires the following warning statement on the medicine label:
			- (PSYLL) 'On medical advice (or words to that effect).
3934	PLANTAGO SEED DRY	A, H	The requirement specified in paragraph (a) below applies to a medicine that contains the ingredient that:
			- is listed in the Register on or after 2 March 2020; or
			- is supplied after 2 March 2021.
			(a) When a dose for children is stated and the plant part is flower, seed or pollen, the following warning statement is required on the label:
			- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).
			The requirement specified in paragraph (b) below applies in relation to a medicine that contains the ingredient that:
			- is listed in the Register before 2 March 2020; and
			- is supplied before 2 March 2021; and
			- does not have the warning statement (PSYLL1) on the label.
			(b) When a dose for children is stated, the medicine requires

Permissible ing	gredients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			the following warning statement on the medicine label:
			- (PSYLL) 'On medical advice' (or words to that effect).
3935	PLATANUS OCCIDENTALIS	А, Е, Н	
3936	PLATANUS RACEMOSA	A, H	
3937	PLATANUS X ACERIFOLIA	А, Н	
3938	PLATYCODON GRANDIFLORUS	А, Е, Н	
3939	PLECTRANTHUS BARBATUS	А, Е, Н	
3940	PLICATONE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3941	PLUM	Е	
3942	PLUMBAGO EUROPAEA	A, H	
3943	PLUMERIA ALBA	А, Е, Н	
3944	PLUMERIA RUBRA	А, Е, Н	
3945	POA NEMORALIS	A, H	
3946	POA PRATENSIS	A, H	
3947	PODOPHYLLUM PELTATUM	A, H	Podophyllin and podophyllotoxin are mandatory

Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2020

components of Podophyllum

The concentration of podophyllin in the medicine must be no more than 1 mg/kg

or 1 mg/L or 0.0001%.

peltatum.

Volume 5

Column 1	column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			The concentration of podophyllotoxin in the medicine must be no more than 10 mg/kg or 10 mg/L or 0.001%.
3948	POGOSTEMON CABLIN	A, E, H	
3949	POLACRILIN	Е	
3950	POLACRILIN POTASSIUM	Е	
3951	POLAPREZINC	Α	<ul> <li>Only for use in oral medicines.</li> <li>Zinc is a mandatory component of Polaprezinc.</li> <li>The maximum recommended daily dose must be no more than 34 milligrams of zinc sourced from polaprezinc.</li> <li>When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc.</li> <li>When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: <ul> <li>(ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.'</li> <li>OR 'WARNING: Contains zinc</li> </ul> </li> </ul>
3952	POLIGLUSAM	А, Е	which may be dangerous if taken in large amounts or for a long period' (or words to that effect). The average molecular mass o poliglusam must be greater

Vol	lume	5
V UI	unit	$\mathcal{I}$

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
	ingreatent nume	Turpose	than 2 kilodaltons.
			When for internal use, the medicine must not contain more than 1750 milligrams of poliglusam per maximum recommended daily dose.
			When for internal use, the following warning statements are required on the medicine label:
			- (CHITO) 'Poliglusam should be taken at least one hour after any other medication as it may reduce the effect of other medication' (or words to that effect); and
			- (SFOOD) 'Derived from seafood'.
			When for internal use and the dosage form is a powdered preparation, the medicine requires the following warning statements on the medicine label:
			- (DNTPOW) 'Do not take powder alone. Mix with food or fluid'.
			When used as an excipient, only for use in topical medicines for dermal application.
3953	POLIGLUSAM DERIVED FROM ASPERGILLUS NIGER	A, E	When for oral use, the medicine must provide no more than 2000 milligrams of Poliglusam derived from Aspergillus niger per maximum recommended daily dose and requires the following warning statement on the

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			medicine label: - (CHITO) 'Poliglusam should be taken at least one hour after any other medication as it may reduce the effect of other medication' (or words to that effect).
			If the medicine is a powdered dosage form, the medicine also requires the following warning statement on the medicine label:
			- 'Do not take powder alone. Mix with food or fluid.'
			When used as an excipient, Poliglusam derived from Aspergillus niger is only permitted for use in topical medicines for dermal application.
3954	POLLACK-LIVER OIL	Α, Ε	Colecalciferol and Vitamin A are mandatory components of Pollack-liver oil.
			When for use in topical medicines, the concentration o Vitamin A in the medicine must be no more than 1%.
			When for internal use, the maximum daily dose must be no more than 3000 microgram of Retinol Equivalents.
			When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning

Column 1	Column 2	Column 3	Column 4
tem	Ingredient name	Purpose	Specific requirements
			statements on the medicine
			label:
			- (VITA2) 'WARNING: If yo
			are pregnant - or considering
			becoming pregnant - do not take vitamin A supplements
			without consulting your docto
			or pharmacist [or words to tha
			effect].' NOTE: Position this
			warning at the beginning of th
			directions for use.
			- (VITA4) 'WARNING -
			When taken in excess of 3000
			micrograms retinol equivalent
			- Vitamin A can cause birth
			defects.' NOTE: Position this
			warning at the beginning of th directions for use.
			- (VITA3) 'The recommended
			daily amount of Vitamin A
			from all sources is 700
			micrograms retinol equivalent for women and 900
			micrograms retinol equivalent
			for men.'
			When for internal use, the
			maximum recommended daily
			dose must be no more than 25
			micrograms of Vitamin D.
955	POLLEN	E	The medicine requires the
			following warning statement on the medicine label:
			- (POLLEN) 'This medicine
			can cause severe allergic
			reactions' (or words to that
			effect).

## Volume 5

Permissible ingredients and requirements				
Column 1	Column 2	Column 3	Column 4	
Item	Ingredient name	Purpose	Specific requirements	
3956	POLOXAMER	Е	Only for use in topical medicines for dermal application.	
3957	POLOXAMINE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.	
3958	POLOXAMINE 1301	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.	
3959	POLY C10-30 ALKYL ACRYLATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 2%.	
3960	POLYACRYLAMIDE	E	Only for use in topical medicines for dermal application. Acrylamide is a mandatory component of Polyacrylamide.	
			The concentration of Acrylamide in the medicine	

840

-	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			must be no more than 0.01%.
3961	POLYACRYLATE CROSSPOLYMER-6	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.
			The concentration in the medicine must be no more than 2%.
3962	POLYACRYLATE-1 CROSSPOLYMER	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.
			The concentration in the medicine must be no more than 0.4%.
3963	POLYACRYLIC ACID	Е	
3964	POLYAMINO SUGAR CONDENSATE	Е	Only for use in topical medicines for dermal application.
3965	POLYAMINOPROPYL BIGUANIDE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than $0.3\%$ .
3966	POLYBUTENE	Е	Only for use in topical

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			medicines for dermal application.
3967	POLYBUTYLENE GLYCOL/PPG- 9/1 COPOLYMER	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 2%.
3968	POLYCAPROLACTONE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.1%.
3969	POLYDECENE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 6%.
3970	POLYDEXTROSE	E	
3971	POLYDIETHYLSILOXANE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.
			The concentration in the

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
	0	<b>.</b>	medicine must be no more that 5%.
3972	POLYDIMETHYL SILOXANE	E	Permitted for use only in combination with other permitted ingredients as a printing ink. If used in a printing ink the total printing ink concentration in a medicine must be no more than 0.1%
3973	POLYESTER-10	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 1.5%.
3974	POLYESTER-25	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 10%.
3975	POLYESTER-7	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			5%.
3976	POLYESTER-8	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration of Polyester
			8 must be no more than 5%.
3977	POLYETHYLENE	Е	
3978	POLYGALA CHINENSIS	A, H	
3979	POLYGALA SENEGA	A, E, H	Except when used in a medicine containing only homoeopathic preparations, a child resistant closure and restricted flow insert must be fitted onto the container.
3980	POLYGALA SIBIRICA	A, E, H	Only for use when the plant part is root or root bark.
3981	POLYGALA TENUIFOLIA	А	Only for use when the plant part is root or root bark.
3982	POLYGLYCERYL-10 PENTASTEARATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 1.5%.
3983	POLYGLYCERYL-2 CAPRATE	Е	Only for use in topical medicines for dermal

Vol	lume	5
101	unit	~

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			application and not to be included in medicines intended for use on damaged skin or in the eye. The concentration in the medicine must not be more than 0.5%.
3984	POLYGLYCERYL-2 DIISOSTEARATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended
			for use in the eye. The concentration in the medicine must be no more than 3.0%.
3985	POLYGLYCERYL-2 DIPOLYHYDROXYSTEARATE	Е	Only for use in topical medicines for dermal application.
			The concentration in the medicine must be no more than 5%.
3986	POLYGLYCERYL-2 DISTEARATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must not be more than 3%.
3987	POLYGLYCERYL-2 TRIISOSTEARATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			When the concentration of polyglyceryl-2 triisostearate is greater than 3%, the medicine must not be intended for use or damaged skin.
			The concentration in the medicine must not be more than 5%.
3988	POLYGLYCERYL-2-PEG-4 STEARATE	E	Only for use in topical medicines for dermal application.
3989	POLYGLYCERYL-3 BEESWAX	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.
			The concentration in the medicine must be no more than 0.5%.
3990	POLYGLYCERYL-3 DIISOSTEARATE	E	Only for use in topical medicines for dermal application.
3991	POLYGLYCERYL-3 DISTEARATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than $0.5\%$ .
3992	POLYGLYCERYL-3 METHYLGLUCOSE	E	Only for use in topical medicines for dermal

Vol	lume	5
101	unit	~

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
	DISTEARATE		application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 6%.
3993	POLYGLYCERYL-3 POLYDIMETHYLSILOXYETHYL DIMETHICONE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 5.5%.
3994	POLYGLYCERYL-3 POLYRICINOLEATE	Е	
3995	POLYGLYCERYL-3 STEARATE/ISOSTEARATE/DIME R DILINOLEATE CROSSPOLYMER	Ε	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.
			The concentration in the medicine must be no more than 5%.
3996	POLYGLYCERYL-4 DIISOSTEARATE/POLYHYDROX YSTEARATE/SEBACATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than $3\%$ .

volume J	Vo	lume	5
----------	----	------	---

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
3997	POLYGLYCERYL-4 ISOSTEARATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 5%.
3998	POLYGLYCERYL-4 OLEATE	E	Only for use in topical medicines for dermal application.
3999	POLYGLYCERYL-6 POLYRICINOLEATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 1%.
4000	POLYGLYCERYL-6 RICINOLEATE	Е	Only for use in topical medicines for dermal application.
4001	POLYGONATUM MULTIFLORUM	А, Н	
4002	POLYGONATUM OFFICINALE	A, H	
4003	POLYGONATUM SIBIRICUM	A, E, H	
4004	POLYGONUM AVICULARE	A, E, H	When used as an excipient, the medicine is only for use in topical medicines for dermal application and not to be included in medicines intended for use on damaged skin or in the eye.

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			When used as an excipient, the concentration in the medicine must be no more than 0.16%.
4005	POLYGONUM BISTORTA	A, H	
4006	POLYGONUM ODORATUM	A, H	
4007	POLYHYDROXYSTEARIC ACID	Е	Only for use in topical medicines for dermal application.
4008	POLYISOBUTYLENE	E	Only for use when the dosage form is 'chewing gum'. Must comply with:
			a) the Polyisobutylene monograph in the Food Chemicals Codex published by the United States Pharmacopeial Convention, as in force or existing from time to time; and b) the requirements for residual solvents and catalysts in the British Pharmacopeia or the United States Pharmacopeia National Formulary, as in force or existing from time to time.
4009	POLYISOPRENE	Е	Only for use in topical medicines for dermal application.
4010	POLYLIMONENE	Е	Permitted for use only in combination with other permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in a

Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2020

Volume 5

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			medicine must be no more than 5%.
4011	POLYMETHACRYLIC ACID	Е	
4012	POLYMETHYL METHACRYLATE	Е	Only for use in topical medicines for dermal application.
4013	POLYMETHYLSILSESQUIOXAN E	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 3%.
4014	POLYPORUS UMBELLATUS	A, H	
4015	POLYPROPYLENE	Е	Only for use in topical medicines for dermal application.
4016	POLYPROPYLENE GLYCOL	Е	Permitted for use only in combination with other permitted ingredients as part of a flavour or fragrance proprietary excipient formulation.
			When used in a flavour, the total flavour proprietary excipient formulation in a medicine must be no more than 5%.
			When used in a fragrance, the total fragrance proprietary excipient formulation in a medicine must be no more than

Permissible ingredients and requirements				
Column 1	Column 2	Column 3	Column 4	
Item	Ingredient name	Purpose	Specific requirements	
			1%.	
4017	POLYQUATERNIUM-10	Е	Only for use in topical medicines for dermal application.	
4018	POLYQUATERNIUM-11	Е	Only for use in topical medicines for dermal application.	
4019	POLYQUATERNIUM-22	E	Only for use in wash-off topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.	
			The concentration in the medicine must be no more than 2%.	
4020	POLYQUATERNIUM-24	E	Only for use in topical medicines for dermal application.	
4021	POLYQUATERNIUM-28	Е	Only for use in topical medicines for dermal application.	
4022	POLYQUATERNIUM-37	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 2.5%.	

## Volume 5

Column 1	redients and requirements Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4023	POLYQUATERNIUM-4	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must not be more than 0.4%.
4024	POLYQUATERNIUM-44	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.3%.
4025	POLYQUATERNIUM-51	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 5%.
4026	POLYQUATERNIUM-7	Е	Only for use in topical medicines for dermal application.
4027	POLYSILICONE-11	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than

	Permissible ingredients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			2.1%
4028	POLYSILICONE-14	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration of Polysilicone-14 must be no more than 1%.
4029	POLYSILICONE-15	А	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye. The concentration in the
			medicine must not be more than 10%.
			When used in primary sunscreen products, the following warning statements are required on the label:
			- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and
			- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
4030	POLYSILICONE-2	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more that

Volume 5

Permissible ing	gredients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			0.13%.
4031	POLYSORBATE 20	E	
4032	POLYSORBATE 40	Е	
4033	POLYSORBATE 60	Е	
4034	POLYSORBATE 65	Е	
4035	POLYSORBATE 80	Е	
4036	POLYSORBATE 85	E	Only for use in topical medicines for dermal application.
4037	POLYTEF	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more that $0.5\%$ .
4038	POLYURETHANE-34	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.
			The concentration in the medicine must be no more tha 2% in spray applications and 6% in non-spray applications.
4039	POLYURETHANE-62	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on

	gredients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements damaged skin. The concentration in the medicine must be no more than 5%.
4040	POLYVINYL ACETATE	Е	Only permitted for use in medicines that are for oral routes of administration.
4041	POLYVINYL ACETATE PHTHALATE	Е	
4042	POLYVINYL ALCOHOL	Е	
4043	POLYVINYL CHLORIDE	Ε	Only for use in topical medicines for dermal application.
4044	POMEGRANATE	E	
4045	PONCEAU SX	E	Permitted for use only as a colour for topical use.
4046	PONCIRUS TRIFOLIATA	А, Н	When used internally, oxedrine is a mandatory component of Poncirus trifoliata. The quantity of Oxedrine in the maximum recommended daily dose must be no more than 30 mg.
4047	PONGAMOL	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 1%.

Volume	5
--------	---

Permissible ing	Permissible ingredients and requirements				
Column 1	Column 2	Column 3	Column 4		
Item	Ingredient name	Purpose	Specific requirements		
4048	POPPY SEED	E, H			
4049	POPPY SEED OIL	E, H			
4050	POPULUS ALBA	A, H			
4051	POPULUS BALSAMIIFERA	А, Е, Н			
4052	POPULUS CANDICANS	A, H			
4053	POPULUS DELTOIDES	A, H			
4054	POPULUS NIGRA	A, H			
4055	POPULUS TREMULA	A, H			
4056	POPULUS TREMULOIDES	A, H			
4057	PORCINE	Н	Only for use as an active homoeopathic ingredient.		
4058	PORPHYRIDIUM PURPUREUM EXTRACT	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.5%.		
4059	PORTULACA OLERACEA	A, E, H			
4060	POTABLE WATER	Е			
4061	POTASSIUM ACETATE	Е			
4062	POTASSIUM ARSENITE	Н	Only for use as an active homoeopathic ingredient.		
4063	POTASSIUM ASCORBATE	А, Е, Н	When for oral or sublingual use, potassium is a mandatory component of potassium ascorbate.		

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4064	POTASSIUM ASCORBATE DIHYDRATE	А, Е, Н	When for oral or sublingual use, potassium is a mandatory component of potassium ascorbate dihydrate.
4065	POTASSIUM ASCORBYL TOCOPHERYL PHOSPHATE	E	Only for use in topical medicines for dermal application.
4066	POTASSIUM ASPARTATE	А, Е, Н	When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium aspartate.
4067	POTASSIUM ASPARTATE DIHYDRATE	А, Е, Н	If used as an active ingredient and the preparation is intended as a mineral supplementation, potassium is a mandatory component of Potassium aspartate dihydrate. The percentage of potassium from potassium aspartate dihydrate should be calculated based on the molecular weight of potassium aspartate dihydrate.
4068	POTASSIUM ASPARTATE MONOHYDRATE	Α, Ε	If used as an active ingredient and the preparation is intended as a mineral supplementation, potassium is a mandatory component of Potassium aspartate monohydrate. The

Volume 5

	redients and requirements	Calar 2	Colores A
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			percentage of potassium from potassium aspartate
			monohydrate should be
			calculated based on the
			molecular weight of potassium aspartate monohydrate.
4069	POTASSIUM BICARBONATE	E	
4070	POTASSIUM BROMIDE	Н	Only for use as an active
			homoeopathic ingredient.
4071	POTASSIUM CARBONATE	E, H	When used in a solid
			preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.
			When used in a liquid or a
			semi-solid preparation, the pH
			of the preparation must not exceed 11.5.
4072	POTASSIUM CETYL PHOSPHATE	Е	Only for use in topical
	PHOSPHATE		medicines for dermal application.
4073	POTASSIUM CHLORIDE	A, E, H	When for oral use:
			a) potassium is a mandatory
			component of potassium chloride;
			b) the medicine requires the following warning statement on the medicine label:
			- (POTAS) 'Contains
			potassium. If you have kidney
			disease or are taking heart or
			blood pressure medicines - consult your doctor or

Column 1	column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
	0	<b>k</b>	pharmacist before use. Keep out of reach of children.'; and
			c) other than when used for oral rehydration therapy, the concentration must be no more than 550 mg per dosage unit.
			Medicines for use as oral rehydration therapy, are subjec to the following conditions:
			a) the medicine complies with the requirements specified in the British Pharmacopoeia, as in force or existing from time to time, for Oral Rehydration Salts;
			<ul> <li>b) the sodium, potassium and glucose content, and total osmolarity of the solution after it has been prepared according to the instructions on the packet are consistent with the criteria specified by the World Health Organisation (WHO) and the United Nations Children's Fund (UNICEF) in the document 'Expert consultation on oral rehydration salts formulation' 18 July 2001; and</li> <li>c) the medicine requires the warning statements:</li> <li>- (UOAD) 'Use only as</li> </ul>
			directed' - (DIAR3) 'If diarrhoea persists, seek medical advice.'
			When for dental use, the concentration in the medicine must be no more than 3.75%.

Volume	5
--------	---

	gredients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4074	POTASSIUM CITRATE	A, E, H	When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium citrate.
4075	POTASSIUM COCOYL HYDROLYSED COLLAGEN	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 10%.
4076	POTASSIUM COCOYL HYDROLYSED SOY PROTEIN	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.15%.
4077	POTASSIUM DICHROMATE	Н	Only for use as an active homoeopathic ingredient.
4078	POTASSIUM GLUCONATE	А, Е, Н	When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium gluconate.

## Volume 5

Permissible ing	gredients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4079	POTASSIUM GLYCEROPHOSPHATE	A, E, H	When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium glycerophosphate.
4080	POTASSIUM HYDROXIDE	E	The concentration in the medicine must be no more than 5%.
			When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.
			When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.
4081	POTASSIUM HYDROXYCITRA	ΓΕ Α, Η	
4082	POTASSIUM IODATE	А, Н	Iodine is a mandatory component of potassium iodate.
		The percentage of iodine from potassium iodate should be calculated based on the molecular weight of potassium iodate.	
			When for use in adults, the medicine must contain a daily dose of no more than 505 micrograms of potassium iodate.
			When for use in children aged 1-3 years, the medicine must contain a daily dose of no more than 337 micrograms of

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			potassium iodate.
4083	POTASSIUM IODIDE	A, E, H	Iodine is a mandatory component of potassium iodide.
			The percentage of iodine from potassium iodide should be calculated based on the molecular weight of potassium iodide.
			When for internal use, the maximum recommended daily dose of the medicine must contains less than 300 micrograms of iodine.
			When for external use, the concentration of iodine in the medicine (excluding salts derivatives or iodophors) must not exceed 2.5%.
4084	POTASSIUM METABISULFITE	E	Permitted for use only in combination with other permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4085	POTASSIUM METAPHOSPHATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than

	column 2	Column 2	Column 4
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements 0.5%.
			0.570.
4086	POTASSIUM NITRATE	A, H	Only for dental use.
			The concentration in the medicine must be no more than 5%.
4087	POTASSIUM OROTATE	А, Е, Н	When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium orotate.
			When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.
			When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.
4088	POTASSIUM PYROPHOSPHATE	E	Only for oral application, dental or topical use.
			Not to be included in topical medicines intended for use in the eye.
			The concentration in the medicine must be no more than 3%.
4089	POTASSIUM SORBATE	Е	The medicine requires the following warning statement on the medicine label:
			- (SORB8) 'Contains sorbates' (or word to this effect) if medicine contains two or more

Volume 5

	Permissible ingredients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			sorbate sources OR 'Contains [insert the approved name of sorbate source used]' (or words to this effect) if medicine contains one sorbate source.
4090	POTASSIUM STANNATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4091	POTASSIUM STEARATE	Е	Only for use in topical medicines for dermal application.
4092	POTASSIUM SULFATE	A, E, H	When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium sulfate.
			When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.
			When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.
4093	POTATO STARCH	E	
4094	POTENTILLA ANSERINA	А, Н	
4095	POTENTILLA CHINENSIS	A, H	

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4096	POTENTILLA DISCOLOR	А, Н	
4097	POTENTILLA ERECTA	А, Е, Н	
4098	POTENTILLA REPTANS	А, Н	
4099	POTERIUM OFFICINALE	А, Е, Н	
4100	POTERIUM SANGUISORBA	A, H	
4101	POVIDONE	E	
4102	POWDERED CELLULOSE	Е	
4103	PPG-1-PEG-9 LAURYL GLYCOL ETHER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the
			medicine must be no more than 5%.
4104	PPG-12/SMDI COPOLYMER	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 2%.
4105	PPG-15 STEARYL ETHER	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 4%.

Volume 5

Volume	5
--------	---

Permissible ing Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4106	PPG-15 STEARYL ETHER BENZOATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 1.4%.
4107	PPG-17/IPDI/DMPA COPOLYMER	Е	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye or on damaged skin.
			The concentration of PPG- 17/IPDI/DMPA Copolymer in the medicine must be no more than 10%.
4108	PPG-2 LANOLIN ALCOHOL ETHER	Е	Only for use in topical medicines for dermal application.
4109	PPG-2 MYRISTYL ETHER PROPIONATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 5%.
4110	PPG-20 LANOLIN ALCOHOL ETHER	Е	Only for use in topical medicines for dermal application.

## Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4111	PPG-20 METHYL GLUCOSE ETHER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.5%.
4112	PPG-20 METHYL GLUCOSE ETHER DISTEARATE	Е	Only for use in topical medicines for dermal application.
4113	PPG-3 HYDROGENATED CASTOR OIL	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 6%.
4114	PPG-3 MYRISTYL ETHER	Е	Only for use in topical medicines for dermal application.
4115	PPG-5-CETETH-20	Е	Only for use in topical medicines for dermal application.
4116	PPG-5-LAUROMACROGOL 250	Е	Only for use in topical medicines for dermal application.
4117	PRALINE	E	Permitted for use only in combination with other permitted ingredients as a

Volume 5

	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4118	PREGELATINISED MAIZE STARCH	Е	
4119	PREGELATINISED POTATO STARCH	Е	
4120	PREGELATINISED RICE STARCH	E	
4121	PREGELATINISED STARCH	E	
4122	PREGELATINISED WHEAT STARCH	Е	When the route of administration is other than topical or mucosal, gluten is a mandatory component of pregelatinised wheat starch.
4123	PRENYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4124	PRICKLY ASH BARK DRY	A, H	
4125	PRICKLY ASH BARK POWDER	A, H	
4126	PRIMULA VERIS	А, Е, Н	
4127	PRIMULA VULGARIS	A, E, H	

Column 1	column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4128	PRINSEPIA UNIFLORA	A, H	Specific requirements
4129	PROBOSCIDEA PARVIFLORA	A, H	
4130	PROGESTERONE	Н	Only for use as an active homoeopathic ingredient.
4131	PROLINE	A, E	
4132	PROPAN-1-OL	Е	Only for use in:
			- topical medicines for dermal application; or
			- in combination with other permitted ingredients as a flavour proprietary excipient formulation.
			The concentration of propan-1- ol in the medicine must not be more than 18%.
			When used in medicines in combination with other permitted ingredients as a flavour proprietary excipient formulation, the total flavour proprietary excipient formulation in a medicine must not be more than 5%.
4133	PROPANE	Е	Only for use as an excipient propellant ingredient.
4134	PROPANEDIOL	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 10%.

Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2020

Volume 5

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4135	PROPENYL GUAETHOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4136	PROPIONALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%
4137	PROPIONIC ACID	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%

4138

## PROPIONYLLEVOCARNITINE A, H

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
	HYDROCHLORIDE		
4139	PROPOLIS	Α, Ε	Lead is a mandatory component of Propolis.
			The concentration of lead in the medicine must be no more than 0.001%.
			When used topically, the medicine requires the following warning statement on the medicine label: -(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'
			When used for other than for topical, the medicine requires the following warning statement on the medicine label:
			- (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'
4140	PROPOLIS BALSAM	Α, Ε	Lead is a mandatory component of Propolis balsam
			The concentration of lead in the medicine must be no more than 0.001%.
			When used topically, the medicine requires the following warning statement on the medicine label:
			-(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'
			When used for other than for topical, the medicine requires the following warning

Volume 5	V	olu	me	5
----------	---	-----	----	---

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			statement on the medicine label: - (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'
4141	PROPOLIS DRY EXTRACT	Α, Ε	Lead is a mandatory component of Propolis dry extract. The concentration of lead in
			the medicine must be no more than 0.001%.
			When used topically, the medicine requires the following warning statement on the medicine label:
			-(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'
			When used for other than for topical, the medicine requires the following warning statement on the medicine label:
			- (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'
4142	PROPOLIS LIQUID EXTRACT	Α, Ε	Lead is a mandatory component of Propolis liquid extract.
			The concentration of lead in the medicine must be no more than 0.001%.
			When used topically, the

	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			medicine requires the following warning statement on the medicine label:
			-(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'
			When used for other than for topical, the medicine requires the following warning statement on the medicine label:
			- (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'
4143	PROPOLIS RESIN	Α, Ε	Lead is a mandatory component of propolis resin.
			The concentration of lead in the medicine must be no more than 0.001%.
			When used topically, the medicine requires the following warning statement on the medicine label:
			-(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'
			When used for other than for topical, the medicine requires the following warning statement on the medicine label:
			- (PROP2) 'Warning: Propolis may cause allergic reactions. In irritation or swelling of the mouth or throat occurs, discontinue use.'

Volume 5

Permissible ingredients and requirements				
Column 1	Column 2	Column 3	Column 4	
Item	Ingredient name	Purpose	Specific requirements	
4144	PROPOLIS TINCTURE	Α, Ε	Lead is a mandatory component of Propolis tincture	
			The concentration of lead in the medicine must be no more than 0.001%.	
			When used topically, the medicine requires the following warning statement on the medicine label: -(PROP1) 'WARNING:	
			Propolis may cause skin irritation. Test before use'	
			When used for other than for topical, the medicine requires the following warning statement on the medicine label:	
			- (PROP2) 'Warning: Propolis may cause allergic reactions. I irritation or swelling of the mouth or throat occurs, discontinue use.'	
4145	PROPYL ACETATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.	
			If used in a flavour the total flavour concentration in a medicine must be no more tha 5%.	
4146	PROPYL CAPROATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.	
			If used in a flavour the total flavour concentration in a	

Permissible ingredients and requirements				
Column 1	Column 2	Column 3	Column 4	
Item	Ingredient name	Purpose	Specific requirements	
			medicine must be no more than 5%.	
4147	PROPYL GALLATE	Е		
4148	PROPYL HYDROXYBENZOATE	Ε	Medicines containing hydroxybenzoates require the following warning statement on the medicine label: - (TOTBNZ) 'Contains hydroxybenzoates' (or words to this effect) if the medicine contains more than one hydroxybenzoate source OR 'Contains [insert the approved name of hydroxybenzoate used]' (or words to this effect) if product contains one hydroxybenzoate source.	
4149	PROPYLENE CARBONATE	Е	Only for use in topical medicines for dermal application.	
4150	PROPYLENE GLYCOL	Е		
4151	PROPYLENE GLYCOL ALGINATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.	
4152	PROPYLENE GLYCOL DIBENZOATE	Е	Only for use in topical medicines for dermal application only and not to be used in topical medicines	

Volume 5

Permissible ingredients and requirements			
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			intended for use in the eye. The concentration in the medicine must be no more than 20%.
4153	PROPYLENE GLYCOL DIDECANOATE	Е	Only for use in topical medicines for dermal application only and not to be used in topical medicines intended for use in the eye. The concentration in the medicine must be no more that 1%.
4154	PROPYLENE GLYCOL DIOCTANOATE	E	Only for use in topical medicines for dermal application.
4155	PROPYLENE GLYCOL DIOCTANOATE/DIDECANOATE	E	Only for use in topical medicines for dermal application.
4156	PROPYLENE GLYCOL DIPELARGONATE	Е	Only for use in topical medicines for dermal application.
4157	PROPYLENE GLYCOL ISOCETETH-3 ACETATE	Е	Only for use in topical medicines for dermal application only and not to be used in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 1%.
4158	PROPYLENE GLYCOL ISOSTEARATE	E	Only for use in topical medicines for dermal

Permissible ingredients and requirements

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			application.
4159	PROPYLENE GLYCOL MONOLAURATE	Е	Only for use in topical medicines for dermal application.
4160	PROPYLENE GLYCOL MONOSTEARATE	E	Only for use in topical medicines for dermal application.
4161	PROPYLENE GLYCOL MYRISTYL ETHER ACETATE	E	Only for use in topical medicines for dermal application.
4162	PROSOPIS JULIFLORA	A, H	
4163	PROTEASE	Α	Must be derived from Aspergillus oryzae or Aspergillus niger. When the dosage form is undivided, the units 'haemoglobin unit on the tyrosine basis per gram' and 'Thousand haemoglobin units on the tyrosine basis per gram' are permitted. When the dosage form is divided, the units 'haemoglobin units on the tyrosine basis' and 'thousand haemoglobin units on the tyrosine basis' are permitted.
4164	PROTEIN HYDROLYSATE	Е	
4165	PRUNE JUICE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2020

Volume 5

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4166	PRUNE JUICE CONCENTRATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4167	PRUNELLA VULGARIS	A, H	
4168	PRUNUS AFRICANA	A, E, H	Amygdalin and hydrocyanic acid are mandatory components of Prunus africana
			The concentration of Amygdalin in the medicine must be 0%.
			The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4169	PRUNUS ARMENIACA	А, Е, Н	Amygdalin and hydrocyanic acid are mandatory components of Prunus armeniaca and must be declared in the application.
			The concentration of Amygdalin in the medicine must be 0%.
			The concentration of Hydrocyanic acid in the medicine must be no more tha

Column 1	column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			1 microgram/kg or 1 microgram/L or 0.0000001%.
4170	PRUNUS AVIUM	А, Е, Н	Amygdalin and hydrocyanic acid are mandatory components of Prunus avium.
			The concentration of Amygdalin in the medicine must be 0%.
			The concentration of Hydrocyanic acid in the medicine must be no more thar 1 microgram/kg or 1 microgram/L or 0.0000001%.
4171	PRUNUS CERASIFERA	А, Е, Н	Amygdalin and hydrocyanic acid are mandatory components of Prunus cerasifera.
			The concentration of Amygdalin in the medicine must be 0%.
			The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4172	PRUNUS CERASUS	А, Е, Н	Amygdalin and hydrocyanic acid are mandatory components of Prunus cerasus.
			The concentration of Amygdalin in the medicine must be 0%.
			The concentration of Hydrocyanic acid in the medicine must be no more thar 1 microgram/kg or 1

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			microgram/L or 0.0000001%.
4173	PRUNUS DOMESTICA	A, E, H	Amygdalin and hydrocyanic acid are mandatory components of Prunus domestica.
			The concentration of Amygdalin in the medicine must be 0%.
			The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4174	PRUNUS DULCIS	A, E, H	Amygdalin and hydrocyanic acid are mandatory components of Prunus dulcis when the plant part is seed.
			When the plant part is seed, the maximum recommended daily dose must be no more than the equivalent of 1 mg of the dry seed.
			The concentration of Amygdalin in the medicine must be 0%.
			The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4175	PRUNUS HUMILIS	A, E, H	Amygdalin and hydrocyanic acid are mandatory components of Prunus humilis.
			The concentration of Amygdalin in the medicine

Vol	lume	5
• •	unit	~

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			must be 0%.
			The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4176	PRUNUS JAPONICA	A, E, H	Amygdalin and hydrocyanic acid are mandatory components of Prunus japonica.
			The concentration of Amygdalin in the medicine must be 0%.
			The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4177 PRUNUS LAUROCERASUS	А, Е, Н	Amygdalin and hydrocyanic acid are mandatory components of Prunus laurocerasus.	
			The concentration of Amygdalin in the medicine must be 0%.
			The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4178	PRUNUS MUME	A, E, H	Amygdalin and hydrocyanic acid are mandatory components of Prunus mume.
			The concentration of Amygdalin in the medicine

Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
Ittim	Ingreutent name	i ui pose	must be 0%.
			The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4179	PRUNUS PERSICA	A, E, H	Amygdalin and hydrocyanic acid are mandatory components of Prunus persica. The concentration of Amygdalin in the medicine must be 0%.
			The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4180	PRUNUS SALICINA	A, E, H	Amygdalin and hydrocyanic acid are mandatory components of Prunus salicina.
			The concentration of Amygdalin in the medicine must be 0%.
			The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4181	PRUNUS SEROTINA	A, E, H	Amygdalin and hydrocyanic acid are mandatory components of Prunus serotina.
			The concentration of Amygdalin in the medicine must be 0%.
			The concentration of

## Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4182	PRUNUS SPINOSA	А, Е, Н	Amygdalin and hydrocyanic acid are mandatory components of Prunus spinosa.
			The concentration of Amygdalin in the medicine must be 0%.
			The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4183	PRUSSIAN BLUE	Е	Permitted for use only as a colour for topical use.
4184	PSEUDOCYDONIA SINENSIS	A, H	
4185	PSEUDOSTELLARIA HETEROPHYLLA	A, E, H	
4186	PSEUDOTSUGA MENZIESII	A, H	
4187	PSEUDOWINTERA COLORATA	А, Н	Only for use when the plant part is leaf.
4188	PSIDIUM GUAJAVA	А, Е, Н	
4189	PSORALEN (OF CULLEN CORYLIFOLIUM)	Е	
4190	PSORINUM	Н	Only for use as an active homoeopathic ingredient.
4191	PSYLLIUM HUSK DRY	А, Н	The requirement specified in paragraph (a) below applies to

Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			a medicine that contains the ingredient that:
			- is listed in the Register on or after 2 March 2020; or
			- is supplied after 2 March 2021.
			(a) When a dose for children i stated, the following warning statement is required on the label:
			- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).
			The requirement specified in paragraph (b) below applies ir relation to a medicine that contains the ingredient that:
			- is listed in the Register befor 2 March 2020; and
			- is supplied before 2 March 2021; and
			- does not have the warning statement (PSYLL1) on the label.
			(b) When a dose for children i stated, the following warning statement is required on medicine label:
			- (PSYLL) 'On medical advice (or words to that effect).
4192	PSYLLIUM HUSK POWDER	А, Е, Н	The requirement specified in paragraph (a) below applies to a medicine that contains the ingredient that:
			- is listed in the Register on or after 2 March 2020; or
			- is supplied after 2 March

Permissible ingredients and requirements			
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			2021.
			(a) When a dose for children is stated, the following warning statement is required on the label:
			- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).
			The requirement specified in paragraph (b) below applies in relation to a medicine that contains the ingredient that:
			- is listed in the Register before 2 March 2020; and
			- is supplied before 2 March 2021; and
			- does not have the warning statement (PSYLL1) on the label.
			(b) When a dose for children is stated, the following warning statement is required on the label:
			- (PSYLL) 'On medical advice' (or words to that effect).
4193	PSYLLIUM SEED DRY	А, Е, Н	The requirement specified in paragraph (a) below applies to a medicine that contains the ingredient that:
			- is listed in the Register on or after 2 March 2020; or
			- is supplied after 2 March 2021.
			(a) When a dose for children is stated the following warning statement is required on the label:

Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).
			The requirement specified in paragraph (b) below applies in relation to a medicine that contains the ingredient that:
			- is listed in the Register before 2 March 2020; and
			- is supplied before 2 March 2021; and
			- does not have the warning statement (PSYLL1) on the label.
			(b) When a dose for children is stated, the following warning statement is required on the label:
			- (PSYLL) 'On medical advice (or words to that effect).

4194	PTELEA TRIFOLIATA	A, H
4195	PTEROCARPUS MARSUPIUM	A, H
4196	PTEROCARPUS SANTALINUS	A, E, H
4197	PUERARIA LOBATA	A, E, H
4198	PUERARIA MONTANA VAR. LOBATA	А, Е, Н
4199	PULLULAN	E
4200	PUMICE	E
4201	PUMPKIN	E
4202	PUMPKIN SEED	E, H
4203	PUMPKIN SEED OIL	E, H
4204	PUNICA GRANATUM	A, E, H

Vo	lume	5
VU	luine	J

Column 1	column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4205	PURE BEE VENOM	Н	Only for use as an active homoeopathic ingredient.
4206	PURIFIED HONEY	A, E	When the route of administration is oral, the medicine requires the following warning statement on the medicine label:
			- (BABY2) 'Not suitable for infants under the age of twelve months' (or words to that effect).
			When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label:
			- (SUGARS) 'Contains [insert name of sugar]' if medicine contains one sugar OR 'Contains sugars' (or words to that effect) if medicine contains two or more sugars.
			If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label:
			- (LACT) 'Contains lactose' (or words to that effect).
4207	PURIFIED SILICEOUS EARTH	I E, H	

4207	PURIFIED SILICEOUS EARTH	E, H
4208	PURIFIED TALC	E

## Volume 5

Permissible ingredients and requirements			
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4209	PURIFIED WATER	Е	
4210	PVM/MA COPOLYMER	Е	
4211	PVM/MA DECADIENE CROSSPOLYMER	Е	Only for use in topical medicines for dermal application.
4212	PVP/EICOSENE COPOLYMER	E	Only for use in topical medicines for dermal application.
4213	PVP/HEXADECENE COPOLYMER	Е	Only for use in topical medicines for dermal application.
4214	PYRETHRINS	E	<ul> <li>Only for use in topical medicines for dermal application.</li> <li>The concentration in the medicine must be no more than 10%.</li> <li>The medicine requires the following warning statement on the medicine label:</li> <li>- (PYRTH3) 'Contains pyrethrins [insert quantity]' (or words to that effect).</li> </ul>
4215	PYRIDOXAL 5-PHOSPHATE	A, E	Pyridoxine is a mandatory component of Pyridoxal 5- phosphate. The percentage of pyridoxine from pyridoxal 5-phosphate should be calculated based on the molecular weight of pyridoxal 5-phosphate. The maximum recommended daily dose must provide no

	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			more than 200 mg of pyridoxine.
			If the medicine contains more
			than 50 mg and no more than 200 mg of pyridoxine per maximum recommended daily dose the medicine requires the
			following warning statement on the medicine label:
			- (VITB6SX) 'WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].'
4216	PYRIDOXAL 5-PHOSPHATE MONOHYDRATE	А	Pyridoxine is a mandatory component of Pyridoxal 5- phosphate monohydrate.
			The percentage of pyridoxine from pyridoxal 5-phosphate monohydrate should be calculated based on the molecular weight of pyridoxal 5-phosphate monohydrate.
			The maximum recommended daily dose must provide no more than 200 mg of pyridoxine.
			If the medicine contains more than 50 mg and no more than 200 mg of pyridoxine per maximum recommended daily dose the medicine requires the following warning statement on the medicine label:
			- (VITB6SX) 'WARNING - Stop taking this medication if you experience tingling,

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].'
4217	PYRIDOXINE HYDROCHLORIDE	А, Е, Н	When not used as an active homoeopathic ingredient, pyridoxine is a mandatory component of Pyridoxine hydrochloride.
			The percentage of pyridoxine from pyridoxine hydrochloride should be calculated based on the molecular weight of pyridoxine hydrochloride.
			The maximum recommended daily dose must provide no more than 200 mg of pyridoxine.
			If the medicine contains more than 50 mg and no more than 200 mg of pyridoxine per maximum recommended daily dose the medicine requires the following warning statement on the medicine label:
			- (VITB6SX) 'WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].'
4218	PYROGLUTAMIC ACID	Е	
4219	PYROLA DECORATA	A, H	
4220	PYROLIGNEOUS ACID	Е	Permitted for use only in

Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2020

combination with other permitted ingredients as a

-	Permissible ingredients and requirements			
Column 1	Column 2	Column 3	Column 4	
Item	Ingredient name	Purpose	Specific requirements	
			flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.	
4221	PYRROSIA LINGUA	А, Н		
4222	PYRROSIA PETIOLOSA	A, H		
4223	PYRROSIA SHEARERI	A, H		
4224	PYRUS COMMUNIS	А, Е, Н	Arbutin is a mandatory component of Pyrus communis.	
			The concentration of arbutin in the medicine must be no more than 25 mg/Kg or 25mg /L or 0.0025 % unless used on the hair. When for use on hair, the concentration of arbutin in the medicine must be no more than 0.74 %.	
4225	PYRUS PYRIFOLIA	А, Н	Arbutin is a mandatory component of Pyrus pyrifolia. The concentration of arbutin in the medicine must be no more than 25 mg/Kg or 25mg /L or 0.0025 % unless used on the hair. When for use on hair, the concentration of arbutin in the medicine must be no more than 0.74 %.	
4226	PYRUVIC ACID	E	Permitted for use only in combination with other	

Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2020

Volume 5

Volume 5

Permissible ingredients and requirements Column 1 Column 2 Column 3 Column 4				
Item	Ingredient name	Purpose	Specific requirements	
Item		1 ur pose	permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.	
4227	QUASSIA	Е	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.	
4228	QUASSIA AMARA	A, E, H		
4229	QUASSIA WOOD JAMAICAN DRY	А, Н		
4230	QUASSIA WOOD JAMAICAN POWDER	А, Н		
4231	QUATERNIUM-15	E	Only for use in topical medicines for dermal application.	
4232	QUATERNIUM-18 BENTONITE	E	Only for use in topical medicines for dermal application.	
4233	QUATERNIUM-18 HECTORITE	E	Only for use in topical medicines for dermal application.	
4234	QUATERNIUM-52	Е	Only for use in wash-on/wash- off topical medicines for dermal application and not to	

892

Permissible ing	Permissible ingredients and requirements				
Column 1	Column 2	Column 3	Column 4		
Item	Ingredient name	Purpose	Specific requirements		
			be included in medicines intended for use in the eye.		
			The concentration in the medicine must be no more than 1%.		
			Not be used in medicines in which N-nitroso compounds may be formed.		
4235	QUATERNIUM-80	Е	Only for use in topical medicines for dermal application and not to be		

4236	QUERCETIN	А	
4237	QUERCETIN DIHYDRATE	А	
4238	QUERCUS ACUTISSIMA	А, Н	
4239	QUERCUS ALBA	А, Е, Н	
4240	QUERCUS PALUSTRIS	А, Н	
4241	QUERCUS ROBUR	А, Н	
4242	QUERCUS RUBRA	А, Н	
4243	QUERCUS VIRGINIANA	А, Н	
4244	QUILLAIA DRY	А, Н	
4245	QUILLAIA POWDER	А, Е, Н	
4246	QUILLAJA SAPONARIA	А, Н	
4247	QUINCE	Е	
4248	QUININE ARSENITE	Н	Only for use as an active homoeopathic ingredient.
			Quinine is a mandatory

Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2020

Volume 5

included in medicines intended

for use in the eye.

2.5%.

The concentration in the medicine must be no more than

Volume 5

Permissible ingredients and requirements				
Column 1	Column 2	Column 3	Column 4	
Item	Ingredient name	Purpose	Specific requirements	
			component of Quinine arsenite The maximum recommended daily dose must be no more than 50 mg of quinine.	
4249	QUININE SULFATE DIHYDRATE	Н	Only for use as an active homoeopathic ingredient. Quinine is a mandatory component of quinine sulfate dihydrate. The maximum recommended daily dose must be no more than 50 mg of quinine.	
4250	QUINOLINE YELLOW	E	Permitted for use only as a colour for oral and topical use.	
4251	QUINOLINE YELLOW ALUMINIUM LAKE	Е	Permitted for use only as a colour for oral and topical use.	
4252	QUISQUALIS INDICA	A, H		
4253	R-ALPHA LIPOIC ACID	А		
4254	RACEMENTHOL	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.	
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.	
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.	
4255	RACEMIC CAMPHOR	E, H	Only for use as an active	

V	പ	lume	5
v	U	unit	J

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			homoeopathic or excipient ingredient. In solid and semi solid preparations, the concentratior of camphor must be no more than 12.5%.
			In liquid preparations other than essential oils, the concentration of camphor mus be no more than 2.5%.
			In essential oil preparations, if the concentration of camphor is more than 2.5% but less than of equal to 10%, and the nominal capacity of the container is less than 25 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label:
			- (CHILD) 'Keep out of reach of children' (or words to that effect); and
			- (NTAKEN) 'Not to be taken' In essential oil preparations, if the concentration of camphor is more than 10%, and the nominal capacity of the container is less than 15 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label:
			- (CHILD) 'Keep out of reach of children' (or words to that effect); and
			- (NTAKEN) 'Not to be taken'

Volume 5

	gredients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			In essential oil preparations, if the concentration of camphor is more than 10%, and the nominal capacity of the container is more than 15 millilitres but less than or equa to 25 millilitres, the medicine must have a restricted flow insert and child resistant closure fitted on the container and include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken' If the concentration of campho is more than 2.5%, the nomina capacity of the container must be no more than 25 millilitres.
4256	RADISH	Е	
4257	RAISIN JUICE CONCENTRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a
			medicine must be no more than 5%.
4258	RANUNCULUS BULBOSUS	А, Н	
4259	RANUNCULUS FICARIA	А, Н	
4260	RANUNCULUS TERNATUS	А, Н	
4261	RAPE SEED OIL	A, E, H	Allyl isothiocyanate is a mandatory component of rape seed oil when the plant part is

Vo	lume	5
۷U	iunic	$\mathcal{I}$

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			seed. The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.
4262	RAPHANUS SATIVUS	А, Н	
4263	RASPBERRY	Е	
4264	RASPBERRY BRANDY	Е	Permitted for use only in combination with other permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4265	RASPBERRY DISTILLATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4266	RASPBERRY ESSENCE	E	Permitted for use only in combination with other permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4267	RASPBERRY JUICE	E	Permitted for use only in

volume J	Vo	lume	5
----------	----	------	---

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
	CONCENTRATE		combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4268	RAUWOLFIA SERPENTINA	А, Н	The concentration of equivalent dry Rauwolfia serpentina in the medicine must be no more than 10mg/Kg or 10mg/L or 0.001%.
4269	RAUWOLFIA SERPENTINA DRY	А, Н	The concentration of Rauwolfia Serpentina Dry in the medicine must be no more than 10mg/Kg or 10mg/L or 0.001%.
4270	RAUWOLFIA SERPENTINA POWDER	А, Н	The concentration of Rauwolfia Serpentina Powder in the medicine must be no more than 10mg/Kg or 10mg/L or 0.001%.
4271	RED 27	Е	Permitted for use only as a colour in medicines limited to topical and oral routes of administration.
			The concentration in the medicine must be no more than 0.5%.
4272	RED 27 ALUMINIUM LAKE	Е	Permitted for use only as a colour in medicines limited to topical and oral routes of administration.

	column 2	Colum- 2	Column 4
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements The concentration in the medicine must be no more than
4273	RED ANT	Н	0.5%. Only for use as an active
407.4		A. 11	homoeopathic ingredient.
4274	RED CLOVER FLOWER DRY	A, H	
4275	RED CLOVER FLOWER POWDER	А, Н	
4276	RED CORAL	Н	Only for use as an active homoeopathic ingredient.
4277	RED DEER	А	
4278	RED MERCURIC IODIDE	Н	Only for use as an active homoeopathic ingredient.
4279	RED MERCURIC OXIDE	Н	Only for use as an active homoeopathic ingredient.
4280	RED MERCURIC SULFIDE	Н	Only for use as an active homoeopathic ingredient.
4281	REHMANNIA GLUTINOSA	A, E, H	
4282	REL-1-((1R,2S)-1,2,3,4,5,6,7,8- OCTAHYDRO-1,2,8,8- TETRAMETHYL-2- NAPHTHALENYL)-1-ETHANONE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4283	RESORCINOL	Е	Permitted for use only in combination with other

Volume 5

	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4284	RESORCINOL DIMETHYLETHER	Е	Permitted for use only in combination with other permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4285	RESVERATROL	А	Only permitted for use in medicines that are for oral routes of administration.
			The maximum recommended daily dose of the medicine must not contain more than 15 milligrams of resveratrol.
			The following warning statements are required on the medicine label:
			- (RESVER) 'Resveratrol may affect the way some medicines work, including Warfarin. Consult your health professional before taking with other medicines (or words to that effect).';
			<ul> <li>- (PREGNT) 'Not recommended for use by pregnant and lactating women (or words to that effect)'; and</li> <li>- (CHILD2) 'Not suitable for children'.</li> </ul>

Column 1	redients and requirements Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
		, F	
4286	RETINOL	Α, Ε	Vitamin A is a mandatory component of retinol.
			When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.
			When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.
			When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:
			- (VITA2) 'WARNING: If you are pregnant - or considering becoming pregnant - do not take Vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].' NOTE: Position this warning at the beginning of the directions for use.
			<ul> <li>- (VITA4) 'WARNING -</li> <li>When taken in excess of 3000 micrograms retinol equivalents</li> <li>- Vitamin A can cause birth defects.' NOTE: Position this warning at the beginning of the directions for use.</li> </ul>
			- (VITA3) 'The recommended daily amount of Vitamin A from all sources is 700

## Volume 5

Permissible ing	gredients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			micrograms retinol equivalent for women and 900 micrograms retinol equivalent for men.'
4287	RETINOL ACETATE	Α, Ε	Vitamin A is a mandatory component of retinol acetate.
			When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.
			When for internal use, the maximum daily dose must be no more than 3000 microgram of Retinol Equivalents.
			When preparations for interna use in adults contain more that 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:
			- (VITA2) 'WARNING: If yo are pregnant - or considering becoming pregnant - do not take Vitamin A supplements without consulting your docto or pharmacist [or words to tha effect].' NOTE: Position this warning at the beginning of th directions for use.
			<ul> <li>- (VITA4) 'WARNING -</li> <li>When taken in excess of 3000 micrograms retinol equivalent</li> <li>Vitamin A can cause birth defects.' NOTE: Position this warning at the beginning of th</li> </ul>

Vo	lume	5
۷U	iunic	$\mathcal{I}$

<b>C 1</b>			
Column 1	Column 2	Column 3	Column 4
ltem	Ingredient name	Purpose	Specific requirements
			directions for use. - (VITA3) 'The recommended daily amount of Vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.'
1288	RETINOL PALMITATE	A, E	<ul> <li>Vitamin A is a mandatory component of retinol palmitate.</li> <li>When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.</li> <li>When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.</li> <li>When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label: <ul> <li>(VITA2) 'WARNING: If you are pregnant - or considering becoming pregnant - do not take Vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].' NOTE: Position this warning at the beginning of the directions for use.</li> <li>(VITA4) 'WARNING -</li> </ul></li></ul>

Volume 5

	contract and requirements		Colore 4
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements micrograms retinol equivalents - Vitamin A can cause birth defects.' NOTE: Position this warning at the beginning of the directions for use.
			- (VITA3) 'The recommended daily amount of Vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.'
4289	REYNOUTRIA JAPONICA	A, E, H	When used as an excipient, only for use in topical medicines for dermal application.
4290	RHAMNOSE	E	Permitted for use only in combination with other permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4291	RHAMNUS CATHARTICA	A, H	When the route of administration is oral, Hydroxyanthracene derivatives is a mandatory component of Rhamnus cathartica. When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			label: - (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX2) 'Prolonged use may cause serious bowel problems'; and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed a a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect).
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the

Volume 5

Permissible ingredients and requirements			
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX1) 'Drink plenty of water' (or words to that effect) and
			- (LAX2) 'Prolonged use may cause serious bowel problems'
4292	RHAMNUS FRANGULA	А, Н	Glucofrangulins calculated as glucofrangulin A is a mandatory component of Rhamnus frangula.
			When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX2) 'Prolonged use may cause serious bowel problems' and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed a

Vol	lume	5
101	unit	~

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect)
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 1 mg of hydroxyanthracene derivatives and is promoted of marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX1) 'Drink plenty of water' (or words to that effect) and
			- (LAX2) 'Prolonged use may cause serious bowel problems

4293	RHATANY ROOT DRY	A, H	
4294	RHATANY ROOT POWDER	A, H	
4295	RHEUM OFFICINALE	А, Е, Н	The plant part must not be leaf.

Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			When the route of administration is oral, Hydroxyanthracene derivative calculated as rhein is a mandatory component of Rheum officinale.
			When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX2) 'Prolonged use may cause serious bowel problems and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed a a laxative, the medicine requires the following warnin statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect)
			When not promoted or marketed as laxative, the medicine requires the following warning statements

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			<ul> <li>When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:</li> <li>- (CHILD3) 'Use in children under 12 years is not recommended';</li> </ul>
			- (LAX1) 'Drink plenty of water' (or words to that effect); and
			- (LAX2) 'Prolonged use may cause serious bowel problems'.
4296	RHEUM PALMATUM	A, E, H	The plant part must not be leaf.
			<ul> <li>When the route of administration is oral,</li> <li>Hydroxyanthracene derivatives calculated as rhein is a mandatory component of Rheum palmatum.</li> <li>When used in oral medicines, if the maximum recommended daily dose contains more than</li> </ul>
			10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine

Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX2) 'Prolonged use may cause serious bowel problems and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcard professional before taking this product' (or words to that effect).
			When promoted or marketed a a laxative, the medicine requires the following warnin statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect)
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 1 mg of hydroxyanthracene derivatives and is promoted of marketed as laxative, the

Vol	lume	5
V UI	unit	$\mathcal{I}$

Column 1	column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
		- u pose	medicine requires the following warning statements on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended'; - (LAX1) 'Drink plenty of
			water' (or words to that effect); and
			- (LAX2) 'Prolonged use may cause serious bowel problems'
4297	RHEUM RHAPONTICUM	A, E, H	The plant part must not be leaf When the route of administration is oral, Hydroxyanthracene derivatives is a mandatory component of Rheum rhaponticum. When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended'; - (LAX2) 'Prolonged use may cause serious bowel problems';
			and - (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that

Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			effect).
			When promoted or marketed a a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect).
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX1) 'Drink plenty of water' (or words to that effect) and
			- (LAX2) 'Prolonged use may cause serious bowel problems'
4298	RHEUM TANGUTICUM	А, Н	The plant part must not be leaf When the route of

Vo	lume	5
VU.	unit	$\mathcal{I}$

Column 1	redients and requirements Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			administration is oral, Hydroxyanthracene derivatives calculated as rhein is a mandatory component of Rheum tanguticum.
			When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX2) 'Prolonged use may cause serious bowel problems' and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed a a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect).
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 1 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX1) 'Drink plenty of water' (or words to that effect) and
			- (LAX2) 'Prolonged use may cause serious bowel problems'
4299	RHODAMINE B	Е	Permitted for use only as a colour for topical use.
4300	RHODINOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more tha 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%

# Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4301	RHODINYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour.
			If used as a flavour the total flavour concentration in a medicine must be no more than 5%.
4302	RHODIOLA ROSEA	А	Only for use in oral medicines.
			Only available for use when the plant preparation is dry root powder, dry root powder as an aqueous extract or dry root powder as a hydroethanolic extract with no more than 70% ethanol v/v.
4303	RHODODENDRON AUREUM	A, H	
4304	RHODODENDRON FERRUGINEUM	А, Н	Arbutin is a mandatory component of Rhododendron ferrugineum.
			The concentration of arbutin in the medicine must be no more than 25 mg/Kg or 25mg /L or 0.0025 % unless used on the hair.
			When for use on hair, the concentration of arbutin in the medicine must be no more than 0.74 %.
4305	RHODODENDRON MOLLE	А, Н	The maximum recommended daily dose of the medicine must be no more than 1mg of the dry herbal material.

Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4306 RHUBARB	RHUBARB	E, H	When the route of administration is oral, Hydroxyanthracene derivatives is a mandatory component of Rhubarb.
		When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:	
		- (CHILD3) 'Use in children under 12 years is not recommended';	
			- (LAX2) 'Prolonged use may cause serious bowel problems' and
		- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).	
		When promoted or marketed a a laxative, the medicine requires the following warning statement on the medicine label:	
			- (LAX1) 'Drink plenty of water' (or words to that effect).
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			<ul> <li>- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and</li> <li>- (LAX4) 'This product may have laxative effect'.</li> <li>When used in oral medicines, if the maximum recommended daily dose contains less than 10</li> </ul>
			mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX1) 'Drink plenty of water' (or words to that effect); and
			- (LAX2) 'Prolonged use may cause serious bowel problems'.
4307	RHUBARB ROOT DRY	A, H	When the route of administration is oral, Hydroxyanthracene derivatives calculated as rhein is a mandatory component of rhubarb root dry.
			When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not

# Volume 5

Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			recommended';
			- (LAX2) 'Prolonged use may cause serious bowel problems' and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed a a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect)
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 1 mg of hydroxyanthracene derivatives and is promoted on marketed as laxative, the medicine requires the following warning statements

Permissible ingredients and requirements

	Volume 5
Column 3	Column 4
Purpose	Specific requirements
	- (CHILD3) 'Use in children

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			<ul> <li>- (CHILD3) 'Use in children under 12 years is not recommended';</li> <li>- (LAX1) 'Drink plenty of water' (or words to that effect); and</li> </ul>
			- (LAX2) 'Prolonged use may cause serious bowel problems'.
4308	RHUBARB ROOT POWDER	А, Н	When the route of administration is oral, Hydroxyanthracene derivatives calculated as rhein is a mandatory component of rhubarb root powder.
			When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX2) 'Prolonged use may cause serious bowel problems'; and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed as a laxative, the medicine

Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect)
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			<ul> <li>- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and</li> <li>- (LAX4) 'This product may have laxative effect'.</li> </ul>
			When used in oral medicines, if the maximum recommended daily dose contains less than 1 mg of hydroxyanthracene derivatives and is promoted of marketed as laxative, the medicine requires the following warning statements on the medicine label: - (CHILD3) 'Use in children
			under 12 years is not recommended';
			- (LAX1) 'Drink plenty of water' (or words to that effect and
			- (LAX2) 'Prolonged use may cause serious bowel problems

4309	RHUS AROMATICA	Α, Ε, Η	
4310	RHUS CHINENSIS	А, Н	
4311	RHUS GLABRA	А, Е, Н	
4312	RHUS VENENATA	Н	Only for use as an active

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			homoeopathic ingredient.
4313	RIBES GROSSULARIA	А, Е, Н	
4314	RIBES NIGRUM	А, Е, Н	
4315	RIBOFLAVIN	Α, Ε	
4316	RIBOFLAVIN SODIUM PHOSPHATE	A, E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label: - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
4317	RIBOFLAVIN TETRAACETATE	E	Only for use in topical medicines for dermal application.
4318	RIBOFLAVINE	A, E	
4319	RIBOFLAVINE SODIUM PHOSPHATE	Α, Ε	
4320	RIBONUCLEIC ACID	E	Only for use in topical medicines for dermal application.
4321	RIBOSE	A	Only for use in oral medicines. When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar,

## Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label:
			- (SUGARS) 'Contains [insert name of sugar]' if medicine contains one sugar OR 'Contains sugars' (or words to that effect) if medicine contains two or more sugars.
			If one of the sugars is lactose then the medicine also require the following warning statement on the medicine label:
			- (LACT) 'Contains lactose' (or words to that effect).

4322	RICE	E	
4323	RICE BRAN	Е	
4324	RICE BRAN OIL	Е	
4325	RICE BRAN WAX	А, Е, Н	
4326	RICE STARCH	Е	
4327	RICE VINEGAR	Е	
4328	RICE WINE	E	Ethanol is a mandatory component of Rice wine. When the concentration of ethanol in the medicine is more than 3%, the medicine requires the following warning statement on the medicine label: - (ETHAN) 'Contains ethanol' or 'contains alcohol'

V	പ	lume	5
v	U	unit	J

Permissible ingredients and requirements			
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4329	RICINOLEIC ACID	Ε	Only for use in topical medicines for dermal application.
4330	RICINUS COMMUNIS	А, Н	Only for use when the plant part must be seed and the plan preparation is oil fixed.
4331	ROBINIA PSEUDOACACIA	A, E, H	When the herbal substance is derived from plant parts other than the leaf or flower, the maximum recommended daily dose of the medicine must be no more than 1 mg of the dry herbal material.
4332	ROHDEA JAPONICA	А, Н	The maximum recommended daily dose must be no more than the equivalent of 1mg of the dry herbal material.
4333	ROSA ARVENSIS	A, E, H	
4334	ROSA CANINA	A, E, H	
4335	ROSA CYMOSA	A, E, H	
4336	ROSA EGLANTERIA	A, E, H	
4337	ROSA GALLICA	А, Е, Н	
4338	ROSA LAEVIGATA	A, E, H	
4339	ROSA MULTIFLORA	А, Е, Н	
4340	ROSA ROXBURGHII FRUIT EXTRACT	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more tha

Volume 5

Permissible ing	Permissible ingredients and requirements			
Column 1	Column 2	Column 3	Column 4	
Item	Ingredient name	Purpose	Specific requirements	
			0.002%.	
4341	ROSA RUGOSA	A, E, H		
4342	ROSA VILLOSA	А, Е, Н		
4343	ROSA X CENTIFOLIA	А, Е, Н		
4344	ROSA X DAMASCENA	А, Е, Н		
4345	ROSANA	Ε	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more thar 1%.	
4346	ROSE ABSOLUTE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.	
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.	
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.	
4347	ROSE FRUIT FRESH	А, Е, Н		
4348	ROSE HIP	E		
4349	ROSE OIL	А, Е, Н		
4350	ROSE OXIDE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.	

Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2020

If used in a flavour the total

Vol	lume	5
101	unit	~

Permissible ing	gredients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4351	ROSEMARY OIL	А, Е, Н	Safrole is a mandatory component of Rosemary oil.
			When for internal use then the concentration of safrole in the medicine must be no more than $0.1\%$ .
			When for topical use then the concentration of safrole in the medicine must be no more than 1%.
4352	ROSMARINUS OFFICINALIS	А, Е, Н	Camphor and cineole are mandatory components of Rosmarinus officinalis.
			In solid and semi solid preparations, the concentration of camphor must be no more than 12.5%.
			In liquid preparations other than essential oils or distillates, the concentration of camphor must be no more than 2.5%.
			When the concentration of cineole in the preparation is more than 25%, the nominal capacity of the container must not be more than 25 millilitres.
			In liquid preparations other than essential oils or distillates when the concentration of cineole in the preparation is more than 25% and the

Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			nominal capacity of the container is more than 15 millilitres but less than or equa to 25 millilitres, the medicine must have a child resistant closure and restricted flow insert fitted on the container and include the following warning statements on the medicine label:
			- (CHILD) 'Keep out of reach of children' (or words to that effect); and
			- (NTAKEN) 'Not to be taken'
			In liquid preparations other than essential oils or distillates when the concentration of cineole in the preparation is more than 25% and the nominal capacity of the container is no more than 15 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and
			- (NTAKEN) 'Not to be taken' If the concentration of campho is more than 2.5%, the nomina capacity of the container must be no more than 25 millilitres.

4353	ROYAL JELLY	Α, Ε	10-Hydroxy-2-decenoic acid is
			a mandatory component of

Volume	5
volume	$\sim$

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
		-	Royal jelly.
			The medicine requires the following warning statements on the medicine label:
			- (CHILD2) 'Not suitable for children'
			- (ROYJ) 'Not to be taken by asthma and allergy sufferers' in 3 mm type, prominent on front and 'This product contains royal jelly which has been reported to cause severe allergic reactions and in rare cases fatalities, especially in asthma and allergy sufferers'.
4354	ROYAL JELLY FRESH	Α, Ε	10-Hydroxy-2-decenoic acid is a mandatory component of Royal jelly fresh.
			The medicine requires the following warning statements on the medicine label:
			- (CHILD2) 'Not suitable for children'
			- (ROYJ) 'Not to be taken by asthma and allergy sufferers' in 3 mm type, prominent on front and 'This product contains royal jelly which has been reported to cause severe allergic reactions and in rare cases fatalities, especially in asthma and allergy sufferers'.
4355	ROYAL JELLY LYOPHILISED	Α, Ε	10-Hydroxy-2-decenoic acid is a mandatory component of Royal jelly lyophilised.
			The medicine requires the following warning statements

Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			on the medicine label:
			- (CHILD2) 'Not suitable for children'
			- (ROYJ) 'Not to be taken by asthma and allergy sufferers' in 3 mm type, prominent on front and 'This product contains royal jelly which has been reported to cause severe allergic reactions and in rare cases fatalities, especially in asthma and allergy sufferers'.
4356	RUBBER NATURAL	Е	Only for use in topical medicines for dermal application.
4357	RUBIA CORDIFOLIA	A, H	
4358	RUBIA TINCTORUM	A, H	
4359	RUBUS CHINGII	A, H	
4360	RUBUS CORCHORIFOLIUS	A, H	
4361	RUBUS COREANUS	А, Е, Н	
4362	RUBUS FRUTICOSUS	А, Е, Н	
4363	RUBUS IDAEUS	А, Е, Н	
4364	RUBUS OCCIDENTALIS	А, Е, Н	
4365	RUBUS PARVIFOLIUS	A, H	
4366	RUBUS ROSIFOLIUS	A, H	
4367	RUDBECKIA HIRTA	A, H	
4368	RUE OIL	A, H	
4369	RUM	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4370	RUMEX ACETOSA	A, H	
4371	RUMEX ACETOSELLA	A, H	
4372	RUMEX CONGLOMERATUS	A, H	
4373	RUMEX CRISPUS	А, Е, Н	
4374	RUMEX PULCHER	A, H	
4375	RUMEX SCUTATUS	A, H	
4376	RUSCUS ACULEATUS	A, H	
4377	RUTA GRAVEOLENS	А, Е, Н	
4378	RUTOSIDE	A, E	
4379	RYE	Е	Gluten is a mandatory component of Rye when the route of administration is other than topical and mucosal.
4380	RYE BRAN	E	Gluten is a mandatory component of Rye bran when the route of administration is other than topical and mucosal.
4381	S-ISOPROPYL 3- METHYLTHIOCROTONATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4382	SABINENE HYDRATE	E	Permitted for use only in

Volume 5

Column 1	column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			combination with other permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4383	SACCHARIDE ISOMERATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin.
			The concentration in the medicine must be no more than 3.66%.
4384	SACCHARIN	Е	When the medicine is for oral use, the following warning statement is required on the medicine label:
			- (SACCH) 'Contains saccharin' (or words to that effect).
4385	SACCHARIN SODIUM	Е	The medicine requires the following warning statement on the medicine label:
			- (SACCH) 'Contains saccharin' (or words to that effect).
			When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
4386	SACCHAROMYCES CEREVISIAE	Α, Ε	When for topical use, the concentration in the medicine must be no more than 1%.
4387	SACCHAROMYCES CEREVISIAE (BOULARDII)	А	
4388	SACCHAROMYCES CERVISIAE POLYSACCHARIDES	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 1%.
4389	SACCHAROMYCES/ZINC FERMENT	E	Only for use in topical medicines for dermal application.
4390	SACCHARUM OFFICINARUM	А, Е, Н	
4391	SAFFLOWER OIL	А, Е, Н	
4392	SAFFRON	Ε	Permitted for use only as a colour for either topical use or with an oral route of administration.
4393	SAGE LEAF DRY	А, Е, Н	Thujone is a mandatory component of Sage leaf dry. The concentration of thujone in the medicine must be no more

Volume 5

	redients and requirements	~ ~ ~ ~	~
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			than 4%.
4394	SAGE LEAF POWDER	А, Н	Thujone is a mandatory component of Sage leaf powder.
			The concentration of thujone in the medicine must be no more than 4%.
4395	SAGE OIL DALMATIAN	А	Thujone is a mandatory component of Sage oil dalmatian.
			The concentration of thujone in the medicine must be no more than 4%.
			When the concentration of Sage oil dalmatian in the medicine is more than 10% and the nominal capacity of the container is no more than 15 mL, a restricted flow insert and child resistant closure must be fitted on the container and the medicine requires the following warning statements on the medicine label:
			- (CHILD) 'Keep out of reach of children' (or word to that effect)
			- (NTAKEN) 'Not to be taken'
4396	SAGE OIL SPANISH	A, E, H	
4397	SALICORNIA EUROPAEA EXTRACT	Ε	Only for use in topical medicines for dermal use and not to be included in medicines intended for use in the eye or on damaged skin.
			The concentration in the

Permissible ing	gredients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			medicine must be no more than 0.002%.
4398	SALICYLALDEHYDE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than
			5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4399	SALICYLIC ACID	E, H	Only for use in topical medicines for dermal application.
			The concentration in the medicine must be no more than 40%.
4400	SALIX ALBA	A, E, H	
4401	SALIX DAPHNOIDES	A, H	
4401	SALIX DISCOLOR	А, Н	
4402	SALIX FRAGILIS	А, Н	
4403	SALIX NIGRA	A, H	
4405	SALIX PURPUREA	А, Н	
4406	SALSOLA KALI	A, H	
4407	SALVIA CHINENSIS	А, Н	
4408	SALVIA FRUTICOSA	A, H	
4409	SALVIA HISPANICA	A, E, H	

Volume	5
--------	---

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4410	SALVIA LAVANDULAEFOLIA	A, H	
4411	SALVIA MILTIORRHIZA	A, H	
4412	SALVIA OFFICINALIS	А, Е, Н	Thujone is a mandatory component of Salvia officinalis.
			The concentration of thujone ir the medicine must be no more than 4%.
4413	SALVIA SCLAREA	А, Е, Н	
4414	SAMBUCUS CANADENSIS	A, H	
4415	SAMBUCUS EBULUS	A, H	
4416	SAMBUCUS NIGRA	А, Е, Н	
4417	SANDALWOOD OIL EAST INDIAN	А, Е, Н	
4418	SANGUINARIA CANADENSIS	Н	Only for use as an active homoeopathic ingredient.
			The potency must be more than 4X.
4419	SANICULA EUROPAEA	A, H	
4420	SANTALUM ALBUM	A, E, H	
4421	SANTALUM SPICATUM	А, Е, Н	The route of administration must be topical or inhalation.
			The plant preparation must be oil.
			The plant part must be root or stem wood including heartwood.
4422	SAPINDUS MUKOROSSI	А, Н	
4423	SAPONARIA OFFICINALIS	A, H	

Column 1	redients and requirements Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4424	SAPOSHNIKOVIA DIVARICATA	A, H	Specific requirements
4425	SARCOSINE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.5%.
4426	SARGASSUM FUSIFORME	А, Н	Iodine is a mandatory component of Sargassum fusiforme.
			Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less.
			Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
4427	SARGASSUM SILIQUASTRUM	А, Н	Iodine is a mandatory component of Sargassum
			siliquastrum. Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less.
			Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4428	SASSAFRAS ALBIDUM	А, Н	Safrole is a mandatory component of Sassafras albidum. When for internal use then the
			concentration of safrole in the medicine must be no more than 0.1%.
			When for topical use then the concentration of safrole in the medicine must be no more than 1%.
4429	SATUREIA HORTENSIS	А, Н	
4430	SATUREIA MONTANA	A, H	
4431	SAUROPUS SPATULIFOLIUS	A, H	
4432	SAURURUS CHINENSIS	A, H	
4433	SAUSSUREA COSTUS	A, H	
4434	SAVORY OIL SUMMER	A, H	
4435	SAXIFRAGA GRANULATA	А, Е, Н	
4436	SAXIFRAGA STOLONIFERA	Ε	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must not be more than 0.0816%.
4437	SCAPHIUM SCAPHIGERUM	A H	
		A, H	
4438	SCHEFFLERA HEPTAPHYLLA	A, H	
4439	SCHINOPSIS QUEBRACHO- COLORADO	А, Н	
4440	SCHINUS MOLLE	A, H	

## Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4441	SCHINUS MOLLE OIL	E	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4442	SCHISANDRA CHINENSIS	А, Е, Н	
4443	SCHIZONEPETA TENUIFOLIA	А, Е, Н	
4444	SCHOENOCAULON OFFICINALE	А, Н	The maximum recommended daily dose must contain no more than the equivalent of 1mg of the dry herbal material.
4445	SCLAREOL	E	Permitted for use only in combination with other permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4446	SCLAREOLIDE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4447	SCLERANTHUS ANNUUS	A, H	
4448	SCLEROTIUM GUM	Е	Only for use in topical medicines for dermal

Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			application.
4449	SCOPOLIA CARNIOLICA	А, Н	The concentration of equivalent dry Scopolia carniolica in the medicine must be no more than 10mg/Kg or 10mg/L or 0.001%.
4450	SCROPHULARIA NINGPOENSIS	A, H	
4451	SCROPHULARIA NODOSA	A, H	
4452	SCURRULA PARASITICA VAR. GRACILIFLORA	A, H	
4453	SCUTELLARIA BAICALENSIS	А, Е, Н	
4454	SCUTELLARIA BARBATA	A, H	
4455	SCUTELLARIA LATERIFLORA	А, Е, Н	
4456	SEA WHIP EXTRACT	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.02%.
4457	SEC BUTYL 3-METHYLBUT-2- ENETHIOATE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4458	SEC-BUTYL THIOISOVALERATE	E	Permitted for use only in combination with other

Permissible ing	gredients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4459	SECALE CEREALE	А, Н	Gluten is a mandatory component of Secale cereale when the plant part is seed and the route of administration is other than topical and mucosal.
4460	SEDUM ACRE	А, Н	
4461	SELAGINELLA TAMARISCINA	A, H	
4462	SELENICEREUS GRANDIFLORUS	А, Е, Н	
4463	SELENIUM	Н	Only for use as an active homoeopathic ingredient.
			Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose. When for oral use, the medicine requires the following warning statement on the medicine label: - (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.'

### Volume 5

## Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4464	SELENOCYSTEINE	А	Selenium is a mandatory component of Selenocysteine for oral and sublingual use.
			Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.
			When for oral use, the medicine requires the following warning statement on the medicine label:
			- (SELE) 'This medicine contains selenium which is toxic in high doses.
			A daily dose of 150 mcg for adults of selenium from dietar supplements should not be exceeded.'
4465	SELENOMETHIONINE	А	Selenium is a mandatory component of Selenomethionine for oral and sublingual use.
			Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.
			When for oral use, the medicine requires the following warning statement on the medicine label:
			- (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micograms for adults of selenium from dietar supplements should not be exceeded.'

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4466	SELF-EMULSIFYING GLYCERYL MONOSTEARATE	E	
4467	SEMECARPUS ANACARDIUM	А, Н	When the plant part is other than seed, the maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material.
4468	SEMOLINA	Е	
4469	SEMPERVIVUM TECTORUM	А, Н	
4470	SENEGA ROOT DRY	A, H	
4471	SENEGA ROOT POWDER	А, Н	
4472	SENNA ALEXANDRINA	А, Н	<ul> <li>When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna alexandrina.</li> <li>When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:</li> <li>- (CHILD3) 'Use in children under 12 years is not recommended';</li> </ul>
			<ul> <li>- (LAX2) 'Prolonged use may cause serious bowel problems and</li> <li>- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare</li> </ul>

Volume 5

Column 1	Column 2	Column 3	Column 4
tem	Ingredient name	Purpose	Specific requirements
			professional before taking this product' (or words to that effect).
			When promoted or marketed a a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect)
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 1 mg of hydroxyanthracene derivatives and is promoted of marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX1) 'Drink plenty of water' (or words to that effect) and
			- (LAX2) 'Prolonged use may cause serious bowel problems

Vol	lume	5
V U	unit	$\mathcal{I}$

	gredients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4473	SENNA FRUIT ALEXANDRIAN DRY	А, Н	When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna fruit alexandrian dry.
			When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX2) 'Prolonged use may cause serious bowel problems'; and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect).
			When not promoted or marketed as laxative, the medicine requires the following warning statements

Volume 5

i ei illissibie illg	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX1) 'Drink plenty of water' (or words to that effect); and
			- (LAX2) 'Prolonged use may cause serious bowel problems'.
4474	SENNA FRUIT ALEXANDRIAN POWDER	А, Н	When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna fruit alexandrian powder. When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

<b>X</b> 7 - 1	_
Volume	Э

Column 1	redients and requirements Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
		I	under 12 years is not recommended'; - (LAX2) 'Prolonged use may cause serious bowel problems and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcard professional before taking this product' (or words to that effect).
			When promoted or marketed a a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect)
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 1 mg of hydroxyanthracene derivatives and is promoted on marketed as laxative, the medicine requires the
			medicine requires the following warning statements

Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX1) 'Drink plenty of water' (or words to that effect) and
			- (LAX2) 'Prolonged use may cause serious bowel problems'
4475	SENNA FRUIT TINNEVELLY DRY	А, Н	When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna fruit tinnevelly dry.
			When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX2) 'Prolonged use may cause serious bowel problems' and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

Vo	lume	5
VU.	unit	$\mathcal{I}$

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect)
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 1 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX1) 'Drink plenty of water' (or words to that effect) and
			- (LAX2) 'Prolonged use may cause serious bowel problems'
4476	SENNA FRUIT TINNEVELLY POWDER	А, Н	When for oral or sublingual, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of

Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			Senna fruit tinnevelly powder.
			When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX2) 'Prolonged use may cause serious bowel problems' and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed a a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect)
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

Volume 5
----------

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			<ul> <li>- (LAX4) 'This product may have laxative effect'.</li> <li>When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:</li> <li>- (CHILD3) 'Use in children under 12 years is not recommended';</li> <li>- (LAX1) 'Drink plenty of water' (or words to that effect); and</li> <li>- (LAX2) 'Prolonged use may cause serious bowel problems'.</li> </ul>
4477	SENNA LEAF DRY	A, H	<ul> <li>When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna leaf dry.</li> <li>When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label: <ul> <li>(CHILD3) 'Use in children under 12 years is not recommended';</li> <li>(LAX2) 'Prolonged use may cause serious bowel problems'; and</li> </ul> </li> </ul>

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed a a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect)
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]';
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 1 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX1) 'Drink plenty of water' (or words to that effect)

	gredients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			and - (LAX2) 'Prolonged use may cause serious bowel problems'.
4478	SENNA LEAF POWDER	A, H	When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna Leaf Powder.
			When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX2) 'Prolonged use may cause serious bowel problems' and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed a a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect)

Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 1 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX1) 'Drink plenty of water' (or words to that effect) and
			- (LAX2) 'Prolonged use may cause serious bowel problems'
4479	SENNA OCCIDENTALIS	А, Н	Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna occidentalis when the route of administration is oral administration.
			When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine

Vol	lume	5
101	unit	~

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			requires the following warning statements on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX2) 'Prolonged use may cause serious bowel problems' and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' [or words to that effect].
			When promoted or marketed a a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' [or words to that effect]
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 1 mg of hydroxyanthracene

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			derivatives and is promoted or marketed as laxative, the medicine the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended;
			- (LAX1) 'Drink plenty of water' [or words to that effect] and
			- (LAX2) 'Prolonged use may cause serious bowel problems'
4480	SENNA TORA	А, Н	When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna tora.
			When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX2) 'Prolonged use may cause serious bowel problems' and
			<ul> <li>- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this</li> </ul>

Vc	olume	5
v c	nume	10

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			product' (or words to that effect).
			When promoted or marketed a a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect)
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 1 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX1) 'Drink plenty of water' (or words to that effect) and
			- (LAX2) 'Prolonged use may cause serious bowel problems'
4481	SEPIA	Н	Only for use as an active

# Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			homoeopathic ingredient.
4482	SEQUOIA SEMPERVIRENS	А, Н	
4483	SEQUOIADENDRON GIGANTEUM	А, Н	
4484	SERENOA REPENS	A, H	
4485	SERINE	A, E	
4486	SERUM ANGUILLAE	Н	Only for use as an active homoeopathic ingredient.
4487	SESAME OIL	А, Е, Н	
4488	SESAME SEED	Е	
4489	SESAMUM INDICUM	А, Е, Н	
4490	SETARIA ITALICA	А, Н	
4491	SHARK CALCIUM CHONDROITIN SULFATE	А	
4492	SHARK CARTILAGE	Α, Ε	The medicine requires the following warning statement on the medicine label:
			- (SHARK) 'Children, pregnant or breastfeeding women, and those who have recently had a heart attack, surgery or a major accident should not consume this product without medical advice' (or words to that effect)
4493	SHARK CHONDROITIN SULFATE	A, E	When used as an excipient: - only for use in topical medicines for dermal application; - not to be included in
			medicines intended for use in the eye; and

Column 1	redients and requirements Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
		1	- the concentration in the medicine must be no more thar 0.001%.
4494	SHARK POTASSIUM CHONDROITIN SULFATE	А	
4495	SHARK SODIUM CHONDROITIN SULFATE	Α, Ε	<ul> <li>When used as an excipient:</li> <li>only for use in topical medicines for dermal application;</li> <li>not to be included in medicines intended for use in the eye; and</li> <li>the concentration in the medicine must be no more thar</li> </ul>
4496	SHARK-LIVER OIL	А, Е	0.001%. Vitamin A and Colecalciferol are mandatory components of Shark-liver oil.
			When for internal use, the maximum recommended daily dose must be no more than 25 micrograms of Vitamin D. When for use in topical
			medicines, the concentration o Vitamin A in the medicine must be no more than 1%. When for internal use, the
			maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.
			When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided

Volume 5

Volume 5

Column 1	Column 2	Column 3	Column 4
ltem	Ingredient name	Purpose	Specific requirements
			requires the following warnin statements on the medicine label: - (VITA2) 'WARNING: If you are pregnant - or considering becoming pregnant - do not take vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].' NOTE: Position this warning at the beginning of the directions for use. - (VITA4) 'WARNING - When taken in excess of 3000 micrograms retinol equivalent - vitamin A can cause birth defects.' NOTE: Position this warning at the beginning of the directions for use. - (VITA3) 'The recommended daily amount of vitamin A from all sources is 700 micrograms retinol equivalent for women and 900 micrograms retinol equivalent for men.'
4497	SHEA BUTTER	Е	
4498	SHEA BUTTER UNSAPONIFIABLES	Е	Only for use in topical medicines for dermal application.
4499	SHELLAC	Е	
4500	SHEPHERD'S PURSE HERB DRY	A, H	
4501	SHEPHERD'S PURSE HERB POWDER	A, H	
4502	SHERRY WINE	Е	Permitted for use only in combination with other

Permissible ingredients and requirements

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4503	SIGESBECKIA ORIENTALIS	А, Е, Н	
4504	SILICA	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4505	SILICA DIMETHYL SILYLATE	Ε	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than
			4%.
4506	SILICA SILYLATE	E	Only for use in topical medicines for dermal application.
4507	SILICIFIED MICROCRYSTALLINE CELLULOSE	E	Only for use when the route of administration is other than inhalation.
4508	SILICON DIOXIDE	A, E, H	Only for use when the route of administration is other than inhalation.

Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2020

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4509	SILICONE QUATERNIUM-8	Е	Only for use in wash-off topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 2.5%.
			The medicine requires the following warning statement on the medicine label:
			- (EYE) 'Avoid contact with eyes' (or words to that effect).
4510	SILVER	Н	Only for use as an active homoeopathic ingredient.
			The concentration in the medicine must be no more than 1%.
4511	SILVER BEET	E, H	
4512	SILVER BOROSILICATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine should be no more than 0.6%.
			Silver is a mandatory component of Silver borosilicate when the route of administration is topical.
			The concentration of silver in the medicine must be no more than 1%.

Permissible ingredients and requirements				
Column 1	Column 2	Column 3	Column 4	
Item	Ingredient name	Purpose	Specific requirements	
4513	SILVER NITRATE	Н	Only for use as an active homoeopathic ingredient.	
4514	SILYBUM MARIANUM	А, Е, Н		
4515	SIMABA CEDRON	А, Н		
4516	SIMETHICONE	Е		
4517	SIMMONDSIA CHINENSIS	А, Е, Н		
4518	SINAPIS ALBA	А, Н	Allyl isothiocyanate is a mandatory component of Sinapis alba when the plant part is seed. The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.	

SINAPIS ARVENSIS	А, Н	
SINOMENIUM ACUTUM	А, Н	
SIPHONESTEGIA CHINENSIS	A, H	
SIRAITIA GROSVENORII	А, Е, Н	
SISYMBRIUM OFFICINALE	А, Н	
SKATOLE	Ε	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
		If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
	SINOMENIUM ACUTUM SIPHONESTEGIA CHINENSIS SIRAITIA GROSVENORII SISYMBRIUM OFFICINALE	SINOMENIUM ACUTUMA, HSIPHONESTEGIA CHINENSISA, HSIRAITIA GROSVENORIIA, E, HSISYMBRIUM OFFICINALEA, H

Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2020

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4525	SKIPJACK-LIVER OIL	Α, Ε	Vitamin A and Colecalciferol are mandatory components of Shark-liver oil.
			When for internal use, the maximum recommended daily dose must be no more than 25 micrograms of Vitamin D.
			When for use in topical medicines, the concentration o Vitamin A in the medicine must be no more than 1%.
			When for internal use, the maximum daily dose must be no more than 3000 microgram of Retinol Equivalents.
			When preparations for interna use in adults contain more tha 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:
			- (VITA2) 'WARNING: If yo are pregnant - or considering becoming pregnant - do not take vitamin A supplements without consulting your docto or pharmacist [or words to tha effect].' NOTE: Position this warning at the beginning of th directions for use.
			<ul> <li>- (VITA4) 'WARNING -</li> <li>When taken in excess of 3000 micrograms retinol equivalent</li> <li>- vitamin A can cause birth defects.' NOTE: Position this warning at the beginning of th</li> </ul>

Column 1	column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements directions for use.
			- (VITA3) 'The recommended daily amount of vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.'
4526	SLIPPERY ELM BARK DRY	A, H	
4527	SLIPPERY ELM BARK POWDER	А, Е, Н	
4528	SMILAX ARISTOLOCHIIFOLIA	A, H	
4529	SMILAX CHINA	A, H	
4530	SMILAX GLABRA	A, H	
4531	SMILAX OFFICINALIS	А, Е, Н	
4532	SMILAX ORNATA	А, Е, Н	
4533	SMOKE EXTRACT	Е	Permitted for use only in combination with other permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4534	SODIUM ACETATE	Е	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label: - (SODIUM) 'The recommended daily dose of this medicine contains [state

# Volume 5

Volume 5

	column 2	Calary 2	Column 4
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements quantity and units] of sodium (or words to that effect).'
4535	SODIUM ACETYLATED HYALURONATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the
			medicine must be no more than 1%.
4536	SODIUM ACID CITRATE	A, E, H	When used as an active ingredient, only for use in oral medicines.
			When used as an active, only for use in oral medicines.
			When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:
			- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
4537	SODIUM ACRYLATES COPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.8%.

Permissible ingredients and requirements

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4538	SODIUM ACRYLATES CROSSPOLYMER-2	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.
			The concentration in the medicine must be no more than $0.7 \%$ (w/w).
4539	SODIUM ACRYLOYDIMETHYLTAURATE/ VP CROSSPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the
			medicine must be no more than $2\%$ (w/w).
4540	SODIUM ALGINATE	Е	
4541	SODIUM ASCORBATE	А, Е, Н	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:
			- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
4542	SODIUM ASCORBYL PHOSPHATE	Е	Only for use in topical medicines for dermal

### Volume 5

# Volume 5

	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			application and not to be included in medicines intended for use in the eye.
			When used in a sunscreen, the concentration in the medicine must be no more than 0.1%.
			When used in products other than sunscreens, the concentration in the medicine must be no more than 0.5%.
4543	SODIUM ASCORBYL/CHOLESTERYL PHOSPHATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 5%.
4544	SODIUM BENZOATE	Ε	Medicines containing benzoates require the following warning statement on the medicine label: - (TBNZO8) 'Contains benzoates' (or words to this effect) if the medicine contains two or more benzoate sources or 'Contains [insert the approved name of benzoate used]' (or words to this effect) if product contains one benzoate source.
			When for oral or sublingual us and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			label: - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
4545	SODIUM BETA-HYDROXY- BETA-METHYLBUTYRATE	А, Н	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label: - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4546	SODIUM BETA-HYDROXY- BETA-METHYLBUTYRATE MONOHYDRATE	А, Н	
4547	SODIUM BICARBONATE	Α, Ε	<ul> <li>When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:</li> <li>- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'</li> <li>When used as an active ingredient, the medicine may</li> </ul>

Volume 5

Column 1	Column 2	Column 3	Column 4
tem	Ingredient name	Purpose	Specific requirements
			only be for oral rehydration salts in powdered and effervescent tablet dosage forms.
			Medicines for use as oral rehydration therapy are subjec to the following conditions:
			a) the medicine complies with the requirements specified in the British Pharmacopoeia, as in force or existing from time to time, for Oral Rehydration Salts;
			b) the sodium content and tota osmolarity of the solution after it has been prepared according to the instructions on the packet are consistent with the criteria specified by the World Health Organisation (WHO) and the United Nations Childrens Fund (UNICEF) in the document 'Expert consultation on oral rehydration salts formulation 18 July 2001.'
			c) the medicine requires the following warning statements on the medicine label:
			- (UOAD) 'Use only as directed.'
			- (DIAR) 'If diarrhoea persists for more than 6 hours in infan under 6 months - 12 hours in children under 3 years - 24 hours in children aged 3-6 years or 48 hours in adults and children over 6 years - seek medical advice (or words to that effect).'

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
		Turpose	persists, seek medical advice.'
4548	SODIUM BISULFITE	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:
			- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
			Medicines containing sulfites salts require the following warning statement on the medicine label:
			- (SULF) 'Contains sulfites' (or words to this effect) if medicine contains two or more sulfite sources or 'Contains (insert the approved name of sulfites used)' (or words to this effect) if medicine contains one sulfite source.
4549	SODIUM BROMIDE	Н	Only for use as an active homoeopathic ingredient.
4550	SODIUM C14-16 OLEFIN SULFONATE	Е	Only for use in topical medicines for dermal application.
4551	SODIUM CARBOMER	Е	Only for use as an excipient in topical medicines for dermal application.

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4552	SODIUM CARBONATE	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:
			- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4553	SODIUM CARBONATE MONOHYDRATE	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:
			- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
4554	SODIUM CARBOXYMETHYL BETAGLUCAN	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.005%.

	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4555	SODIUM CARRAGEENAN	Ε	
4556	SODIUM CASEINATE	Ε	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4557	SODIUM CETOSTEARYL SULFATE	Е	Only for use in topical medicines for dermal application.
4558	SODIUM CHLORIDE	A, E, H	
4559	SODIUM CHONDROITIN SULFATE	Α, Ε	When used as an excipient ingredient:
			<ul> <li>a) only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye;</li> </ul>
			b) the concentration in the medicine must not be more than 0.001%.
			When used as an active ingredient:
			a) the route of administration must only be oral;
			b) the maximum daily dose must not provide more than 1,200 mg of sodium chondroitin sulfate;
			c) the following statements must be included on the

Volume	5
--------	---

Column 1	column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
		-	medicine label: - (ADULT) 'Adults only' (or words to that effect);
			<ul> <li>(PREGNT) 'Not</li> <li>recommended for use by</li> <li>pregnant and lactating women'</li> <li>(or words to that effect).</li> </ul>
4560	SODIUM CITRATE	Α, Ε	Only for oral use when used as an active ingredient.
			When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:
			- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4561	SODIUM CITRATE DIHYDRATE	Α, Ε	Only for oral use when used as an active ingredient.
			When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:
			- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
Item		T ut pose	Specific requirements
4562	SODIUM COCO PG-DIMONIUM CHLORIDE PHOSPHATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.05%.
4563	SODIUM COCOAMPHOACETATE	E	Only for use in topical medicines for dermal application.
4564	SODIUM COCOYL SARCOSINATE	E	Only for use in topical medicines for dermal application.
4565	SODIUM CYCLAMATE	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:
			- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4566	SODIUM DEHYDROACETATE	E	Only for use in topical medicines for dermal application.
4567	SODIUM DNA	Е	Only for use in topical

Volume 5

	culture 2		Colorer 4
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.1%.
4568	SODIUM DODECYLBENZENESULFONAT E	Е	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 30%.
4569	SODIUM ERYTHORBATE	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label: - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4570	SODIUM ETHYL HYDROXYBENZOATE	E	
4571	SODIUM FLUORIDE	А, Е, Н	Fluoride is a mandatory component of Sodium fluoride. Only for use when the route of administration is dental and the dosage form is pastes, powders or gels for dental hygiene. When used as an active

Column 1	Column 2	Column 3	Column 4
ltem	Ingredient name	Purpose	Specific requirements
		i ui pose	ingredient, it is subject to the following conditions:
			a) Only for use in combination with at least one other listable therapeutically active ingredient.
			b) The concentration of fluoride ion must be no more than 1,500 mg/kg.
			When the concentration of fluoride ion is more than 1000 mg/kg, the medicine requires the following statements on th medicine label:
			- (DNTSW) 'Do not swallow.'
			- (CHILD4) 'Do not use [this product/insert name of produc in children 6 years of age or less.'
			When for oral or sublingual us and the total amount of sodiur from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:
			- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
4572	SODIUM FUMARATE	E	When for oral or sublingual us and the total amount of sodium
			and the total amount of sodiur from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine

Column 1	column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
Item		1 ui pose	label:
			- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4573	SODIUM GLYCEROPHOSPHATE	A, E, H	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label: - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
4574	SODIUM HYALURONATE	Е	Only for use in topical medicines for dermal application.
4575	SODIUM HYDROGENATED TALLOW GLUTAMATE	Е	Only for use in topical medicines for dermal application.
4576	SODIUM HYDROXIDE	Ε	The concentration in the medicine must be no more than 5%. When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			statement on the medicine label: - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect). When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5. When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.
4577	SODIUM HYDROXYCITRATE	А	
4578	SODIUM HYDROXYETHYL ACRYLATE/ACRYLOYLDIMETH YL TAURATE COPOLYMER	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 1.5%.
4579	SODIUM HYDROXYMETHYLGLYCINATE	Е	Only for use in topical medicines for dermal application.
4580	SODIUM HYPOCHLORITE	E	Chlorine is a mandatory component of Sodium hypochlorite. The concentration of chlorine in the medicine must be no
			more than 4%. When for oral or sublingual use and the total amount of sodium

Volume 5

Column 1	redients and requirements Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
Item		i ui pose	from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:
			- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4581	SODIUM ISOSTEAROYL LACTYLATE	Е	Only for use in topical medicines for dermal application.
4582	SODIUM LACTATE	Е	When for oral or sublingual us and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label: - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4583	SODIUM LAURETH SULFATE	Е	When for oral or sublingual us and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label: - (SODIUM) 'The

Volume 5	Vo	lume	5
----------	----	------	---

Column 1	column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4584	SODIUM LAUROAMPHOACETATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.
4585	SODIUM LAUROYL METHYL ISETHIONATE	E	Only for use in wash-off topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.
			The concentration in the medicine must be no more than 11%.
4586	SODIUM LAUROYL SARCOSINATE	Е	Only for use in topical medicines for dermal application.
4587	SODIUM LAURYL PHOSPHATE	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label: - (SODIUM) 'The
			recommended daily dose of

Volume 5

Permissible ingredients and requirements				
Column 1	Column 2	Column 3	Column 4	
Item	Ingredient name	Purpose	Specific requirements	
			this medicine contains [state quantity and units] of sodium' (or words to that effect).	
4588	SODIUM LAURYL SULFATE	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label: - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).	
4589	SODIUM LAURYL SULFOACETATE	Е	Only for use in topical medicines for dermal application.	
4590	SODIUM MAGNESIUM SILICATE	Е	Only for use in topical medicines for dermal application.	
4591	SODIUM MANNOSE PHOSPHATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.5%.	
4592	SODIUM METABISULFITE	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the	

Vol	lume	5
V UI	unit	$\mathcal{I}$

	redients and requirements		
Column 1	Column 2	Column 3	Column 4
ltem	Ingredient name	Purpose	Specific requirements
			maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:
			- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
			Medicines containing sulfites salts require the following warning statement on the medicine label:
			- (SULF) 'Contains sulfites' (or words to this effect) if medicine contains two or more sulfite sources or 'Contains (insert the approved name of sulfites used)' (or words to this effect) if medicine contains on sulfite source.
4593	SODIUM METAPHOSPHATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or damaged skin.
			The concentration in the medicine must not be more than 0.1%.
4594	SODIUM METHYL COCOYL	Е	Only for dental use.
	TAURATE		The concentration in the medicine must be no more than 2%.
4595	SODIUM METHYL	E	When for oral or sublingual us

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
	HYDROXYBENZOATE		and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:
			- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
			Medicines containing hydroxybenzoates require the following warning statement on the medicine label:
			- (TOTBNZ) 'Contains hydroxybenzoates' (or words to this effect) if the medicine contains more than one hydroxybenzoate source OR 'Contains [insert the approved name of hydroxybenzoate used]' (or words to this effect) if product contains one hydroxybenzoate source.
4596	SODIUM MOLYBDATE	А	Only for use in oral medicines
	DIHYDRATE		Molybdenum is a mandatory component of Sodium molybdate dihydrate.
			The percentage of molybdenum from sodium molybdate dihydrate should be calculated based on the molecular weight of sodium molybdate dihydrate.
			The maximum daily dose of molybdenum from Sodium molybdate dihydrate must be

Vol	lumo	5
V OI	lume	3

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
		•	no more than 125 micrograms.
4597	SODIUM MONOFLUOROPHOSPHATE	А	Fluoride is a mandatory component of sodium monofluorophosphate.
			Only for use when the route of administration is dental and the dosage form is pastes, powders or gels for dental hygiene.
			When used as an active ingredient, it is subject to the following conditions:
			a) Only for use in combination with at least one other listable therapeutically active ingredient.
			b) The concentration of fluoride ion must be no more than 1,500 mg/kg.
			When the concentration of fluoride ion is more than 1000 mg/kg, the medicine requires the following statements on the medicine label:
			- (DNTSW) 'Do not swallow.'
			- (CHILD4) 'Do not use [this product/insert name of product in children 6 years of age or less.'
			When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:
			- (SODIUM) 'The recommended daily dose of

Volume 5

	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			this medicine contains [state quantity and units] of sodium (or words to that effect).'
4598	SODIUM MYRISTOYL GLUTAMATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.0164%.
4599	SODIUM NITRATE	Н	Only for use as an active homoeopathic ingredient.
4600	SODIUM NONOXYNOL-4 SULFATE	E	Only for use in topical medicines for dermal application.
4601	SODIUM PANTOTHENATE	A, E, H	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label: - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4602	SODIUM PCA	E	Only for use in topical medicines for dermal application.

Vol	lume	5
V U	unit	$\mathcal{I}$

	column 2	Column 3	Column 4
Column 1			
Item	Ingredient name	Purpose	Specific requirements
4603	SODIUM PERBORATE	А, Н	Boron is a mandatory component of sodium perborate.
			When for internal use, the maximum recommended daily dose must not provide more than 6 mg of boron.
			When used in preparations for dermal use, which are not for paediatric or antifungal use, the concentration of boron from all ingredients in the product must not exceed 3500 mg/kg or 3500 mg/L or 0.35%.
		When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the label:	
			- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
			The requirements specified in paragraphs (a) to (d) below apply to a medicine that contains the ingredient that:
		<ul><li>is listed in the Register on or after 2 March 2020; or</li><li>is supplied after 2 March</li></ul>	
			<ul><li>2021.</li><li>(a) When the maximum recommended daily dose of the medicine provides more than 3 mg of boron and the medicine is for internal use and/or oral</li></ul>

Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			application, one of the following warning statements is required on the label: - (NTAKEN12) 'Not to be taken by children under 12 years old' (or words to that effect); or
			- (ADULT) 'Adults only' (or words to that effect).
			(b) When the maximum recommended daily dose of the medicine provides more than mg boron and up to, and including, 3 mg of boron, and the medicine is for internal us and/or oral application, one of the following warning statements is required on the label:
			<ul> <li>- (NTAKEN2) 'Not to be take by children under 2 years old' (or words to that effect); or</li> <li>- (ADULT) 'Adults only' (or</li> </ul>
			words to that effect).
			(c) When for excipient use and the maximum recommended daily dose of the medicine provides more than 1 mg of boron and the medicine is for internal use and/or oral application, the following warning statement is required on the label:
			- (BORON) 'Contains boron' (or words to that effect).
			(d) When the medicine is for topical use for dermal application, the following warning statement is required on the label:

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			- (BROKEN) 'Use on unbroker skin only' (or words to that effect).
4604	SODIUM PERCARBONATE	Е	Only for use in topical medicines for dermal application.
			The concentration in the medicine must be no more than 15%.
4605	SODIUM POLYACRYLATE	Е	Only for use in topical medicines for dermal application.
4606	SODIUM POLYACRYLATE STARCH	E	<ul> <li>Only to be used in a medicine where Procter &amp; Gamble</li> <li>Australia Pty Ltd (Client ID 11364), who applied to have the ingredient included in this Determination, is the sponsor of the medicine or has given written authorisation to the sponsor of a medicine to include the ingredient in the medicine. This paragraph ceases to be a requirement for this ingredient after 27 September 2020.</li> <li>Only for use in topical medicines for dermal</li> </ul>
			application and not to be included in medicines intended for use in the eye. The concentration in the medicine must not be more

## Volume 5

Permissible ing	Permissible ingredients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4607	SODIUM POLYMETAPHOSPHATE	Е	
4608	SODIUM PROPIONATE	Ε	Only for use in topical medicines for dermal application.
4609	SODIUM PROPYL HYDROXYBENZOATE	E	<ul> <li>When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:</li> <li>- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).</li> <li>Medicines containing hydroxybenzoates require the following warning statement on the medicine label:</li> <li>- (TOTBNZ) 'Contains hydroxybenzoates' (or words to this effect) if the medicine contains more than one hydroxybenzoate source OR 'Contains [insert the approved name of hydroxybenzoate used]' (or words to this effect) if product contains one hydroxybenzoate source.</li> </ul>
4610	SODIUM RNA	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

Vol	lume	5

Permissible ing	gredients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			The concentration in the medicine must be no more than 0.2%.
4611	SODIUM SELENATE	A, H	Selenium is a mandatory component of sodium selenate. Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose. When for oral use, the medicine requires the following warning statement on the medicine label: - (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.'
4612	SODIUM SELENATE DECAHYDRATE	A	<ul> <li>Selenium is a mandatory component of sodium selenate decahydrate.</li> <li>Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.</li> <li>When for oral use, the medicine requires the following warning statement on the medicine label:</li> <li>- (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary</li> </ul>

Volume 5

Permissible ing	gredients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			supplements should not be exceeded.'
4613	SODIUM SELENITE	А, Н	Selenium is a mandatory component of Sodium selenite
			Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.
			When for oral use, the medicine requires the following warning statement on the medicine label:
			- (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.'
4614	SODIUM SELENITE PENTAHYDRATE	A	Selenium is a mandatory component of Sodium selenite pentahydrate.
			Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.
			When for oral use, the medicine requires the following warning statement on the medicine label:
			- (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietar

Vol	lume	5
101	unit	~

	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			supplements should not be exceeded.'
4615	SODIUM SILICATE	Е	When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.
			When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.
			<ul> <li>When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:</li> <li>- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).</li> </ul>
4616	SODIUM STARCH GLYCOLLATE	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label: - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4617	SODIUM STARCH GLYCOLLATE TYPE A	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:
			- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4618	SODIUM STEARATE	Е	Only for use in topical medicines for dermal application.
4619	SODIUM STEAROXY PG- HYDROXYETHYLCELLULOSE SULFONATE	E	Only for use in topical medicines for dermal application and not to be used in topical medicines intended for use in the eye.
			The concentration in the medicine must be no more than 2%.
4620	SODIUM STEAROYL GLUTAMATE	E	Only for use in topical medicines for dermal application and not to be used in topical medicines intended for use in the eye.
			The concentration in the medicine must be no more than 2.5%.
4621	SODIUM STEAROYL	Е	Only for use in topical

	redients and requirements	~	~
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
	LACTYLATE		medicines for dermal
			application.
4622	SODIUM STEARYL	E	Only for use in medicines for
	PHTHALAMATE		dermal application and not to
			be used in topical medicines intended for use in the eye.
			The concentration in the
			medicine must be no more than 1.5%.
4623	SODIUM SUCCINATE	Е	Only for use in topical
			medicines for dermal
			application.
4624	SODIUM SULFATE	A, E, H	When it is not intended to be a
			laxative, the medicine requires
			the following warning statement on the medicine
			label:
			- (LAX4) 'Substance may have
			a laxative effect'.
			When for oral or sublingual use and the total amount of sodium
			from all ingredients in the
			maximum daily dose is more
			than 120 mg, the medicine
			requires the following warning statement on the medicine
			label:
			- (SODIUM) 'The
			recommended daily dose of
			this medicine contains [state quantity and units] of sodium'
			(or words to that effect).
4625	SODIUM SULFATE	A, E, H	When it is not intended to be a
	DECAHYDRATE	,,	laxative, the medicine requires

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			the following warning statement on the medicine label:
			- (LAX4) 'Substance may have a laxative effect'.
			<ul> <li>When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:</li> <li>- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).</li> </ul>
4626	SODIUM SULFITE	E	<ul> <li>When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:</li> <li>- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).</li> <li>Medicines containing sulfites salts require the following warning statement on the medicine label:</li> <li>- (SULF) 'Contains sulfites' (or the salts' of the substitute of the sulfites' (or the substitute of the sulfites' (or the sulfites').</li> </ul>
			words to this effect) if medicine contains two or more sulfite sources or 'Contains

Vol	lume	5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			(insert the approved name of sulfites used)' (or words to this effect) if medicine contains on sulfite source.
4627	SODIUM SULFITE HEPTAHYDRATE	E	Only for use in topical medicines for dermal application. Medicines containing sulfites salts require the following warning statement on the medicine label: - (SULF) 'Contains sulfites' (or words to this effect) if medicine contains two or more sulfite sources or 'Contains (insert the approved name of sulfites used)' (or words to this effect) if medicine contains one sulfite source.
4628	SODIUM TRIPOLYPHOSPHATE	Ε	Only for use when the route of administration is topical for dermal application, mucous membrane (buccal mucosa) or dental. Not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.
4629	SOLANUM DULCAMARA	A, H	When for internal use, steroida alkaloids calculated as solanine is a mandatory component of Solanum dulcamara. When for internal use, the maximum recommended daily

Volume 5

	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			dose must not provide more than 10mg of steroidal alkaloids calculated as solanine.
4630	SOLANUM FEROX	А, Н	When for internal use, steroida alkaloids calculated as solanine is a mandatory component of Solanum ferox.
			When for internal use, the maximum recommended daily dose must not provide more than 10mg of steroidal alkaloids calculated as solanine.
4631	SOLANUM LYCOCARPUM FRUIT EXTRACT	E	Only for use in topical medicines for dermal use and not to be included in topical medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.02%.
4632	SOLANUM MELONGENA	А, Н	When for internal use, steroidal alkaloids calculated as solanine is a mandatory component of Solanum melongena.
			When for internal use, the maximum recommended daily dose must not provide more than 10mg of steroidal alkaloids calculated as solanine.
4633	SOLANUM NIGRUM	А, Н	When for internal use, steroidal alkaloids calculated as solanine

V	0	lume	5
v	U	unit	2

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			is a mandatory component of Solanum nigrum. When for internal use, the maximum recommended daily dose must not provide more than 10mg of steroidal alkaloids calculated as solanine.
4634	SOLANUM TUBEROSUM	А, Н	When for internal use, steroidal alkaloids calculated as solanine is a mandatory component of Solanum tuberosum. When for internal use, the maximum recommended daily dose must not provide more than 10mg of steroidal alkaloids calculated as solanine.
4635	SOLIDAGO GIGANTEA	A, H	
4636	SOLIDAGO GIGANTEA MIS	А, Е, Н	
4637	SOLIDAGO VIRGAUREA	А, Е, Н	
4638	SOLUBLE MAIZE STARCH	Е	
4639	SOLUBLE POTATO STARCH	Е	
4640	SOLVENT GREEN 3	Е	Permitted for use only as a colour for topical use.
4641	SOLVENT RED 1	Е	Permitted for use only as a colour for topical use.
4642	SOLVENT VIOLET 13	E	Permitted for use only as a colour for topical use.
4643	SOLVENT YELLOW 172	Е	Permitted for use only as a

Volume 5

Permissible ingredients and requirements			
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			colour for topical use. The concentration in the medicine must be no more than 0.3%.
4644	SOLVENT YELLOW 33	Е	Permitted for use only as a colour for topical use.
4645	SOPHORA FLAVESCENS	А, Е, Н	
4646	SOPHORA TONKINENSIS	A, H	
4647	SORBIC ACID	Ε	The medicine requires the following warning statement on the medicine label: - (SORB8) 'Contains sorbates' (or word to this effect) if medicine contains two or more sorbate sources OR 'Contains [insert the approved name of sorbate source used]' (or words to this effect) if medicine contains one sorbate source.
4648	SORBITAN ISOSTEARATE	E	Only for use in topical medicines for dermal application.
4649	SORBITAN MONO-OLEATE	Е	
4650	SORBITAN MONOLAURATE	E	
4651	SORBITAN MONOSTEARATE	E	
4652	SORBITAN OLEATE	E	
4653	SORBITAN OLIVATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

Vol	lume	5
101	unit	$\mathcal{I}$

	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			The concentration in the medicine must be no more than 10%.
4654	SORBITAN PALMITATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 2%.
4655	SORBITAN SESQUIISOSTEARATE	Е	Only for use in topical medicines for dermal application.
4656	SORBITAN SESQUIOLEATE	Е	Only for use in topical medicines for dermal application.
4657	SORBITAN STEARATE	Е	
4658	SORBITAN TRISTEARATE	Е	Only for use in topical medicines for dermal application.
4659	SORBITOL	Α, Ε	When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4660	SORBITOL SOLUTION (70 PER CENT) (CRYSTALLISING)	A, E	Sorbitol is a mandatory component of Sorbitol solution (70 per cent) (crystallising). When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time. When the quantity of sugar alcohols per maximum recommended daily dose is more than 2 grams, the quantity of the sugar alcohols must be declared on the label and the medicine requires the following warning statement on the medicine label: - (SUGOLS) 'Products containing [insert name of sugar alcohol(s)] may have a laxative effect or cause diarrhoea (or words to that effect).'
4661	SORBITOL SOLUTION (70 PER CENT) (NON-CRYSTALLISING)	A, E	Sorbitol is a mandatory component of Sorbitol solution (70 per cent) (non- crystallising). When used as an active
			ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply

Vol	lume	5
• 01	unit	$\boldsymbol{\cdot}$

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			<ul> <li>with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.</li> <li>When the quantity of sugar alcohols per maximum recommended daily dose is more than 2 grams, the quantity of the sugar alcohols must be declared on the label and the medicine requires the following warning statement on the medicine label:</li> <li>- (SUGOLS) 'Products containing [insert name of sugar alcohol(s)] may have a laxative effect or cause diarrhoea (or words to that effect).'</li> </ul>

4662	SORBUS AUCUPARIA	А, Н	
4663	SORBUS DOMESTICA	А, Н	
4664	SORGHUM	Е	
4665	SORGHUM VULGARE	А, Н	
4666	SOY PHOSPHATIDYLSERINE- ENRICHED SOY LECITHIN LIQUID	Α	Soy phosphatidylserine is a mandatory component of soy phosphatidylserine-enriched soy lecithin liquid.
			The concentration of soy phosphatidylserine in the medicine must be no more than 15%.
4667	SOY PHOSPHATIDYLSERINE- ENRICHED SOY LECITHIN POWDER	A	Soy phosphatidylserine is a mandatory component of soy phosphatidylserine-enriched soy lecithin powder.

Volume 5

	gredients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			The concentration of soy phosphatidylserine in the medicine must be no more than 15%.
4668	SOY POLYSACCHARIDE	Е	
4669	SOY PROTEIN	Е	
4670	SOY STEROL	Е	
4671	SOYA BEAN	Е	
4672	SOYA BRAN	Е	
4673	SOYA OIL	А, Е, Н	
4674	SOYBEAN FLOUR	Ε	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4675	SOYBEAN GLYCERIDES	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 4%.
4676	SPARGANIUM STOLONIFERUM	А, Н	
4677	SPARTIUM JUNCEUM	A, H	
4678	SPATHOLOBUS SUBERECTUS	A, H	
4679	SPEARMINT OIL	А, Е, Н	Menthol is a mandatory component of spearmint oil.

1002

Vo	lume	5
VU.	unit	$\mathcal{I}$

	coloring 2	Calaria 2	Colores 4
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements When the medicine is for topical use for dermal application:
			<ul><li>(i) the medicine must not be intended for use in the eye or on damaged skin;</li></ul>
			(ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use;
			(iii) the following warning statement is required on the medicine label:
			- (EYE) Avoid contact with eyes (or words to that effect).
			(iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label:
			- (SKTEST) If you have sensitive skin, test this produc on a small area of skin before applying it to a large area;
			- (IRRIT) If irritation develops discontinue use.
			(v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label
			- (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation.
			When the medicine is for

## Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.
4680	SPEARMINT OIL TERPENELESS	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more tha 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%
			Menthol is a mandatory component of spearmint oil terpeneless.
			When the medicine is for topical use for dermal application:
			<ul><li>i) the medicine must not be intended for use in the eye or on damaged skin;</li></ul>
			ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use;
			<ul><li>iii) the following warning statement is required on the medicine label:</li></ul>
			- (EYE) Avoid contact with eyes (or words to that effect).
			iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			following warning statements are required on the medicine label:
			<ul> <li>- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;</li> <li>- (IRRIT) If irritation develops discontinue use.</li> </ul>
			v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label
			<ul> <li>– (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation.</li> </ul>
			When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.
4681	SPHINGOLIPIDS	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.1%.
4682	SPIGELIA ANTHELMIA	A, H	
4683	SPIGELIA MARILANDICA	А, Н	The maximum recommended daily dose must be no more than the equivalent of 1mg of the dry herbal material.

Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4684	SPIKE LAVENDER OIL	А, Е, Н	Camphor is a mandatory component of spike lavender oil.
			In solid and semi solid preparations, the concentration of camphor must be no more than 12.5%.
			In liquid preparations other than essential oils, the concentration of camphor mus be no more than 2.5%.
			In essential oil preparations, if the concentration of camphor is more than 2.5% but less than c equal to 10%, and the nominal capacity of the container is less than 25 millilitres, the medicine must have a restricte flow insert fitted on the container and include the following warning statements on the medicine label:
			- (CHILD) 'Keep out of reach of children' (or words to that effect); and
			- (NTAKEN) 'Not to be taken'
			In essential oil preparations, if the concentration of camphor is more than 10%, and the nominal capacity of the container is less than 15 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label:
			- (CHILD) 'Keep out of reach of children' (or words to that

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			effect); and
			- (NTAKEN) 'Not to be taken'.
			In essential oil preparations, if the concentration of camphor is more than 10%, and the nominal capacity of the container is more than 15 millilitres but less than or equa to 25 millilitres, the medicine must have a restricted flow insert and child resistant closure fitted on the container and include the following warning statements on the medicine label:
			- (CHILD) 'Keep out of reach of children' (or words to that effect); and
			- (NTAKEN) 'Not to be taken'.
			If the concentration of campho is more than 2.5%, the nominal capacity of the container must be no more than 25 millilitres.

SPINACH	Е	
SPINACIA OLERACEA	А, Е, Н	
SPIRODELA POLYRRHIZA	A, H	
SPIRULINA	E	
SPRAY-DRIED GLUCOSE SYRUP	Ε	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
	SPINACIA OLERACEA SPIRODELA POLYRRHIZA SPIRULINA	SPINACIA OLERACEAA, E, HSPIRODELA POLYRRHIZAA, HSPIRULINAE

Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2020

Volume 5

Volume	5
--------	---

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4690	SPRAY-DRIED LIQUID GLUCOSE	Е	Permitted for use only in combination with other permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4691	SPRUCE OIL	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4692	SQUALANE	Е	Only for use in topical medicines for dermal application.
4693	SQUALENE	A, E	
4694	SQUID OIL	А	Only for use in oral medicines. The medicine requires the following warning statement on the medicine label: - (SFOOD) 'Derived from seafood'.
			Must be obtained from species of the order Teuthida of the class Cephalopoda, be used in combination with other ingredients in the medicine and be presented in a therapeutic dosage form for therapeutic use.

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4695	SQUILL DRY	A, H	
4696	SQUILL INDIAN DRY	A, H	
4697	SQUILL INDIAN POWDER	A, H	
4698	SQUILL POWDER	A, H	
4699	ST JOHN'S WORT DRY EXTRACT QUANTIFIED	A	<ul> <li>When used for oral ingestion the medicine requires the following warning statement on the medicine label:</li> <li>- (STJOHN) 'St John's Wort affects the way many prescription medicines work including oral contraceptives Consult your doctor.'</li> </ul>
4700	ST JOHN'S WORT HERB DRY	А, Н	When used for oral ingestion, the medicine requires the following warning statement on the medicine label: - (STJOHN) 'St John's Wort affects the way many prescription medicines work including oral contraceptives. Consult your doctor.'
4701	ST JOHN'S WORT HERB POWDER	А, Н	When used for oral ingestion, the medicine requires the following warning statement on the medicine label: - (STJOHN) 'St John's Wort affects the way many prescription medicines work including oral contraceptives. Consult your doctor.'
4702	STACHYS OFFICINALIS	A, E, H	
4703	STACHYS PALUSTRIS	A, H	

Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2020

Volume 5

## Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4704	STACHYURUS HIMALAICUS	А, Н	
4705	STANNIC OXIDE	Ε	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.005%.
4706	STANNOUS CHLORIDE	Н	Only for use as an active homoeopathic ingredient.
4707	STAR ANISE OIL	Α, Ε	When the concentration in the medicine is more than 50% and the nominal capacity of the container is equal to or less than 50mL, a restricted flow insert must be fitted on the container and the medicine requires the following warning statement on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect).
4708	STARCH	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4709	STARCH SODIUM OCTENYL	E	

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
Item	SUCCINATE	1 ui pose	Speenie requirements
4710	STEARALKONIUM CHLORIDE	Е	Only for use in topical medicines for dermal application.
4711	STEARALKONIUM HECTORITE	Е	Only for use in topical medicines for dermal application.
4712	STEARAMIDE	Е	Only for use in topical medicines for dermal application.
4713	STEARAMIDOETHYL DIETHYLAMINE	Е	Only for use in topical medicines for dermal application.
4714	STEARAMIDOPROPYL DIMETHYLAMINE	Е	Only for use in topical medicines for dermal application.
4715	STEARAMIDOPROPYL PG- DIMONIUM CHLORIDE PHOSPHATE	Е	<ul> <li>Only for use in topical medicines for dermal application.</li> <li>The concentration in the medicine must be no more than 2%.</li> <li>When the medicine is intended to be used on the eye, the medicine requires the following warning statement on the medicine label:</li> <li>- (EYE2) 'May be irritant to the eyes' (or words to that effect).</li> </ul>
4716	STEARETH-10	E	Only for use in topical

Volume 5

Column 1	redients and requirements Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
		<u> </u>	medicines for dermal application.
4717	STEARETH-100	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 1.5%.
4718	STEARETH-2	Е	Only for use in topical medicines for dermal application.
4719	STEARETH-20	Е	Only for use in topical medicines for dermal application.
4720	STEARETH-21	E	Only for use in topical medicines for dermal application.
4721	STEARETH-5	Е	Only for use in topical medicines for dermal application.
4722	STEARIC ACID	Е	
4723	STEAROPTENES	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than

-	column 2	Column 2	Calumn 4
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements 1%.
4724	STEAROXY DIMETHICONE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 4%.
4725	STEAROXYTRIMETHYLSILANE	E	Only for use in topical medicines for dermal application.
4726	STEAROYL MACROGOLGLYCERIDES	Е	Only for use in oral medicines. The concentration in the medicine must be no more than 0.6%.
4727	STEARYL ACETATE	E	Only for use in topical medicines for dermal application.
4728	STEARYL ALCOHOL	E	
4729	STEARYL BEHENATE	Ε	Only for use as an excipient ingredient for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must not be more than 3.5% in the final formulation.
4730	STEARYL DIMETHICONE	E	Only for use in topical

Volume 5

Permissible ing Column 1	Column 4		
Item	Column 2 Ingredient name	Column 3 Purpose	Specific requirements
			medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more thar
			4.5%.
			The medicine requires the following warning statements on the medicine label:
			- (EYE2) 'May be irritant to the eyes' (or words to that effect)
			- (EYE) 'Avoid contact with eyes' (or words to that effect).
4731	STEARYL GLYCYRRHETINATE	Е	Only for use in topical medicines for dermal application.
4732	STEARYL HEPTANOATE	Е	Only for use in topical medicines for dermal application.
4733	STEARYL MYRISTATE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4734	STEARYL STEARATE	Е	Only for use in topical medicines for dermal application.
4735	STELLARIA CHAMAEJASME	A, H	

-	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4736	STELLARIA DICHOTOMA	A, H	
4737	STELLARIA MEDIA	А, Е, Н	
4738	STEMONA JAPONICA	А, Н	
4739	STEMONA SESSILIFOLIA	А, Н	
4740	STENOTAPHRUM SECUNDATUM	A, H	
4741	STEPHANIA TETRANDA	A, H	
4742	STERCULIA	A, H	
4743	STERCULIA TRAGACANTHA	A, H	
4744	STERCULIA URENS	A, H	
4745	STEVIA REBAUDIANA	А, Е, Н	
4746	STEVIOL GLYCOSIDES	Е	Only for use in oral medicines.
4747	STILLINGIA SYLVATICA	A, H	
4748	STORAX PREPARED	А, Е, Н	
4749	STRAWBERRY	Е	
4750	STRAWBERRY ESSENCE	Ε	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4751	STREPTOCOCCUS SALIVARIUS	А	Only permitted for use in medicines: - that are for oral routes of administration; and - when the strain of Streptococcus salivarius is confirmed to be K12 or M18.

Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2020

Volume 5

Volume 5

Column 1	column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			The name of the Streptococcus salivarius strain must be declared on the label.
			The following warning statement is required on the medicine label:
			- (CHILD5) 'Use in children under 3 years is not recommended'.
4752	STREPTOCOCCUS THERMOPHILUS	A	
4753	STROBILANTHES CUSIA	A, H	
4754	STRONG AMMONIA SOLUTION	E	Ammonia is a mandatory component of dilute ammonia solution.
			The concentration of ammonia in the medicine must be no more than 0.5%.
			When for internal use, the concentration in the medicine must be no more than 0.25%.
4755	STRONTIUM CARBONATE	Н	Only for use as an active homoeopathic ingredient.
4756	STROPHANTHUS GRATUS	Н	Only for use as an active homoeopathic ingredient.
4757	STROPHANTHUS HISPIDUS	Н	Only for use as an active homoeopathic ingredient.
4758	STRYCHNOS IGNATII	Н	Only for use as an active homoeopathic ingredient.
			Strychnine (of Strychnos spp.) is a mandatory component of

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			Strychnos ignatii. The concentration of Strychnine (of Strychnos spp.) must be no more than 1 milligram/Kg or 1 milligram/L or 0.1%.
4759	STRYCHNOS NUX-VOMICA	А, Н	Strychnine (of Strychnos spp.) is a mandatory component of Strychnos nux-vomica. The concentration of Strychnine (of Strychnos spp.) must be no more than 1 milligram/Kg or 1 milligram/L or 0.1%.
4760	STYPHNOLOBIUM JAPONICUM	А, Е, Н	
4761	STYRALLYL PROPIONATE	E	Only for use in medicines in combination with other permitted ingredients as a fragrance proprietary excipient formulation.
			The total fragrance proprietary excipient formulation in a medicine must not be more than 1%.
4762	STYRAX BENZOIN	А, Е, Н	
4763	STYRAX OIL	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more that 5%.
			If used in a fragrance the total fragrance concentration in a

## Volume 5

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			medicine must be no more 1%.
4764	STYRAX PARALLELONEURUM	A, H	
4765	STYRAX TONKINENSIS	A, H	
4766	STYRENE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4767	STYRENE/ACRYLATES COPOLYMER	Е	Only for use in topical medicines for dermal application.
4768	STYROLYL ACETATE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4769	SUBLIMED SULFUR	Н	Only for use as an active homoeopathic ingredient.
4770	SUCCINIC ACID	Е	
4771	SUCRALOSE	E	
4772	SUCROSE	Е	When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar,

	Permissible ingredients and requirements			
Column 1	Column 2	Column 3	Column 4	
ltem	Ingredient name	Purpose	Specific requirements	
			lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label:	
			<ul> <li>- (SUGARS) 'Contains [insert name of sugar]' if medicine contains one sugar OR</li> <li>'Contains sugars' (or words to that effect) if medicine contains two or more sugars.</li> </ul>	
			If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label:	
			- (LACT) 'Contains lactose' (o words to that effect).	
4773	SUCROSE ACETATE ISOBUTYRATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.	
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.	
4774	SUCROSE ACETATE PALMITATE STEARATE	Е	Only for use in topical medicines for dermal application and not intended for use in the eye or on damaged skin.	
			The concentration in the medicine must be no more than 0.3%.	
4775	SUCROSE COCOATE	Е	Only for use in topical	

Volume 5

Column 1	gredients and requirements Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
	Ingreutent nume	r ur pose	medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more that 2%.
4776	SUCROSE DISTEARATE	Е	Only for use in topical medicines for dermal application.
4777	SUCROSE LAURATE	E	<ul> <li>When for oral or sublingual use, Sucrose is a mandatory component of Sucrose laurate.</li> <li>When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label: <ul> <li>(SUGARS) 'Contains [insert name of sugar]' if medicine contains one sugar OR</li> <li>'Contains sugars' (or words to that effect) if medicine contains two or more sugars.</li> </ul> </li> <li>If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label: <ul> <li>(LACT) 'Contains lactose' (o words to that effect).</li> </ul> </li> </ul>

Vol	lume	5
• •	unit	~

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4778	SUCROSE OCTAACETATE	E	When for oral or sublingual use, sucrose is a mandatory component of sucrose octaacetate.
			When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label:
			- (SUGARS) 'Contains [insert name of sugar]' if medicine contains one sugar OR 'Contains sugars' (or words to that effect) if medicine contains two or more sugars.
			If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label:
			- (LACT) 'Contains lactose' (or words to that effect).
4779	SUCROSE PALMITATE	E	Only for use in topical medicines for dermal application.
4780	SUCROSE POLYCOTTONSEEDATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			The concentration in the medicine must be no more tha 1%. The medicine requires the following warning statements on the medicine label: - (EYE) 'Avoid contact with the eyes' (or words to that
			effect) - (EYE2) 'May be irritant to th eyes' (or words to that effect).
4781	SUCROSE STEARATE	E	For use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. When for topical use, the concentration in the medicine must be no more than 0.25%. For oral use as a manufacturin aid only. When for oral use, the concentration in the medicine must be no more than 0.2 mg per dosage unit.
4782	SUCROSE TRISTEARATE	E	Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin. The concentration in the medicine must be no more than 2%.
4783	SUDAN III	Е	Permitted for use only as a colour for topical use.

	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4784	SUGAR CANE WAX ALCOHOLS	А, Н	The maximum recommended daily dose must not provide more than 12mg.
			The medicine requires the following warning statements on the medicine label:
			- (PREGNT) 'Not recommended for use by pregnant and lactating women' (or words to that effect).
4785	SUGARCANE	E, H	<ul> <li>When for oral or sublingual use, sucrose is a mandatory component of Sugarcane.</li> <li>When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label: <ul> <li>(SUGARS) 'Contains [insert name of sugar]' if medicine contains one sugar OR 'Contains sugars' (or words to that effect) if medicine contains two or more sugars.</li> </ul> </li> </ul>
			If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label:
			- (LACT) 'Contains lactose' (o words to that effect).

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4786	SULFATED CASTOR OIL	E	Only for use in topical medicines for dermal application.
4787	SULFATED LOW MOLECULAR WEIGHT FUCANS	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.025%.
4788	SULFUR DIOXIDE	E	Medicines containing sulfites salts require the following warning statement on the medicine label:
			- (SULF) 'Contains sulfites' (or words to this effect) if medicine contains two or more sulfite sources or 'Contains (insert the approved name of sulfites used)' (or words to this effect) if medicine contains on sulfite source.
4789	SULFUR IODIDE	Н	Only for use as an active homoeopathic ingredient.
4790	SULFURIC ACID	Е, Н	Only for use as an active homoeopathic ingredient or excipient ingredient.
			The concentration in the medicine must be no more than 0.5%.

Vo	lume	5
VU.	unit	$\mathcal{I}$

Permissible ing	gredients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4791	SULFURISED 1-METHYL-4-(1- METHYLETHENYL)- CYCLOHEXENE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more that 1%.
4792	SULISOBENZONE	А	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must not be more than 10%.
			When used in primary sunscreen products, the following warning statements are required on the label:
			- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and
			- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
4793	SULISOBENZONE SODIUM	А	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must not be more than 10%.
			When used in primary sunscreen products, the

Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
	9		following warning statements
			are required on the label:
			- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and
			- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
4794	SUNFLOWER OIL	А, Е, Н	
4795	SUNFLOWER SEED	E, H	
4796	SUNSET YELLOW FCF	E	Permitted for use only as a colour for either topical use or with an oral route of administration.
4797	SUNSET YELLOW FCF ALUMINIUM LAKE	E	Permitted for use only as a colour in medicines limited to topical and oral routes of administration.
4798	SUPEROXIDE DISMUTASE	E	Only for use in topical medicines for dermal application.
4799	SWEDE	Е	
4800	SWEET ORANGE OIL TERPENES AND TERPENOIDS	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%
4801	SWEET POTATO	Е	
4802	SWERTIA CHIRATA	A, H	
4803	SWIETENIA MAHOGANI	A, H	
4804	SYAGRUS ROMANZOFFIANA	А, Е, Н	
4805	SYMPHYTUM OFFICINALE	Н	When used orally as an active homoeopathic ingredient, the concentration must be a dilution of 12X or more.
			When used in topical medicines for dermal application, the concentration in the preparation must be no more than 10mg/kg or 10mg/L or 0.001%.
4806	SYMPLOCARPUS FOETIDUS	A, H	
4807	SYNTHETIC BEESWAX	Е	Only for use in topical medicines for dermal applications.
4808	SYNTHETIC TERPENE RESIN	Е	Only for use in topical, oral or oral application medicines.
			When the route of administration is oral, the dosage form must be chewing gum.
4809	SYNTHETIC WAX	Е	
4810	SYRINGA RETICULATA	A, H	
4811	SYRINGA VULGARIS	A, H	

Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2020

Volume 5

Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4812	SYZYGIUM AROMATICUM	А, Е, Н	When the plant preparation is oil or distillate and the concentration of this oil or distillate in the product is greater than 25%, the nominal capacity of the container must be no more than 25 millilitres and the medicine must include the following warning statements on the medicine label:
			- (CHILD) 'Keep out of reach of children' (or words to that effect); and
			- (NTAKEN) 'Not to be taken'
			When the plant preparation is oil or distillate, the concentration of this oil or distillate in the medicine is greater than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equa to 25 millilitres, a child resistant closure and restricted flow insert must be fitted on the container.
			When the plant preparation is oil or distillate, the concentration of oil or distillat in the product is greater than 25% and the nominal capacity of the container is less than 15 millilitres, a restricted flow insert must be fitted on the container.
			When the plant preparation is oil or distillate and the preparation is for topical use i the mouth, the preparation ma not contain more than 5

Volume :	5
----------	---

Column 1	column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
		1 11 1030	millilitres of the oil or distillate and the concentration of oil or distillate in the product must not be greater than 25%.
4813	SYZYGIUM CUMINI	A, H	
4814	SYZYGIUM JAMBOS	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must not be more than 0.0693%.
4815	TABEBUIA SERRATIFOLIA	А, Е, Н	
4816	TAGETES ERECTA	А, Е, Н	When used as an excipient ingredient, only for use in combination with other permitted ingredients as a flavour proprietary excipient formulation. The total flavour proprietary excipient formulation in a medicine mus not be more than 5%.
4817	TAGETES MINUTA	А, Е, Н	
4818	TAGETES OIL	Ε	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a

Volume 5

-	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			medicine must be no more 1%.
4819	TAIPAN SNAKE	Н	Only for use as an active homoeopathic ingredient.
			nomocopaune ingredient.
4820	TALLOW	Е	Only for use in topical medicines for dermal
			application.
4821	TALLOW GLYCERIDES	E	
4822	TAMARINDUS INDICA	Е	Permitted for use only in combination with other
			permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a
			medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a
			medicine must be no more 1%.
4823	TAMARIX APHYLLA	A, H	
4824	TAMARIX CHINENSIS	A, H	
4825	TAMARIX GALLICA	A, H	
4826	TAMUS COMMUNIS	A, H	If the plant part is fruit or root,
			the maximum recommended daily dose must be no more
			than 1mg of the equivalent dry
			fruit or dry root of Tamus communis.
4827	TANACETUM	A U	The concentration in the
4021	CINERARIIFOLIUM	А, Н	medicine must be no more than 10%.

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4828	TANACETUM PARTHENIUM	A, E, H	
4829	TANACETUM VULGARE	А, Н	Oil (of Tanacetum vulgare) is a mandatory component of Tanacetum vulgare.
			The concentration of oil (of Tanacetum vulgare) in the medicine must be no more than 0.8%.
4830	TANGERINE OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4831	TANGERINE OIL COLDPRESSED	А, Е, Н	When used internally, oxedring is a mandatory component of tangerine oil coldpressed.
			The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 milligrams.
4832	TANNIC ACID	Е	
4833	TAPIOCA STARCH	Е	
4834	TARAXACUM MONGOLICUM	А, Е, Н	
4835	TARAXACUM OFFICINALE	А, Е, Н	
4836	TARO	Е	

Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2020

Volume 5

Volume 5

	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4837	TARRAGON OIL	А, Е, Н	
4838	TARTARIC ACID	Е	
4839	TARTRAZINE	Ε	Permitted for use only as a colour in medicines limited to topical and oral routes of administration.
			The medicine requires the following warning statement on the medicine label:
			- (TART) 'Contains tartrazine' (or words to that effect).
4840	TARTRAZINE ALUMINIUM LAKE	Е	Permitted for use only as a colour in medicines limited to topical and oral routes of administration.
			The medicine requires the following warning statement on the medicine label:
			- (TART) 'Contains tartrazine' (or words to that effect).
4841	TASMANNIA LANCEOLATA	Е	Permitted for use only in combination with other permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4842	TAURINE	A, E	
4843	TEA-STEARATE	Е	Only for use in topical medicines for dermal application.

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4844	TERMINALIA ARJUNA	А	Only for use in oral medicines.
			Only for use when the plant part is bark.
			The maximum recommended daily dose must be no more than 6 grams of Terminalia arjuna dried bark or its extract equivalents.
			The medicine requires the following warning statements on the medicine label:
			- (PREGNT) 'Not recommended for use by pregnant and lactating women' (or words to that effect)
			- (CHILD2) 'Not suitable for children'.
4845	TERMINALIA BELLIRICA	А	Only for use when the preparation is as an aqueous extract of the fruit pericarp.
4846	TERMINALIA CATAPPA	A, H	
4847	TERMINALIA CHEBULA	A, H	
4848	TERMINALIA FERDINANDIANA	А, Е, Н	Only for use when the plant part is fruit flesh, fruit flesh dry or the preparation is as an aqueous extract of the fruit flesh.
			When used as an excipient, the ingredient is only for use in topical medicines for dermal application and not to be included in medicines intended for use on damaged skin or in the eye.
			When used as an excipient, the concentration in the medicine

Volume 5

Column 1	column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
	ingreutent nume	i ui pose	must be no more than 0.3%.
4849	TERMINALIA SERICEA	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. Only for use when the plant part is root bark.
			Only methanol/water (90:10; V/V) extract of Terminalia sericea bark of the root is approved.
			The concentration in the medicine must be no more than 0.1%.
4850	TERPINEN-4-OL	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4851	TERPINEOL	Е	
4852	TERPINEOL ACETATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Vo	lume	5
VU	lume	J

-	redients and requirements	~ ~ ~ ~	~
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4853	TERPINOLENE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4854	TERPINYL ACETATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4855	TERPINYL BUTYRATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour.
			If used as a flavour the total flavour concentration in a medicine must be no more than 5%.
4856	TERPINYL METHYL ETHER	E	Permitted for use only in

Volume 5

-	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4857	TERT-BUTYL ALCOHOL	E	Only for use in topical medicines for dermal application.
4858	TERT-BUTYL HYDROQUINONE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4859	TERT-BUTYL METHYL ETHER	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4860	TERT-BUTYLPYRAZINE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4861	TETRACLINIS ARTICULATA	А, Е, Н	
4862	TETRADECYL AMINOBUTYROYLVALYLAMIN OBUTYRIC UREA TRIFLUOROACETATE	Ε	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.
			The concentration in the medicine must be no more than 0.002%.
4863	TETRADIUM RUTICARPUM	А, Н	When for internal use, oxedrine is a mandatory component of Tetradium ruticarpum.
			The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 mg.
4864	TETRAHEXYLDECYL ASCORBATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 1%.
4865	TETRAHYDRO LINALYLACETATE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Volume 5

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4866	TETRAHYDRO PARA- METHYLQUINOLINE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4867	TETRAHYDRO-6-(3-PENTENYL)- 2H-PYRAN-2-ONE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4868	TETRAHYDRODIFERULOYLME THANE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.1%.
4869	TETRAHYDROFURFURYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
	-		medicine must be no more 1%.
4870	TETRAHYDROGERANYL ACETATE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4871	TETRAHYDROLINALOOL	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4872	TETRAHYDROMUGUOL	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4873	TETRAHYDROMYRCENOL	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Volume 5

-	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4874	TETRAHYDROXYPROPYL ETHYLENEDIAMINE	Ε	Only for use in topical medicines for dermal application.
4875	TETRAMETHYL ACETYLOCTAHYDRONAPHTHA LENES	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4876	TETRAPANAX PAPYRIFER	A, H	
4877	TETRASODIUM ETIDRONATE	E	Only for use in topical medicines for dermal application.
4878	TETRASODIUM PYROPHOSPHATE	Ε	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label: - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4879	TEUCRIUM CHAMAEDRYS	А, Н	The maximum recommended daily dose must be no more than 1 mg of the equivalent dry

Permissible ing	gredients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			herbal material of Teucrium
			chamaedrys.
4880	TEUCRIUM MARUM	A, H	The maximum recommended
			daily dose must be no more
			than 1 mg of the equivalent dry herbal material of Teucrium
			marum.
4881	TEUCRIUM SCORODONIA	A, H	The maximum recommended
		,	daily dose must be no more
			than 1mg of the equivalent dry
			herbal material of Teucrium scorodonia.
4882	THAPSIA GARGANICA	A, H	
4883	THAUMATIN	E	
4884	THEASPIRANE	Е	Permitted for use only in
			combination with other permitted ingredients as a
			flavour or a fragrance.
			If used in a flavour the total
			flavour concentration in a medicine must be no more thar
			5%.
4885	THEMEDA TRIANDRA	A, H	
4886	THEOBROMA CACAO	А, Е, Н	Caffeine is a mandatory
			component of Theobroma cacao.
			When the medicine is
			packaged for supply as an
			undivided preparation and is for internal use or oral
			application, the medicine must
			not contain a concentration of
			total caffeine greater than 4%.

Volume 5

Column 1	Column 2	Column 3	Column 4
ltem	Ingredient name	Purpose	Specific requirements
			When the medicine is packaged for supply as a divided preparation and is for internal use or oral application the medicine must not contain a concentration of total caffeine greater than 33%.
			The requirements specified in paragraphs (a) to (e) below apply in relation to a medicine that contains the ingredient that:
			- is listed in the Register on or after 2 September 2019; or
			- is supplied after 2 March 2021.
			A medicine that contains the ingredient and that:
			- was listed in the Register before 2 September 2019; and
			- is supplied before 2 March 2021;
			may comply with the requirements in paragraphs (a) to (e) below.
			a) When for internal use or ora application, the maximum recommended daily dose of th medicine must provide no more than 400mg of total caffeine.
			b) When the medicine is packaged for supply as an undivided preparation and is for internal use or oral application, the medicine mus not contain a concentration of total caffeine greater than 1%.
			c) When the medicine is for internal use or oral application

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			a maximum recommended dose of the medicine must not provide more than 100 mg of total caffeine within a 3 hour period.
			<ul> <li>d) When the maximum</li> <li>recommended daily dose of the medicine provides greater than 10 mg of total caffeine and the medicine is for internal use or oral application, the following warning statements are</li> <li>required on the label:</li> <li>- (ADULT) 'Adults only' (or</li> </ul>
			words to that effect). - (CAFF) 'Contains [state quantity per dosage unit or per mL or per gram of product] total caffeine [per dosage unit or per mL or per gram]. A cup of instant coffee contains approximately 80mg of caffeine.'
			- (CAFFPREG) 'Caffeine intake more than 200 mg per day is not recommended durin pregnancy or breastfeeding.'
			e) When the maximum recommended daily dose of the medicine provides greater than 80 mg of total caffeine and the medicines is for internal use or oral application, the following warning statements are required on the label:
			<ul> <li>- (CAFFLMT) 'Limit the use of caffeine-containing products (including tea and coffee) when taking this product.'</li> <li>- (CAFFCYP) 'Caffeine</li> </ul>
			interacts with enzyme CYP1A

Volume 5

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
	_		in the liver. Consult your health professional before taking with other medicines' (or words to that effect).
4887	THEOBROMA OIL	А, Е, Н	
4888	THIAMINE	A, E	
4889	THIAMINE HYDROCHLORIDE	A, E	
4890	THIAMINE NITRATE	A, E	
4891	THIOCINEOLE	Ε	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4892	THIOTAURINE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.02%.
4893	THLASPI ARVENSE	А, Е, Н	
4894	THREONINE	Α, Ε	
4895	THUJA OCCIDENTALIS	A, H	
4896	THUJA PLICATA	А, Е, Н	
4897	THYME HERB DRY	А, Е, Н	
4898	THYME OIL	А, Е, Н	When the concentration of Thyme oil in the medicine is

1044

volume J	Vol	lume	5
----------	-----	------	---

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			more than 50%, the nominal capacity of the container must be no more than 25 mL, a restricted flow insert must be fitted on the container and the medicine requires the warning statement: - (CHILD) 'Keep out of reach of children' (or words to that effect).
4899	THYMOL	A, E	When used as an active ingredient, the medicine must be medicated space spray or medicated throat lozenges. When used as an excipient, only for use in medicated throat lozenges or topical medicines for dermal applications.
4900	THYMUS CAPITATUS	A, E, H	<ul> <li>When the plant preparation is an oil, and the concentration in the medicine is more than 50% the nominal capacity of the container must be no more than 25 mL, a restricted flow insert must be fitted on the container and the medicine requires the following warning statement on the medicine label:</li> <li>- (CHILD) 'Keep out of reach of children' (or words to that effect).</li> </ul>
4901	THYMUS GLAND	Н	Only for use as an active homoeopathic ingredient.

Volume	5
--------	---

Permissible ing Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4902	THYMUS MASTICHINA	A, E, H	When the plant preparation is an oil, and the concentration in the medicine is more than 50% the nominal capacity of the container must be no more than 25 mL, a restricted flow insert must be fitted on the container and the medicine requires the following warning statement on the medicine label:- (CHILD) 'Keep out of reach of children' (or words to that effect).
4903	THYMUS SERPYLLUM	А, Е, Н	When the plant preparation is an oil, and the concentration in the medicine is more than 50% the nominal capacity of the container must be no more than 25 mL, a restricted flow insert must be fitted on the container and the medicine requires the following warning statement on the medicine label:- (CHILD) 'Keep out of reach of children' (or words to that effect).
4904	THYMUS VULGARIS	А, Е, Н	<ul> <li>When the plant preparation is oil or distillate, and the concentration of Thymus vulgaris oil or distillate in the preparation is greater than 50%:</li> <li>(a) the nominal capacity of the container must not be more than 25 millilitres;</li> <li>(b) a restricted flow insert must be fitted on the container; and</li> <li>(c) the following warning</li> </ul>

volume J	Vol	lume	5
----------	-----	------	---

Permissible ing	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
		i urpose	statement is required on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect).
4905	THYMUS VULGARIS MIS	A, E, H	When the plant preparation is an oil or distillate, and the concentration of Thymus vulgaris MIS oil or distillate in the preparation is greater than 50%:
			(a) the nominal capacity of the container must not be more than 25 millilitres;
			(b) a restricted flow insert mus be fitted on the container; and
			(c) the following warning statement is required on the label:
			- (CHILD) 'Keep out of reach of children' (or words to that effect).
4906	THYMUS ZYGIS	A, H	When the plant preparation is an oil or a distillate, and the concentration of Thymus zygis oil or distillate in the preparation is greater than 50%:
			(a) the nominal capacity of the container must not be more than 25 millilitres;
			(b) a restricted flow insert mus be fitted on the container; and
			(c) the following warning statement is required on the

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			label: - (CHILD) 'Keep out of reach of children' (or words to that effect).
4907	TIGER SNAKE	Н	Only for use as an active homoeopathic ingredient.
4908	TILACTASE	А	Must be derived from Aspergillus oryzae and comply with the relevant USP monograph.
			When the dosage form is undivided, the units 'acid lactase units per gram' and 'Thousand acid lactase units per gram' are permitted.
			When the dosage form is divided, the units 'acid lactase units' and 'thousand acid lactase units' are permitted.
4909	TILIA CORDATA	A, E, H	
4910	TILIA PLATYPHYLLOS	А, Е, Н	
4911	TILIA TOMENTOSA	А, Н	
4912	TILIA X VULGARIS	А, Е, Н	
4913	TILIANTOL	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

	redients and requirements	~	~
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4914	TIN	Н	Only for use as an active homoeopathic ingredient.
4915	TINOSPORA CORDIFOLIA	A, H	
4916	TINOSPORA SINENSIS	А, Н	
4917	TITANIUM DIOXIDE	Α, Ε	For use as an active ingredient only in sunscreens for dermal application. The concentration in
			sunscreens must be no more than 25%.
			For use as an excipient only as a colour and only in medicines limited to oral and topical routes of administration.
			Not to be included in medicines intended for use in the eye.
			When used in primary sunscreen products, the following warning statements are required on the label:
			- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and
			- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
4918	TOCOCYSTEAMIDE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more tha 0.01%.

## Volume 5

Volume 5

Permissible ingredients and requirements			
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4919	TOCOFERSOLAN	E	Only for oral and topical use.
			When for oral use, the concentration in the medicine must be no more than 10% w/w.
			When used in topical medicines for dermal application, it is not to be included in medicines intended for use in the eye.
			When for topical use, the concentration in the medicine must be no more than 0.1%
4920	TOCOPHEROL	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4921	TOCOPHERYL GLUCOSIDE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use on damaged skin or in the eye.
			The concentration in the medicine must be no more than 0.05%

Vol	lume	5
• •	unit	~

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4922	TOCOPHERYL LINOLEATE	E	Only for use in topical medicines for dermal application.
4923	TOCOPHERYL NICOTINATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration must not exceed 0.3%.
4924	TOLU BALSAM	А, Е, Н	
4925	TOLUENE	Е	The residual solvent limit for toluene is 8.9 mg per maximum recommended daily dose.
			The concentration in the medicine must be no more than 0.089%.
4926	TOLYL ALDEHYDE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4927	TOLYLALDEHYDE GLYCERYLACETAL	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4928	ТОМАТО	E	
4929	TONKA	E	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4930	TONKA BEAN EXTRACT	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4931	TONONE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4932	TOXICODENDRON	Н	Only for use as an active

Column 1	column 2	Column 3	Column 4
Item	Ingredient name DIVERSILOBUM	Purpose	Specific requirements homoeopathic ingredient.
	DIVERSILODOW		noniocoputite ingreatent.
4933	TOXICODENDRON PUBESCENS	Н	Only for use as an active homoeopathic ingredient.
			The maximum recommended daily dose must be no more than 1 mg of the equivalent dry herbal material of
			Toxicodendron pubescens.
4934	TOXICODENDRON RADICANS	А, Н	The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material of Toxicodendron radicans.
4935	TOXICODENDRON SUCCEDANEUM	Н	Only for use as an active homoeopathic ingredient.
4936	TRACHELOSPERMUM JASMINOIDES	А, Е, Н	
4937	TRACHYSPERMUM AMMI	A, E	Only for use in oral medicines when the plant part is fruit or seed.
			The medicine requires the following warning statements on the medicine label:
			- (PREGNT) 'Not recommended for use by pregnant and lactating women
			(or words to that effect)
			- (PREGNT2) 'Do not use if pregnant or likely to become pregnant' (or words to that effect).
			Permitted for use only in

Volume 5

Column 1	column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
	0		combination with other permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4938	TRAGACANTH	A, E	
4939	TRAMETES VERSICOLOR	A, H	
4940	TRAMETES VERSICOLOR PROTEOGLYCAN CONCENTRATE	А, Н	Only for use in oral medicines.
4941	TRANS,TRANS-2,4-DECADIEN-1- AL	Ε	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4942	TRANS,TRANS-2,4- HEXADIENAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in the medicine must be no more than 1%.
			The maximum daily dose must provide no more than 13.5 mg of Trans, Trans-2,4-Hexadienal

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4943	TRANS-1-(2,4,4-TRIMETHYL-2- CYCLOHEXEN-1-YL)-2-BUTEN- 1-ONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4944	TRANS-2-DECENAL	Е	Permitted for use only in combination with other permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4945	TRANS-2-DODECENAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4946	TRANS-2-HEPTEN-1-AL	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more thar

Volume 5

Permissible ingredients and requirements			
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			5%.
4947	TRANS-2-HEXENAL	E	<ul> <li>Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.</li> <li>If used in a flavour the total flavour concentration in a medicine must be no more tha 5%.</li> <li>If used in a fragrance the total fragrance concentration in a medicine must be no more 1%</li> </ul>
4948	TRANS-2-HEXENOIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4949	TRANS-2-HEXENOL	E	<ul> <li>Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.</li> <li>If used in a flavour the total flavour concentration in a medicine must be no more than 5%.</li> <li>If used in a fragrance the total fragrance concentration in a medicine must be no more 1%</li> </ul>
4950	TRANS-2-HEXENYL ACETATE	Е	Permitted for use only in combination with other permitted ingredients as a

Vol	lume	5

	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4951	TRANS-2-HEXENYL PHENYLACETATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4952	TRANS-2-HYDROXYCINNAMIC ACID	Е	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than
4953	TRANS-2-UNDECENAL	Е	5%. Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4954	TRANS-3-HEXENOIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total

Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2020

1057

Volume 5

Permissible ing	Permissible ingredients and requirements				
Column 1	Column 2	Column 3	Column 4		
Item	Ingredient name	Purpose	Specific requirements		
			flavour concentration in a medicine must be no more than 5%.		
4955	TRANS-4-DECENAL	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.		
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.		
4956	TRANS-8-(1-METHYLETHYL)-1- OXASPIRO(4.5)DECAN-2-ONE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.		
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.		
4957	TRANS-ETHYL 2-OCTENOATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.		
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.		
4958	TRANS-METHYL-2-HEXENOATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour.		
			If used in a flavour the total flavour concentration in a medicine must be no more thar		

1058

Permissible ingredients and requirements			
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			5%.
4959	TREACLE	Е	When for oral or sublingual use, sucrose is a mandatory component of Treacle.
			When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement

num	ingi culcite name	1 ui pose	Specific requirements
			5%.
4959	TREACLE	Е	When for oral or sublingual use, sucrose is a mandatory component of Treacle.
			<ul> <li>When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label:</li> <li>(SUGARS) 'Contains [insert name of sugar]' if medicine contains one sugar OR 'Contains sugars' (or words to that effect) if medicine contains two or more sugars. If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label:</li> <li>(LACT) 'Contains lactose' (or words to that effect).</li> </ul>
4960	TREEMOSS ABSOLUTE	Е	Permitted for use only in combination with other permitted ingredients as part of a fragrance proprietary excipient formulation.
			When included in a medicine for use on the lips the concentration of treemoss absolute must be no more than

Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2020

Volume 5

Volume 5

	redients and requirements	~	~ ~ ~ ~
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			0.02%. When for dermal use or use on the hair the concentration of treemoss absolute must be no more than 0.1%
			The total fragrance proprietary excipient formulation in a medicine must be no more than 1%.
4961	TREFRIW WELLS MINERAL WATER	А	When for internal use, iron is a mandatory component of Trefriw Wells mineral water.
			Solid dosage forms containing more than 5 milligrams of elemental iron in each dosage unit are required to have a child resistant closure.
			Liquid Preparations containing more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure.
			Only able to be used when presented in single use sachets for therapeutic use as an iron supplement.
4962	TREHALOSE DIHYDRATE	E	When for oral use and the quantity of trehalose dihydrate per maximum recommended daily dose exceeds 20 grams, the quantity of trehalose dihydrate must be declared on the label.
4963	TREMELLA FUCIFORMIS	A, H	

1060

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4964	TRIACETIN	Е	
4965	TRIACONTANYL PVP	E	Only for use in topical medicines for dermal application.
4966	TRIADICA SEBIFERA	A, H	
4967	TRIBASIC POTASSIUM PHOSPHATE	A, E, H	When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of tribasic potassium phosphate. When used in a solid medicine containing this ingredient, the pH of a 10 g/L aqueous solution must not be more than 11.5. When used in a liquid or a semi-solid medicine containing this ingredient, the pH of the medicine must be no more than 11.5.
4968	TRIBASIC SODIUM PHOSPHATE	Ε	<ul> <li>When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.</li> <li>When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.</li> <li>When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine</li> </ul>

Volume 5

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			label: - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4969	TRIBEHENIN	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 6%.
4970	TRIBEHENIN PEG-20 ESTERS	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 6%.
4971	TRIBULUS TERRESTRIS	A, E, H	
4972	TRIBUTYL ACETYLCITRATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more thar
4973	TRICALCIUM PHOSPHATE	E	1%.
4974	TRICAPRYLIN	Е	Only for use in topical

Vol	lume	5
101	unit	~

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 5%.
4975	TRICAPRYLYL CITRATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 7%.
4976	TRICETEARETH-4 PHOSPHATE	Е	Only for use in topical medicines for dermal application.
4977	TRICHLOROMETHYLPHENYLC ARBINYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4978	TRICHODERMA VIRIDE	А, Е, Н	
4979	TRICHOSANTHES KIRILOWII	А, Е, Н	
4980	TRICLOSAN	E	The concentration in the medicine must be no more than 1%.

volume J	Vo	lume	5
----------	----	------	---

Column 1	column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
4981	TRICYCLODECENYL PROPIONATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4982	TRIDECANAL	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4983	TRIDECETH-4 PHOSPHATE	E	Only for use in topical medicines for dermal application.
4984	TRIDECETH-6	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than
4985	TRIDECYL ALCOHOL	Е	0.5%. Permitted for use only in
			combination with other permitted ingredients as a fragrance.
			If used as in a fragrance the total fragrance concentration ir

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			a medicine must be no more than 1%.
4986	TRIDECYL BEHENATE	E	Behenic acid is a mandatory component of Tridecyl behenate.
			Only for use in topical medicines for dermal application.
4987	TRIDECYL NEOPENTANOATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 23%.
4988	TRIDECYL SALICYLATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 5%.
4989	TRIDECYL STEARATE	Е	Only for use in topical medicines for dermal application.
4990	TRIDECYL TRIMELLITATE	Е	Only for use in topical medicines for dermal application.
4991	TRIETHOXYCAPRYLYLSILANE	Е	Only for use in topical

Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2020

1065

Volume 5

	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 1%.
4992	TRIETHYL CITRATE	Е	
4993	TRIETHYLENE GLYCOL	Е	
4994	TRIFOLIUM PRATENSE	А, Е, Н	
4995	TRIFOLIUM REPENS	A, H	
4996	TRIGONELLA FOENUM- GRAECUM	А, Е, Н	
4997	TRIHYDROXYPALMITAMIDOH YDROXYPROPYL MYRISTYL ETHER	Ε	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.02%.
4998	TRIHYDROXYSTEARIN	Е	Only for use in topical medicines for dermal application.
4999	TRIISOCETYL CITRATE	Е	Only for use in topical medicines for dermal application.
5000	TRIISODECYL TRIMELLITATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended

1066

Column 1	redients and requirements Column 2	Column 3	Column 4
Item			
Item	Ingredient name	Purpose	Specific requirements for use in the eye.
			The concentration in the medicine must be no more than 5%.
5001	TRIISONONANOIN	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.
5002	TRIISOSTEARIN	E	Only for use in topical medicines for dermal application.
5003	TRILAURIN	Е	Only for use in topical medicines for dermal application.
5004	TRILISA ODORATISSIMA	A, H	
5005	TRILLIUM ERECTUM	A, H	
5006	TRIMETHOXYCAPRYLYL SILANE	Ε	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.25%.
5007	TRIMETHYL HYDROXYPENTYL ISOBUTYRATE	Е	Permitted for use only in combination with other permitted ingredients as a

Volume 5

	~ -	~
Column 2	Column 3	Column 4
Ingredient name	Purpose	Specific requirements
		fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
TRIMETHYL UNDECYLENIC ALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
TRIMETHYL-BICYCLO- HEPTANE- SPIROCYCLOHEXENONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
TRIMETHYLBENZENEPROPANO L	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
TRIMETHYLHEXANOL	Е	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total
	TRIMETHYL UNDECYLENIC ALDEHYDE TRIMETHYL-BICYCLO- HEPTANE- SPIROCYCLOHEXENONE TRIMETHYLBENZENEPROPANO L	TRIMETHYL UNDECYLENIC       E         ALDEHYDE       E         TRIMETHYL-BICYCLO-       E         HEPTANE-       SPIROCYCLOHEXENONE         SPIROCYCLOHEXENONE       E         TRIMETHYLBENZENEPROPANO       E         L       E

Volume 5

Permissible ingredients and requirements				
Column 1	Column 2	Column 3	Column 4	
Item	Ingredient name	Purpose	Specific requirements	
			fragrance concentration in a medicine must be no more than 1%.	
5012	TRIMETHYLOPROPANE TRIOCTANOATE	E	Only for use in topical medicines for dermal application.	
5013	TRIMETHYLPENTANEDIOL/ADI PIC ACID/GLYCERIN CROSSPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the	
			medicine must be no more than 5%.	
5014	TRIMETHYLSILOXYSILICATE	E	Only for use in topical medicines for dermal application.	
5015	TRINITROPHENOL	Н	Only for use as an active homoeopathic ingredient.	
5016	TRIOCTANOIN	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.	
			The concentration in the medicine must be no more than 5%.	
5017	TRIOCTYLDODECYL CITRATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended	

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			for use in the eye. The concentration in the medicine must be no more than 12%.
5018	TRIOLEIN	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.1%.
5019	TRIOSTEUM PERFOLIATUM	A, H	
5020	TRIOXAUNDECANEDIOIC ACID	Е	
5021	TRIPAL	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
5022	TRIPEPTIDE-1	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.
			The concentration in the medicine must be no more than 0.002%.
5023	TRIS-BIPHENYL TRIAZINE	A	Only for use as an active ingredient in sunscreens for

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must not be more than 10%.
			When used topically, the dosage form must not be spray
			When used in primary sunscreen products, the following warning statements are required on the label:
			- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and
			- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
5024	TRISILOXANE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 40%.
5025	TRISODIUM EDETATE	Е	Only for use in topical medicines for dermal application.
5026	TRISODIUM ETHYLENEDIAMINE DISUCCINATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

Volume 5

Permissible ing	redients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			The concentration in the medicine must be no more than 0.2%.
5027	TRISODIUM NTA	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.005%.
5028	TRISTEARIN	Е	
5029	TRITICUM AESTIVUM	А, Е, Н	Gluten is a mandatory component when the plant part is seed and the route of administration is other than topical and mucosal.
5030	TRITICUM DURUM	А, Е, Н	Gluten is a mandatory component when the plant part is seed and the route of administration is other than topical and mucosal.
5031	TRIUNDECANOIN	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 11.2%.
5032	TROLAMINE	Е	Only for use in topical

V	0	lume	5
v	U	unit	2

Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			medicines for dermal application.
			The concentration in the medicine must be no more than 5%.
5033	TROLAMINE LAURIL SULFATE	Е	Only for use in topical medicines for dermal application.
5034	TROLAMINE SALICYLATE	А	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must not be more than 12%.
			When used in primary sunscreen products, the following warning statements are required on the label:
			- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and
			- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

5035	TROLLIUS CHINENSIS	A, H	
5036	TROMETAMOL	Е	
5037	TROMETAMOL HYDROCHLORIDE	E	
5038	TROPAEOLUM MAJUS	А, Е, Н	
5039	TROPICAL RATTLESNAKE	Н	Only for use as an active

Volume 5

Permissible ing	gredients and requirements		
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
			homoeopathic ingredient.
5040	TROPOLONE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the
			medicine must be no more than 0.01%.
5041	TSUGA CANADENSIS	A, H	
5042	TULIPA EDULIS	А, Н	Colchicine is a mandatory component of Tulipa edulis.
			The concentration of colchicing in the medicine must be no more than 10 mg/kg or 10 mg/L or 0.001%.
5043	TURMERIC	Е	Permitted for use only in combination with other permitted ingredients as a colour.
5044	TURNERA DIFFUSA	А, Е, Н	Arbutin is a mandatory component of Turnera diffusa.
			The concentration of arbutin in the medicine must be no more than 25 mg/Kg or 25mg /L or 0.0025 % unless used on the hair.
			When for use on hair, the concentration of arbutin in the medicine must be no more than 0.74 %.
5045	TURNIP	Е	

Permissible ingredients and requirements			
Column 1	Column 2	Column 3	Column 4
Item	Ingredient name	Purpose	Specific requirements
5046	TURPENTINE OIL	Α, Ε	The concentration in the medicine must be no more than 25%.
5047	TYPHA ANGUSTIFOLIA	A, H	
5048	TYPHA LATIFOLIA	A, H	
5049	TYPHONIUM GIGANTEUM	A, H	
5050	TYROSINE	A, E	